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ABSTRACT OF THE DISSERTATION 
 
Expression and function of small noncoding RNAs in psoriatic skin 
 
by 
 
Cailin Elizabeth Joyce 
 
Doctor of Philosophy in Molecular Genetics and Genomics 
 
Washington University in Saint Louis, 2012 
 
Anne Bowcock, PhD, Chairperson 
 
 
 
 
Psoriasis is a chronic, inflammatory skin disease characterized by 
hyperproliferation and altered differentiation of keratinocytes, and infiltration of activated 
immune cells in the epidermis. Array based genome-wide expression studies by our lab 
and others have revealed over 1,300 alterations in mRNA transcript levels in psoriatic 
skin. microRNAs (miRNAs) are a class of short, regulatory RNAs that play critical roles 
in human development and disease. I hypothesized that differential expression of 
miRNAs might underlie some of the gene expression changes in psoriatic skin. Thus, I 
sought to characterize the global landscape of miRNA expression in human skin, and to 
investigate the functional roles of miRNAs with respect to psoriasis pathogenesis. I 
profiled small RNAs in human skin with Next Generation sequencing, and detected 
known miRNAs, variants of known miRNAs, and novel miRNAs with unprecedented 
sequencing depth. Eighty known and 18 novel miRNAs were two- to 42-fold 
differentially expressed in psoriatic skin. Computational and experimental analysis of 
miRNA targets revealed that three differentially expressed miRNAs directly regulate 
 iii 
components of the skin barrier, and that these regulatory interactions have recent 
evolutionary origins. I also identified other species of small RNAs, such as endogenous 
small interfering RNAs (siRNAs) in skin, but determined that they are typically less 
abundant than miRNAs. Like miRNAs, some of these are differentially expressed in 
psoriasis, and may function as regulators of gene expression. Overall, this work has 
greatly increased our understanding of the depth and breadth of small RNA species 
expressed in human skin, and implicated a large number of small RNAs in psoriasis 
pathogenesis. 
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Clinical and molecular features of psoriasis 
Human skin is a complex organ that serves many vital functions; these include 
preventing dehydration, forming a barrier against infection, and regenerating in response 
to injury (1). The epidermis is the outermost layer of the skin. It consists of the basal 
layer, spinous layer, granular layer, and stratum corneum. The basal layer is populated by 
proliferative keratinocytes and epidermal stem cells (2). As basal keratinocytes migrate 
outwards through the spinous and granular layers, they undergo a process called terminal 
differentiation (2). Many transcriptional and morphological changes occur as terminal 
differentiation progresses such that by the time keratinocytes reach the skin surface, they 
are enucleated and encased in a proteinaceous cornified envelope (2). Terminally 
differentiated keratinocytes, termed corneocytes, are cemented together by a lipid-rich 
matrix, forming an organized, impenetrable, and renewable epidermal barrier (2). In 
normal skin, the process of terminal differentiation occurs over approximately 40 days 
(3).  
In addition to keratinocytes, immune cells such as T cells and dendritic cells are 
present at low levels in normal skin (4). Cytokine signaling between keratinocytes and 
immune cells is an important regulator of proliferation, differentiation, inflammation, and 
regeneration in the skin. Indeed, defective cross talk between these cells is thought to be a 
key mediator of the common skin disease psoriasis (4,5,6).  
Psoriasis is a chronic, inflammatory skin disease characterized by the presence of 
inflamed, scaly lesions on the skin (Figure 1-1). Psoriasis affects 2-3% of Caucasians, 
and is less prevalent in Asians and Africans (7). There are several types of psoriasis, the 
most common of which is psoriasis vulgaris, or plaque psoriasis, which accounts for 
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~90% of cases (8). Other less common forms of psoriasis include guttate, inverse, 
pustular and erythrodermic (8). Psoriasis patients experience profound psychosocial 
effects and are at increased risk for metabolic syndrome, cardiovascular disease and 
stroke (9,10,11,12). Moreover, 10-30% of psoriasis patients develop a progressive, 
inflammatory arthritis termed psoriatic arthritis (13). There is currently no cure for 
psoriasis, although treatments such as phototherapy, topical medications, and systemic 
biologics can reduce the frequency and severity of outbreaks (14). 
Cellular alterations in involved psoriatic skin include hyperproliferation and 
altered differentiation of keratinocytes, and infiltration and activation of immune cells 
(Figure 1-2; 5). Involved psoriatic keratinocytes undergo an alternative differentiation 
program similar to that seen during regeneration (15), and they reach the surface of the 
skin within 6-8 days (3,5). Involved psoriatic keratinocytes also secrete a number of 
factors that promote leukocyte adhesion and activation, such as beta-defensin and the 
S100 proteins (16). Immune cell subsets thought to be involved in psoriasis pathogenesis 
include Th1 and Th17 cells (17,18). Th1 cells secrete inflammatory cytokines such as 
interleukin-1 (IL1), tumor necrosis factor alpha (TNFA), and interferon gamma (IFNG), 
while Th17 cells secrete interleukin-17 (IL17) and interleukin-22 (IL22). All of these 
cytokines are upregulated in involved skin compared to uninvolved and normal skin 
(17,18,19). These cytokines likely act on resident keratinocytes to promote 
hyperproliferation and serve to recruit additional immune cell populations which 
perpetuates inflammation.  
  The onset and severity of psoriasis depends on genetic and environmental factors. 
While many cases are sporadic, siblings of psoriasis patients have a 4-6 fold increased 
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risk of developing the disease compared to the general population (7). Environmental 
triggers include skin trauma, HIV infection, and certain drugs (20,21,22). Genetic studies 
have identified risk alleles related to the immune system and skin barrier. 
 
Genomic approaches to understanding psoriasis 
Family based linkage studies have implicated up to 20 loci as contributing to 
psoriasis susceptibility (6). However, most of these loci failed to replicate in multiple 
families or populations. This may be due to weak effects; contribution of population 
specific, familial, or private risk alleles; or confounding environmental factors.  The 
major histocompatibility complex (MHC) is the one locus that has been replicated in all 
of these linkage studies, and has also been robustly linked to other autoimmune diseases 
such as systemic lupus erythematosus, type 1 diabetes, and rheumatoid arthritis (6). 
Another locus that was replicated in two large families is PSORS2 on 17q.25 (23,24). 
Recent exome sequencing of the region of linkage has revealed independent gain of 
function mutations in the CARD14 gene in two independent multiplex psoriasis families 
(25). CARD14 is expressed in keratinocytes and encodes an activator of NF-kB. The 
familial mutations augment NF-kB activation (25,26). This finding adds to the increasing 
body of evidence that keratinocyte-derived factors can drive psoriasis pathogenesis. 
Genome wide association studies (GWAS) have unveiled additional psoriasis risk 
loci, many of which are related to immunity and inflammation. Consistent with linkage 
analyses, the strongest of these associations is the HLA-Cw6 allele within the MHC, 
which is present in ~46% of psoriasis patients, but only ~7% of controls (27). 
Components of the Th17 pathway (IL12B, IL23A, IL23R) are also associated with 
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psoriasis, as are regulators of NF-kB (TNFAIP3, TNIP1) (28,29,30). Additionally, 
GWAS has uncovered epidermal genes that contribute to psoriasis susceptibility. One 
example is the cluster of genes on chromosome 8 encoding B-defensin (DEFB), which is 
secreted by keratinocytes in psoriatic skin. DEFB copy number is highly polymorphic in 
the population, and increased copy number is associated with psoriasis (31). A deletion 
polymorphism within the epidermal differentiation complex (EDC) on chromosome 1 is 
associated with psoriasis in European and Chinese populations (30,32). This deletion 
results in the loss of the late cornified envelope genes LCE3B and LCE3C, and an 
enhancer element related to keratinocyte differentiation.  
Our lab and others have performed genome-wide expression studies with array 
based technologies, and identified over 1,300 alterations in mRNA transcript levels in 
involved and uninvolved psoriatic skin (Table 1-1; 18,19). Keratinocyte derived 
transcripts such as defensin-B4 (DEFB4), S100 calcium binding proteins, keratin 16 
(KRT16), and late cornified envelope-3D (LCE3D; are among the most highly 
upregulated. Macrophage-derived interleukin-8 (IL8) is the most highly upregulated 
cytokine (19). Strongly downregulated genes include the Wnt inhibitory factor-1 (WIF1), 
interleukin-1 family member 7 (IL1F7), chemokine (C-C motif) ligand-27 (CCL27), 
keratin-1B (KRT1B), and fatty acid binding protein 7 (FABP7; 19). Overall, upregulated 
genes are enriched for immune/defense/wounding response, mitotic cell cycle, ectoderm 
development, and keratinocyte differentiation functions; downregulated genes are 
enriched for organismal/system/organ development, fatty acid and lipid metabolic 
processes, and blood circulation functions (19).  
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Systems biology of psoriasis 
Linkage analysis, GWAS, and microarray studies undertaken over the last 20 
years have revealed many psoriasis susceptibility factors and led to a greater 
understanding of the pathways involved in disease pathogenesis. Despite this, a recent 
study combining ten of the most significant psoriasis risk loci could only account for 
~12% of the genetic susceptibility to psoriasis (33). Moreover, the identification of true 
causative variants and assessment of their contribution to psoriasis susceptibility and 
pathogenesis will require innovative new approaches.  
Along these lines, the Bowcock laboratory is taking an integrative approach 
towards a systems biological understanding of psoriasis. That is to say, we are interested 
in the in the cumulative and sometimes combinatorial effects of coding and noncoding 
DNA sequence variation, quantitative and qualitative changes in gene expression, and 
perturbation of regulatory networks mediated by protein and RNA on psoriasis 
susceptibility and pathogenesis. One important piece of this puzzle is the expression and 
function of small noncoding regulatory RNAs (sncRNAs). sncRNAs play critical roles in 
gene regulation for nearly all biological processes in eukaryotic organisms including 
mRNA cleavage, RNA degradation, translation inhibition, and DNA methylation (34). 
microRNAs (miRNAs) in particular have been heavily studied in recent years and shown 
to be essential gene regulators that broadly contribute to disease pathogenesis. 
 
miRNAs: Discovery, biogenesis and function 
The founding member of the miRNA family, lin-4, was discovered as part of a 
screen for developmental phenotypes in C. elegans (35,36). Mutations in lin-4 lead to 
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reiteration of the earliest larval (L1) cell division patterns during a later developmental 
stage (L2; 36). Conversely, mutations in another gene, lin-14, lead to the opposite 
developmental phenotype, premature exit from L1 (37). Twelve years later, it was found 
that the lin-4 gene encodes a 22 nucleotide (nt) noncoding RNA, which is partially 
complementary to seven sites within the 3’UTR of the lin-14 mRNA transcript (38). 
Thus, it was hypothesized that direct interactions between lin-4 and the lin-14 3’UTR 
resulted in repression of lin-14 expression. Indeed, biochemical experiments confirmed 
the physical interaction between the lin-4 small RNA and lin-14 3’UTR and suggested 
that translational inhibition was the mechanism underlying lin-14 repression (39,40,41). 
A second developmentally regulated gene in C. elegans, lin-28, also harbors lin-4 sites 
within its 3’UTR and is negatively regulated by the miRNA (42). This finding highlights 
one key feature of the miRNA family, which is the ability to regulate multiple target 
genes. 
To date, nearly 2000 distinct human miRNAs have been cataloged in the miRNA 
database miRBase (v18; 43,44,45). miRNA genes can be intergenic or intronic, and some 
are found within genomic clusters that are transcribed as polycistronic primary transcripts 
(pri-miRNAs; 46,47). Most miRNA genes are transcribed by RNA polymerase II, and 
pri-miRNAs are polyadenylated RNAs that can be up to several kilobases long and 
contain one or more hairpin sequences (48,49). These hairpins are typically comprised of 
a ~33nt double stranded region connected by a terminal loop and flanked by single 
stranded RNA(50). Such structures are recognized and cleaved by the RNase type III 
enzyme Drosha and its binding partner DGCR8 in the nucleus, resulting in the release of 
a ~60nt precursor miRNA (pre-miRNA) hairpin (50). The pre-miRNA is exported to the 
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cytoplasm via the nuclear transport receptor exportin-5 (XPO5; 51,52,53). In the 
cytoplasm, the pre-miRNA is recognized and cleaved by another RNase type III enzyme, 
Dicer, resulting in the release of a ~22nt double stranded RNA (54,55,56,57,58). 
Following Dicer cleavage, the RNA duplex is unwound by an as yet unknown helicase 
and a single strand of the RNA duplex (miRNA strand) is incorporated into the RNA-
induced silencing complex (RISC). The unincorporated strand (miRNA* strand) was 
thought to be rapidly degraded, although subsequently a number of retained miRNA* 
species have been identified (59,60). Strand selection depends partially on 
thermodynamic properties of the miRNA/miRNA* duplex, but tissue specific variability 
in strand selection supports either some amount of stochasticity or the existence of 
additional regulatory mechanisms (61).  
 Mature miRNAs function as guide sequences which direct the RISC complex to 
particular target mRNAs. The components of RISC have been somewhat difficult to pin 
down, and RNA silencing activity has been associated with a variety of complexes 
ranging from 160-550kDa (62). However, it is known that an Argonaute family protein 
and a GW182 protein are essential to the complex (63). In humans, there are four Ago 
family members, referred to as Ago1-4. Ago family proteins contain three domains: a 
Piwi/Argonaute/Zwille (PAZ) domain, a middle (MID) domain, and a P-element induced 
wimpy testes in Drosophila (PIWI) domain. The PAZ and MIDI domains recognize the 
3’ and 5’ ends of the miRNA, respectively, while PIWI is an RNase H domain that can 
mediate single stranded RNA cleavage and also binds GW182 (64,65,66). In humans, 
Ago1-4 associate with largely overlapping sets of miRNAs and proteins, although Ago2 
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is the only human Ago protein for which the PIWI RNase H domain is catalytically 
active  (67,68).   
 GW182 is another essential RISC component. In fact, it is likely to be an 
important functional subunit, as tethering of the C-terminal fragment of GW182 to an 
mRNA is sufficient to induce translational repression and mRNA destabilization 
(69,70,71). There are three GW182 proteins in humans, which are encoded by the genes 
TNRC-A, -B, and –C. The GW182 proteins contain four known domains: a N-terminal 
glycine-tryptophan (GW) repeat domain, a ubiquitin-associated domain (UBA), a 
glutamine-rich domain (Q-rich), and an RNA recognition motif (RRM). The N-terminal 
GW repeat domain interacts with Ago proteins while a domain of unknown function and 
the C-terminal RRM comprise the RNA silencing region (70,71). 
miRNA target recognition is largely dependent on reverse complementarity 
between the 5’ end of the miRNA and a short segment of the target 3’UTR (72). The key 
bases for target recognition appear to be nucleotides 2-8 of the miRNA, which are 
collectively referred to as the “seed” sequence (72). The rest of the miRNA typically 
exhibits degenerate complementarity, with a characteristic bulge at positions ~9-11 
(73,74,75). This bulge interrupts base pairing at the potential Ago2 cleavage site (76), 
such that direct mRNA cleavage is not a common mechanism for miRNA-mediated 
repression in humans. In addition to seeded binding sites, there exist “3’ compensatory” 
binding sites, where degeneracy in the seed region can be overcome by complementarity 
in the remaining sequence (77). Target recognition may also be influenced by local 
sequence context; for example, sequence flanking miRNA target sites tends to be AU-
rich (72). Overall, the principles governing target recognition are still not well 
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understood. Nevertheless, various target prediction algorithms exist, such as 
TargetScanS, miRanda, and PicTar. Each of these algorithms applies some combination 
of weighted  parameters accounting for seed match, free energy of binding, and 
conservation (78). Recent estimates indicate that ~60% of human mRNAs contain 
conserved miRNA binding sites in the 3’UTR and that a particular miRNA family 
(comprised of miRNAs with identical seed regions) targets ~500 conserved 3’UTR sites, 
on average (79). 
Early miRNA studies in C. elegans, among others, found that miRNA binding 
resulted in decreased protein levels, independent of mRNA levels (40,63). Thus, it was 
thought that translational repression was the primary mechanism of miRNA-mediated 
RNA silencing in metazoans. Despite this, more recent work has pointed towards mRNA 
destabilization via deadenylation and decapping. In 2005, it was shown that decreases in 
lin-14 and lin-28 mRNA levels in L2 stage worms are lin-4 dependent (80). More 
recently, ribosome profiling experiments on exogenous and endogenous miRNA-targeted 
transcripts have indicated that mRNA destabilization accounts for a large proportion of 
miRNA-mediated repression (81). Based on the number of conflicting studies, it remains 
unclear which mechanism is dominant in metazoans. However, it seems likely that both 
mechanisms may contribute to some extent, depending on the exact nature of the 
miRNA:mRNA interaction, transcript abundance, or expression of cofactors in particular 
cells and organisms. Key features of miRNA biogenesis and function are summarized in 
Figure 1-3. 
 
Role of miRNAs in human development and disease 
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miRNAs have important roles in development and disease. Indeed, deletion of the 
miRNA processing enzyme Dicer is lethal in mice and zebrafish (82,83). This is perhaps 
not surprising in light of the myriad biological processes mediated by miRNAs, including 
cell differentiation, apoptosis, metabolism, developmental timing and patterning, and 
organogenesis, among others (84). In the case of skin, epidermal specific knockouts of 
Dicer1 or its binding partner Dgcr8 in the mouse embryo perturb the development of the 
epidermal barrier and epidermal appendages (Figure 1-3; 85,86).  Knockout animals are 
born in expected Mendelian ratios and appear normal at birth, despite increased apoptosis 
in the prenatal epidermis and hair germ. However, by postnatal day 1.5 (P1.5), epidermal 
cysts begin to form due to evagination of hair germs. By P2, knockout mice begin to lose 
body mass due to dehydration, and perish by P6. 
Individual miRNAs have been implicated in skin homeostasis by expression 
profiling during the course of keratinocyte differentiation. Calcium-induced 
differentiation of normal human epidermal keratinocytes resulted in differential 
expression of many miRNAs after three or seven days (87). Moreover, populations of 
epidermal stem cells, transient amplifying keratinocytes, and terminally differentiated 
keratinocytes derived from human skin biopsies exhibited differential miRNA expression 
(87). A few miRNAs are also upregulated during the formation of cultured epidermal 
equivalents, in which primary keratinocytes are exposed to an air/liquid interface that 
stimulates epidermal stratification (88).  
In addition to keratinocytes, human skin contains small populations of immune 
and immune-regulatory cells, which modulate the cutaneous response to injury and 
infection. These include skin homing T cells, resident dendritic cells, neutrophils, 
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Langerhan’s cells, and regulatory T cells. miRNAs have been shown to influence the 
development, survival, and activation of these cells (89), and immune cell-derived 
miRNAs have been shown to modulate cytokine expression in the skin (90). Thus, 
immune-derived miRNAs also influence proliferation, differentiation, inflammation, and 
regeneration in the skin. 
Recently, genomic miRNA profiling techniques and identification of miRNA 
targets in human tissues and cell lines have provided insights into many human diseases, 
particularly cancer (91,92,93,94). For example, in the case of melanoma, microarray-
based miRNA profiling led to the observation that miR-211 was downregulated in an 
invasive melanoma derivative cell line compared to a non-invasive derivative (91). 
Interestingly, miR-211 lies within an intron of the melastatin-1 (MLSN1) gene, long 
thought to be a melanoma tumor suppressor. In fact, expression of miR-211, but not the 
melastatin protein, suppress cell migration and invasiveness in melanoma cell lines, 
indicating that the miRNA is the true tumor suppressor (95). miR-211 likely exerts its 
tumor suppressor function by targeting at least two central node genes in the melanoma 
metastasis gene expression network: TGFBR2 and NFAT5 (95). 
 
Current understanding of miRNAs in psoriasis 
 In the case of psoriasis, two independent miRNA microarray studies interrogating 
~561 known miRNAs have implicated 82 miRNAs (Table 1-2). The first study reported 
±1.4-fold differential expression of 29 miRNAs in involved psoriatic versus normal skin, 
and noted that 20 of these are not differentially expressed in another inflammatory skin 
disease, atopic dermatitis (96). The second study reported ±1.2-fold differential 
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expression of 53 miRNAs, including 10 miRNAs that are differentially expressed in 
uninvolved psoriatic versus normal skin (97). Discordance between these studies was 
fairly high, with only 9 overlapping differentially expressed miRNAs overall.  A lower 
rate of discordance is observed for more highly differentially expressed genes: nine of 23 
miRNAs (39%) with two- to eight-fold changes were concordant between the two 
studies. Overall, high rates of discordance between the two studies are likely a reflection 
of natural variation (genotype, disease severity, etc.), low sensitivity of microarrays, and 
hybridization nuances that are particularly relevant to short sequences. Moreover, the 
small number of consistent miRNA expression changes and the low magnitude of 
differential expression are inconsistent with the dramatic shift in cellular composition, 
differentiation, and gene expression characteristic of involved psoriatic skin.  
 Likewise, little progress has been made on the identification of biologically 
relevant miRNA targets in psoriatic skin. This is likely due to technical obstacles and to 
the complex cellular architecture of the skin, particularly in the case of inflamed psoriatic 
skin. It was initially reported that upregulation of miR-203 in involved skin led to 
repression of the suppressor of cytokine signaling-3 (SOCS-3) mRNA (96), but 
subsequent studies have failed to replicate this finding (98,99). These studies point 
towards miR-203 repression of a particular p63 isoform (ΔNp63) in the suprabasal layers 
as a mechanism for decreasing the proliferative potential of terminally differentiating 
keratinocytes (98,99). Other studies have reported miRNA mediated repression of tissue 
inhibitor of metalloproteinase-3 (TIMP3), insulin-like growth factor-1 receptor (IGF1R), 
and fibroblast growth factor receptor-2 (FGFR2) by miR-221/222, miR-99a, and miR-
125b, respectively, in involved skin (97,100). 
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The paucity of consistent results from microarrays indicated that more 
sophisticated techniques were needed to advance our understanding of the role of 
miRNAs in psoriasis. Successful applications of Next Generation sequencing (NGS) to 
small RNA expression profiling highlight the utility of this platform (92,93,94). Thus, I 
have used NGS to comprehensively profile small RNA expression in normal and 
psoriatic skin. This approach confers distinct advantages over microarray platforms such 
as the ability to detect low abundance small RNAs; novel small RNAs; and small RNA 
sequence variants due to underlying DNA sequence variation, RNA editing, or variability 
in small RNA processing. In the following chapters, I describe the global landscape of 
sncRNAs in human skin, the misexpression of a subset of sncRNAs in psoriatic skin, and 
potentially pathogenic functions of differentially expressed sncRNAs. This work has 
greatly improved our understanding of sncRNA expression in normal and diseased 
human skin and provided a valuable resource for the psoriasis and small RNA 
communities.  
 
 
 
 
 
 
 
 
 
 15 
TABLES AND FIGURES 
Table 1-1. Top differentially expressed genes in involved psoriatic versus normal 
skin, from Gudjonsson et al. 2010 (19). 
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Table 1-2. Summary of previously described differentially expressed miRNAs in 
psoriatic skin, adapted from Sonkoly et al., 2007 (96) and Zibert et al., 2010 (97). 
 
 
 
 
 
 
 
 
 
 
 
Upregulated miRNAs
miRNA Fold change Comparisona miRNA Fold change Comparison
miR-146bb 3.31 PP vs. NN let-7g 1.5 PP vs. NN
miR-20a 2.9 PP vs. NN, AD vs. NN let-7i 1.79 PP vs. NN
miR-146a 3.3 PP vs. NN, AD vs. NN miR-141 1.56 PP vs. NN
miR-31 4.69 PP vs. NN miR-200a 2.01 PP vs. NN
miR-200a 2.75 PP vs. NN miR-16 2.33 PP vs. NN
miR-17-5p 3.77 PP vs. NN, AD vs. NN miR-17 1.73 PP vs. NN
miR-30e-5p 3.61 PP vs. NN miR-20a 2.4 PP vs. NN
miR-141 3.45 PP vs. NN miR-106b 1.68 PP vs. NN
miR-203 5.86 PP vs. NN miR-21 7.65 PP vs. NN
miR-142-3p 2.55 PP vs. NN miR-27a 2.36 PP vs. NN
miR-21 2.51 PP vs. NN, AD vs. NN miR-27b 1.71 PP vs. NN
miR-106a 2.37 PP vs. NN, AD vs. NN miR-29a 1.65 PP vs. NN
miR-29c 1.73 PP vs. NN
miR-30b 1.53 PP vs. NN
miR-30cb 1.4 PP vs. NN
miR-31 4.14 PP vs. NN
miR-107 1.47 PP vs. NN
miR-125a-3p 1.53 PP vs. NN
miR-126 2.13 PP vs. NN
miR-136 1.34 PP vs. NN
miR-142-3p 4.69 PP vs. NN
miR-142-5p 2.32 PP vs. NN
miR-146a 3.1 PP vs. NN
miR-146b-5p 2.73 PP vs. NN
miR-148b 1.48 PP vs. NN
miR-155 1.24 PP vs. NN
miR-183 1.24 PP vs. NN
miR-193a-3p 2.34 PP vs. NN
miR-199a-3p 1.89 PP vs. NN
miR-203 2.02 PP vs. NN
miR-205 1.8 PP vs. NN
miR-221 1.54 PP vs. NN
miR-222 1.47 PP vs. NN
miR-223 4.82 PP vs. NN
miR-324-3p 1.31 PP vs. NN
miR-342-3p 1.68 PP vs. NN
miR-378 2.15 PP vs. NN
miR-518a-5p 1.87 PP vs. NN
miR-22 2.3, 1.41 PP vs. NN, PN vs. NN
miR-24-1 1.51, 1.41 PP vs. NN, PN vs. NN
miR-498 1.54, 1.71 PP vs. NN, PN vs. NN
miR-551a 1.36, 1.98 PP vs. NN, PN vs. NN
miR-10b 1.32 PN vs. NN
miR-501-3p 1.58 PN vs. NN
miR-612 1.62 PN vs. NN
miR-654 1.51 PN vs. NN
miR-760 1.47 PN vs. NN
Downregulated miRNAs
miRNA Fold change Comparison miRNA Fold change Comparison
miR-125b -1.82 PP vs. NN miR-138 -1.48 PP vs. NN
miR-99b -1.72 PP vs. NN miR-183* -1.44 PP vs. NN
miR-122a -5.56 PP vs. NN, AD vs. NN miR-338-5p -1.31 PP vs. NN
miR-197 -1.56 PP vs. NN miR-627 -1.24 PP vs. NN
miR-100 -1.69 PP vs. NN miR-659 -1.25 PP vs. NN
miR-381 -1.41 PP vs. NN miR-518c* -1.35 PN vs. NN
miR-518b -1.79 PP vs. NN
miR-524* -2.00 PP vs. NN
let-7e -1.67 PP vs. NN
miR-30c -1.59 PP vs. NN
miR-365 -1.61 PP vs. NN
miR-133b -4.55 PP vs. NN, AD vs. NN
miR-10a -1.49 PP vs. NN
miR-133 -2.50 PP vs. NN
miR-22 -1.64 PP vs. NN
miR-326 -1.79 PP vs. NN, AD vs. NN
miR-215 -1.79 PP vs. NN, AD vs. NN
Normal skin, NN; Uninvolved psoriatic skin, PN; Involved psoriatic skin, PP; Atopic dermatitis skin, AD
miRNAs in bold were concordant between the two studies; miRNAs in italics were discordant
Sonkoly et al. 2007 Zibert et al. 2010
Sonkoly et al. 2007 Zibert et al. 2010
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Figure 1-1. Clinical manifestations of psoriasis, from Roberson & Bowcock, 2010 
(5). a) plaque psoriasis, b) inverse psoriasis, c) seborrheic psoriasis, d) guttate psoriasis, 
e) pustular psoriasis, f) palmoplantar psoriasis, and g) nail pitting associated with 
psoriasis. 
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Figure 1-2. Molecular and cellular alterations in involved psoriatic skin, from 
Roberson & Bowcock, 2010 (5). 
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Figure 1-3. microRNA biogenesis and function, adapted from Chen et al. 2005 (101). 
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Figure 1-4. Conditional knockout of Dicer in the developing epidermis, from Yi et al. 
2006 (85). Gross morphological features of wild-type and epidermal Dicer1 knockout 
litter mates at a) P0.5 and b) P5.5. Development of follicular cysts in knockouts at c) P1.5 
and d) P6.5. e) Normal epidermal stratification in WT and knockout littermates. f) 
Apoptosis in the epidermis and hair follicles labeled by f) TUNEL at E17.5 and g) 
caspase-3 at P6.5. P-cadherin labels hair germs and integrin-β4 labels basement 
membrane. 
 
 
 21 
 
 
 
 
 
 
 
 
 
 
Chapter 2. 
The global miRNA landscape in human skin 
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ABSTRACT 
microRNAs (miRNAs) are a class of short, regulatory RNAs that play critical 
roles in human development and disease. In the skin, conditional knockout of the miRNA 
processing enzyme, Dicer, leads to epidermal abnormalities. I profiled global miRNA 
expression in human skin with Next Generation sequencing. I generated 6.7x108 qualified 
small RNA reads, representing the largest small RNA sequencing dataset derived from 
any human tissue to date. The global landscape of miRNAs in normal and psoriatic skin 
included 717 known miRNAs and 176 cognate miRNA*s; a number of previously 
undescribed miRNA*s from known miRNA loci; known miRNA variants such as 
isomiRs and edited miRNAs; and 284 expressed novel miRNA loci. I validated the 
endogenous expression and processing of three novel miRNAs in skin and other human 
cell lines or tissues. Of particular note was the discovery and validation of a novel 
antisense miRNA derived from the miR-203 locus, which has a role in epidermal 
differentiation. The global profiling of miRNAs in human skin is a critical first step 
towards understanding how miRNAs contribute to the skin’s ability to regenerate and 
respond to the environment. 
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INTRODUCTION 
 microRNAs (miRNAs) are a class of short, regulatory RNAs that play critical 
roles in human development and disease (38,47,84,102). They are transcribed as long 
stem-loop precursors, which undergo a number of processing steps resulting in the 
generation of a functional ~22 nucleotide (nt) single-stranded miRNA. Most miRNA 
precursors are cleaved through a canonical pathway involving the RNase type III 
enzymes Drosha and Dicer (103). One key exception is some intronic miRNAs, termed 
miRtrons, for which spliceosome processing replaces the Drosha cleavage step (104,105).  
Following cleavage, one or both strands of the RNA duplex (RISC; 59,60). Because 
double stranded miRNA precursors encode two potential mature miRNAs (the miRNA 
and miRNA*, also referred to as -3p and -5p arms) with distinct seed sequences and 
target profiles, strand selection is an important regulatory step in miRNA biogenesis. 
Mature miRNAs function by directing the RNA silencing machinery to partially 
complementary target mRNA transcripts. A single miRNA has the potential to regulate 
many different targets within a given cell (106,107), and thus the spatial and temporal 
regulation of miRNAs is likely to be of critical importance for the proper development 
and maintenance of many human cells and tissues. 
 The first evidence for a role for miRNAs in skin differentiation came from the 
observation that epidermal specific knockouts of Dicer1 (and later Dgcr8) in the mouse 
embryo perturb development of the epidermis and epidermal appendages (85,86). 
Subsequently, the roles of a few specific miRNAs have been examined. For example, the 
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expression of miR-203 is induced in the skin at the onset of epidermal stratification, 
where it is restricted to the suprabasal epidermis (99). Precocious expression of miR-203 
in the basal epidermis leads to a decrease in proliferative potential whereas inhibition of 
miR-203 in the suprabasal epidermis enhances proliferation (99). A key evolutionarily 
conserved target of miR-203 is the transcription factor, p63 (98,99). p63 is expressed in 
the highly proliferative keratinocytes of the basal epidermis, and p63-/- mice have no 
epidermis (108). The current model is that miR-203 expression in the suprabasal layers of 
the epidermis inhibits expression of p63, thereby suppressing the proliferative potential of 
terminally differentiating keratinocytes. Induction of miR-203 in proliferating 
keratinocytes is not sufficient to induce differentiation (98) and p63 is indeed regulated 
by other regulatory interactions, such as ubiquitination (109). However, it is likely that 
miR-203 regulation is one of many factors contributing to the establishment and 
maintenance of the stratified epidermis.  
A deeper understanding of miRNA expression in normal and diseased human skin 
would provide insights into the gene regulatory networks that are critical to the skin’s 
ability to regenerate and respond to the environment. Here, I describe miRNA expression 
profiling of 67 normal and psoriatic human skin biopsies with Next Generation 
sequencing (NGS) of small RNAs. The global landscape of miRNAs in normal and 
psoriatic skin included 717 known miRNAs and 176 cognate miRNA*s; a number of 
previously undescribed miRNA*s from known miRNA loci; known miRNA variants 
such as isomiRs and edited miRNAs; and 284 expressed novel miRNA loci.  This work 
has greatly increased our understanding of miRNA expression in human skin and 
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provides a critical foundation for functional characterization of miRNAs in normal and 
diseased human skin. 
RESULTS 
 
Next Generation deep sequencing of small RNAs 
I obtained punch biopsies from the involved (PP) and uninvolved (PN) skin of 
psoriasis patients and normal skin (NN) from healthy donors (Table 2-1). Such biopsies 
are predominantly composed of keratinocytes, but also contain cells derived from 
epidermal appendages, vasculature, dermal fibroblasts, and skin homing immune cell 
populations. I extracted total RNA with a method that preserved small RNAs and 
constructed small RNA libraries from 20 NN, 23 PN, and 24 PP biopsies. I independently 
sequenced each of the 67 libraries on the Illumina GAIIx platform, generating 1.1 billion 
raw and 670 million (M) qualified reads. Three technical replicates produced from a 
single PP skin biopsy were highly correlated in pairwise comparisons (r2=0.994, 0.990, 
and 0.989; Figure 2-1A). The lengths of the adapter-trimmed, qualified reads were 
normally distributed around an average length of 22 nt (Figure 2-1B). I aligned qualified 
reads to miRNA precursors, functional noncoding RNAs (ncRNAs), and build 37 (hg19) 
of the human genome. The number of reads and mapping proportions were roughly 
equivalent in the NN, PN, and PP skin categories (Table 2-2).  
The distribution of read alignments in the cumulative dataset (NN, PN, and PP 
combined) is summarized in Figure 2-2. Briefly, 305M (46%) reads aligned to known 
miRNA precursors, with 99.9% of these overlapping the annotated, mature miRNA or 
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miRNA* sequence ±3nt. Another 187M reads aligned to a variety of other functional 
ncRNAs such as small nucleolar RNAs, small cajal body associated RNAs, and transfer 
RNAs (data not shown). An additional 41M reads aligned to other regions of the human 
reference sequence, including intergenic, intronic, and less frequently, exonic regions. 
Novel miRNA predictions were derived from this pool of reads. The remaining 136M 
reads that did not align perfectly to any of these databases were re-mapped to known 
mature miRNAs with relaxed stringency for the analysis of global miRNA editing 
patterns, leaving only 6.6% of reads unaligned. 
Known miRNAs expressed in human skin  
We first characterized the expression of known miRNAs in skin by examining 
reads that aligned perfectly to mature miRNA sequences with a 3nt extension at either 
end. This flexibility was introduced to allow the detection of various miRNA isoforms 
that differ at the 3’ or 5’ end because of imperfect enzymatic processing, termed isomiRs 
(Figure 2-3; 110,111). While 3’ heterogeneity between isomiRs is thought to be largely 
inconsequential for target recognition, heterogeneity at the 5’ end is predicted to change 
the function of the miRNA by shifting the seed sequence. Consistent with this, 5’ 
heterogeneity was much less prevalent than 3’ heterogeneity, indicating that the vast 
majority of mature miRNAs derived from a given precursor strand have identical target 
profiles (Figure 2-3 and data not shown). 
A total of 717 mature miRNAs and 176 mature miRNA*s were represented by at 
least one read in the cumulative dataset (222). I also detected miRNA* production from 
several known miRNA loci that are currently lacking miRNA* annotations, including the 
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well-characterized keratinocyte miRNA, miR-1-1 and miR-203 (Figure 2-3 and data not 
shown). The ten miRNAs represented by the most reads in each skin category (NN, PN 
and PP) were largely overlapping and accounted for 70% of miRNA reads overall (Table 
2-3). Notably, eight of the ten most highly represented miRNAs in NN skin (let-7a/b/c/f, 
miR-143, miR-203, miR-21, and miR-24) overlapped with a set of 47 highly abundant 
miRNAs previously cloned and sequenced from murine skin (85). The two highly 
represented miRNAs in human skin that were not detected by cloning and sequencing in 
murine skin, miR-26a and miR-451, have murine homologs. Thus, their absence may 
reflect species-specific differences in skin architecture (112). Alternatively, their high 
read counts in this dataset may be due to intrinsic bias introduced by miRNA library 
preparation (113,114), resulting in an overestimation of abundance. All other highly 
expressed miRNAs in murine skin were also detected by NGS in human skin. Differential 
expression for these and other known miRNAs in psoriasis will be discussed in Chapter 
3, following a description of the global miRNA landscape in skin.  
MiRNA strand selection in skin and other human tissues  
To gain insight into miRNA strand selection in the skin, I queried the relative 
relationships of miRNA/miRNA* pairs in the dataset. By definition, miRNA* strands are 
incorporated into RISC at a lower frequency than their miRNA counterparts, and are 
thought to be rapidly degraded in the cytoplasm. However, for 12/139 pairs (9%) in the 
dataset, the miRNA* strand was more abundant than the miRNA strand in NN skin 
(Table 2-4). I validated the relative expression levels of four miRNA/miRNA* pairs with 
stem-loop quantitative real time PCR (qRT-PCR). In agreement with the digital read 
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counts, miR-431, miR-624, and miR-675 were all less abundant than their respective 
miRNA*s while miR-205 was more abundant than miR-205* (Figure 2-4A). 
I hypothesized that the high relative abundance of  the miRNA* strand for miR-
431, miR-624, and miR-675 may be skin specific, and assessed the relative abundance of 
these miRNA/miRNA* pairs in a panel of 20 human tissues. Each miRNA/miRNA* pair 
displayed a unique tissue specific expression pattern. The only pair that was ubiquitously 
expressed in all tissues was miR-675/675*. MiR-624 was undetectable by qRT-PCR in 
all tissues, so we excluded the miR-624/624* pair from subsequent analyses. miR-675* 
was more abundant than miR-675 in all tissues, although the miRNA:miRNA* ratio 
varied substantially. Thus, it appears that this miRNA has been improperly annotated 
(Figure 2-4C). In contrast, miR-431* was more abundant than miR-431 in skin, but not in 
the two other tissues where the pair was expressed (Figure 2-4B). Overall, these results 
suggest that there are mechanisms beyond thermodynamic stability that modulate tissue 
specific miRNA strand selection. 
Global patterns of miRNA editing in skin 
In order to analyze global editing patterns for known miRNAs in the skin, I 
examined reads that aligned to mature miRNAs with one mismatch. I first filtered out 
spurious editing events by removing mismatches with a low quality score or mismatches 
that were consistent with non-templated nucleotide additions at the 3’ terminus. The 
remaining single mismatch reads represented 1% of total miRNA reads, indicating that 
miRNA editing occurs at a low frequency. I next analyzed the frequencies of all possible 
single base substitutions, with particular focus on the two forms of substitutional RNA 
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editing that have been previously described in mammals: cytosine deamination (CàU 
conversions), and adenosine deamination (AàI conversions; 115,116). AàI and CàU 
conversions would appear as AàG and CàT mismatches in the sequencing dataset, 
respectively. If there were an unbiased distribution of all possible substitutions, each 
would represent ~8.3% of mismatched reads. However, I observed a clear over-
representation of AàG and CàT substitutions, which accounted for 16.3% and 12.3% 
of single mismatch reads in the cumulative dataset, respectively (p<0.0001; Figure 2-5A). 
A high relative frequency of TàC substitutions (14.7%) was also observed, although the 
underlying mechanism is unknown (Figure 2-5A).  
I next examined the frequency of single base substitutions specifically in the 
miRNA seed region, which is the primary determinant of target recognition. I found that 
the frequency of AàG substitutions in the seed region was 8.7% higher than in the full-
length miRNA (p<0.0001; Figure 2-5B). In contrast, the frequency of CàT substitutions 
in the seed region was 4.3% lower than in the full-length miRNA, restoring the frequency 
of CàT substitutions to background levels within the seed (Figure 2-5B). Taken 
together, these results suggest that mature miRNAs are subject to cytosine and adenosine 
deamination, and that adenosine, but not cytosine, deamination in the miRNA seed region 
might be an important mechanism for modulating miRNA target interactions.  
Features and genomic distribution of novel miRNAs 
Over 1200 mature human miRNAs are registered in miRBase v16. However, as 
NGS methods improve the depth and quality of miRNA profiling, much debate remains 
about the true number of human miRNAs. I computationally predicted and prioritized 
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novel miRNAs from small RNA reads that mapped to the human reference sequence on 
the basis of four criteria: 1) predicted RNA hairpin structure, 2) presence of miRNA and 
miRNA* reads aligning to the hairpin stems, 3) characteristic 3’ overhangs of the Dicer-
cleaved miRNA/miRNA* duplex, and 4) evidence of spliceosome processing for some 
predicted intronic novel miRNAs.  
I identified 284 putative novel miRNA loci which produced 284 mature miRNAs 
and 227 cognate miRNA*s that were represented by at least one read in the cumulative 
dataset (222). However, pending additional validation of loci associated with very few 
reads, the bulk of subsequent analyses focused on the 57 novel miRNA loci that were 
represented by at least four reads per library (268 total reads). 
Compared to the known miRNAs expressed in skin, novel miRNAs were 
typically represented by fewer reads. For example, the most highly represented novel 
miRNA overall, novel #117, would have ranked in the 72nd percentile for known miRNA 
read count. Collectively, the top ten most highly represented mature novel miRNAs 
accounted for less than 0.01% of miRNA reads overall (Table 2-5). In addition to these 
novel miRNAs, I validated 21 newly reported miRNA loci from other recent high-
throughput sequencing studies as well as a previously described but unannotated 
noncanonical miRNA processed from the ACA45 snoRNA (92,117,118,119,222). 
 Table 2-6 provides the genomic distribution of novel miRNAs with respect to 
intergenic regions, introns, 3’UTRs, 5’UTRs, exons, and ncRNAs compared to the 
distribution of the known miRNAs detected in skin. Novel miRNAs showed a higher 
frequency of intronic localization and a lower frequency of intergenic localization 
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compared to known miRNAs. Of the 183 novel miRNAs that aligned to introns, 68 
(37%) aligned to the 3’ end such that the 3’ end of the mature miRNA sequence was 
within 2nt of the intron-exon boundary.  Ten intronic novel miRNAs aligned to putative 
miRtrons that were less than 100nt in length. Six novel miRNAs aligned uniquely to the 
antisense strand of known miRNA loci: novel #195/miR-33b, #117/miR-203, #220/miR-
371, #273-1/miR-219-1, #273-2/miR-219-2, and #233/miR-1245.  
Comparative genomic analysis reveals a recent origin for novel miRNAs 
I used comparative genomics to assess conservation of the 57 most highly 
represented novel and recently described miRNA loci in skin (data not shown). miRNAs 
were classified as conserved if both the seed sequence and local hairpin structure were 
maintained. Interestingly, 24/47 (51%) novel and 5/10 (50%) recently described miRNAs 
were human-specific. An additional 21/47 (45%) novel and 4/10 (40%) recently 
described miRNAs were conserved in M. mulatta but not M. musculus, suggesting that 
they may be primate specific. Only three novel or recently described miRNAs were 
conserved further down the mammalian lineage: novel #116 (L. africana), novel #117 
(C.l. familiaris), and ACA45 small RNA/novel #2456 (L. africana). However, these loci 
overlapped with other conserved genomic elements: miR-203 (antisense strand), TRAF3 
3’UTR, and ACA45. Thus, conservation of these three miRNAs is likely to be an indirect 
consequence of the conservation of overlapping genomic features. The overall lack of 
conservation of novel and recently described miRNAs suggests they may have human or 
primate specific functions. However, the possibility remains that some of these newly 
evolved miRNAs are transient evolutionary intermediates that have yet to develop 
important regulatory functions. 
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Experimental validation of computationally predicted novel miRNAs  
Experimental validation of novel miRNAs is important, particularly in the face of 
low abundance and poor conservation. I used quantitative RT-PCR (qRT-PCR) to 
validate the expression and processing of two novel and one recently described miRNAs: 
novel #107, novel #117, and miR-3613/novel #115. I found that all three miRNAs 
yielded a PCR product of the same length as an abundant known miRNA, miR-203, in 
NN skin, indicating that these novel miRNAs are endogenously expressed in skin (Figure 
2-6A). To further confirm that the predicted novel miRNA precursors were recognized by 
the human miRNA processing machinery, I ectopically expressed the novel #107, novel 
#117, and miR-3613/novel #115 precursors in HEK293 cells. Each over-expressed 
precursor yielded a mature miRNA product that was at a substantially higher level than 
that seen in wild-type cells indicating that these novel miRNA precursors were indeed 
processed into mature miRNAs in human cells (Figure 2-6B). Variability in the degree of 
over-expression from each novel miRNA construct probably reflects differences in 
precursor processing efficiency.  
 I next assessed whether these three novel miRNAs were skin-specific by 
performing qRT-PCR on RNA from 20 different human tissues. Each miRNA was 
expressed in other human tissues at highly variable levels, indicating that these miRNAs 
are not skin-specific and are subject to tissue-specific transcriptional or post-
transcriptional regulation (Figure 2-6C).  
Novel #117 was of particular significance because it appeared to be an antisense 
miRNA derived from the miR-203 locus (Figure 2-7A). The existence of #117 as a bona 
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fide miRNA was confirmed by several lines of evidence. First, it displayed all of the 
features of miRNA biogenesis including hairpin formation, the presence of miRNA and 
miRNA* reads, and 3’ overhangs on the highest likelihood miRNA/miRNA* duplex 
(Figure 2-7B,C). Second, ectopic expression of the #117 locus in HEK293 cells (which 
do not endogenously express this miRNA) resulted in two distinct northern blot bands of 
~65nt and ~22nt, a pattern that is consistent with the expected sizes of the precursor and 
mature miRNA species, respectively (Figure 2-7D). Third, ectopically expressed #117 
co-immunoprecipitated with Argonaute 2 (Ago2), a core component of the RISC 
complex, in HEK293 cells, suggesting that the mature miRNA is functionally competent 
(Figure 2-7E). Fourth, there was no correlation between the expression patterns of miR-
203 and novel #117 in a panel of human tissues (Figure 2-7F). Taken together, these 
results support the transcription and processing of two distinct miRNAs derived from the 
sense and antisense strands at this locus. Henceforth, I will refer to novel #117 as miR-
203-AS. Notably, miR-203 and miR-203-AS do share sequence similarity, but the 
imperfect palindromic nature of the locus leads to the production of distinct sense and 
antisense products. Of particular importance is a single base difference in their seed 
regions, which would indicate that the two miRNAs have distinct target profiles. 
Predicted targets of miR-203-AS are listed in Table 2-7. Because miR-203 is more 
abundant than novel #117 in all human tissues, and has long been recognized as a 
miRNA, we conclude that miR-203-AS is the minor product derived from this locus.  
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DISCUSSION 
Deep sequencing of small RNAs has made it possible to comprehensively define 
the miRNAome of human tissues. I have leveraged this technology in skin to produce the 
largest small RNA dataset from any human tissue to date. The depth of sequencing 
allowed detection of low abundance, novel, and edited miRNAs with unparalleled 
sensitivity. 
New variation in known miRNAs  
Known miRNAs detected in this study exhibited a striking amount of subtle 
variation. Most notably, the high prevalence of isomiRs may be indicative of stochastic 
or regulated heterogeneity in miRNA processing. While 3’ isomiRs, which were widely 
detected in this study, would be inconsequential for target recognition, the possibility 
remains that such isomiRs would be differentially incorporated into the RISC complex 
and/or targeted for specific modifications. Indeed, the adenylation and uridylation of 
miRNAs (not analyzed in this study) appear to modulate their stability in mammalian 
cells (120). Secondly, the analysis of miRNA* sequences in this dataset indicates that 
some miRNA* sequences do accumulate in cells, and thus may not always be subject to 
rapid degradation. Moreover, the variability in miRNA* abundance that I observed point 
to thermodynamic features and sequence content of individual miRNAs as well as tissue-
specific regulatory mechanisms as determinants of miRNA strand selection. 
Significance of miRNA editing 
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Analysis of single mismatch miRNA reads led to the observation that miRNAs 
are subject to adenosine and cytidine deamination. There are various examples of 
functionally important AàI editing of miRNAs catalyzed by adenosine deaminases 
acting on RNA (ADARs; 121,122). For example, targeted AàI editing within the seed 
region of miR-376 in some human tissues alters the recognition of mRNA targets (122). 
The role of cytidine deaminases, such as APOBECs, in miRNA editing is not well 
understood.  However, a recent meta-analysis of small RNA sequences derived from O. 
sativa and A. thaliana revealed a similar over-representation of CàT substitutions, 
suggesting that cytidine deamination may be a predominant mechanism for miRNA 
editing in eukaryotes (123). Further experiments will be required to determine whether 
the majority of cytidine deamination events are spontaneous or enzymatically catalyzed.  
Novel miRNA identification  
I have reported 284 putative novel miRNA genes, and 22 recently described 
miRNA genes that were expressed in skin, three of which were subjected to extensive 
experimental validation. Recently described miRNAs were initially characterized as 
novel, but were independently annotated by other groups while I was analyzing and 
validating my findings. These annotations were largely due to the recent publication of 
miRNA profiles from melanoma cell lines and tissues of the female reproductive tract, 
which each applied similar prediction criteria as the present study (92,117,119). The 
partial overlap between this study and others provides reassuring validation of my NGS-
based in silico method, and suggests that the unprecedented size of our dataset was 
responsible for the identification of such a large number of completely novel miRNAs. 
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 The majority of novel miRNA loci were poorly conserved, which is perhaps not 
surprising, based on the fact that some miRNA discovery studies have relied on 
conservation as a prediction criterion. However, in more recent NGS-based studies as 
well as the present study, conservation was excluded as a prediction criterion in order to 
obtain a comprehensive profile of all miRNAs that are expressed in human skin, 
including those that may be newly evolved or evolutionarily transient (92,117,119).  
One small class of novel miRNAs was comprised of miRNAs derived from the 
antisense strand at known miRNA loci. To date, only a few known miRNA loci in 
humans, such as miR-103-1 and miR-103-2, have antisense miRNAs registered in 
miRBase. However, this phenomenon has been described in detail at the miR-iab-4 locus 
in D. melanogaster. Both miR-iab-4 and its antisense counterpart miR-iab-8 regulate Hox 
genes during larval development, but they are functionally distinct based on their 
discordant expression patterns and unique target profiles (124). While there were many 
antisense reads present in my dataset, most were consistent with RNA degradation, 
potential siRNA production, or artifacts of palindromic sequence. However, six antisense 
miRNAs reported in this study showed strongly convincing features of miRNA 
biogenesis. These sense and antisense miRNAs could functionally interact to create 
complex regulatory networks or feedback loops.  
The largest class of novel miRNAs aligned to introns, which has important 
implications for biogenesis and function. MiRtrons were first described in Drosophila as 
~60nt introns that resembled pre-miRNAs, and thus do not require Drosha for biogenesis 
(105). While such small introns are rare in humans, I identified ten putative novel 
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miRtrons ranging from 55-94nt in length. The remaining intronic miRNAs aligned to 
longer introns, but were biased towards 3’-5’ intron-exon boundaries. This non-random 
distribution of intronic novel miRNAs strongly supports spliceosome involvement in the 
processing of some human miRNAs. The processing of intronic miRNAs may also vary 
with the expression of alternatively spliced transcripts. 
Conclusions and future directions 
 Further characterization of the miRNA landscape in skin should include editing 
analysis for individual miRNAs at the single nucleotide level. Additionally, it would be 
interesting to investigate whether the novel miRNAs described in this chapter were 
produced by the canonical Drosha/Dicer pathway, or whether some of them may rely on 
noncanonical biogenesis pathways, such as the Ago2 pathway which generates the 
abundant miR-451 in skin (125). The functionality of novel miRNAs should be 
confirmed by RISC loading assays. Overall, the global patterns of miRNA expression 
described in this chapter provide an unprecedented glimpse into the breadth and diversity 
of miRNA expression in an adult human tissue. This work also laid the foundation for the 
characterization of miRNA expression and function in psoriatic skin, described in 
Chapters 3 and 4. 
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MATERIALS AND METHODS 
Samples. 4-6mm punch skin biopsies were collected from healthy controls and 
the uninvolved and involved skin of PS patients. PS patients enrolled in this study 
received no systemic, photo, or topical therapy in the four weeks prior to sample 
collection. Biopsies were stored in RNAlater (Qiagen) at -80°C prior to RNA extraction. 
Small RNA library preparation and sequencing. RNA was extracted with the 
miRNeasy Mini Kit (Qiagen), with on-column DNase I digestion. RNA was prepared for 
sequencing on the Illumina GAIIx platform with the Small RNA Sample Prep Kit 
(Illumina) according to manufacturer’s instructions (protocol v1.5). This protocol 
required the use of a proprietary 3’ adapter that has a high affinity for Dicer cleavage 
products. Briefly, 3’ and 5’ adapters were ligated to 1ug total RNA. cDNA was 
synthesized with SuperScript II Reverse Transcriptase (Invitrogen) and subjected to  12 
cycles of PCR amplification with high fidelity Phusion Polymerase (Finnzymes Oy). 
Each library was loaded on a single Illumina lane at 20pM and subjected to 36 cycles of 
sequencing. 
Read processing and mapping. Each deep sequencing library was processed 
independently. Reads with a 3’ adapter substring less than 6nt or trimmed sequence 
length less than 17nt were removed from the dataset. Trimmed reads were mapped to 
multiple human sequencing databases with Bowtie: miRNA precursors (miRBase v.16, 
http://www.mirbase.org/ftp.shtml), ncRNAs (fRNAdb, 
 39 
http://www.ncrna.org/frnadb/download), and the hg19 build of the human genome 
(UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/hgTables?command=start) 
(43,44,45,126,127,128,129).  Reads that mapped to miRNA precursors were attributed to 
mature miRNAs if they aligned to the annotated mature sequences with 3nt up- and 
downstream extensions.  
Novel miRNA prediction. Qualified reads that aligned to the hg19 build of the 
human genome were subjected to our novel miRNA prediction pipeline. Any reads that 
mapped to previously described miRNA loci were removed, and loci that shared adjacent 
reads within a gap ≤30nt were merged. For each locus, a series of overlapping DNA 
sequence segments was extracted for secondary structure analysis with RNAfold 
(http://www.tbi.univie.ac.at/~ivo/RNA/; 130,131,132). The starting sequence segment 
extended 220nt upstream of the locus, and subsequent segments were extracted by a 
sliding window of 250nt, with an increment of 100nt, until the window reached 220nt 
downstream of the sequence reads. Segments lacking stems of at least 18nt and segments 
lacking reads that mapped to any of their stems were excluded. Candidate miRNAs were 
prioritized based on 1) occurrence of sequencing reads on the stem of a predicted hairpin 
structure (minimum free energy less than -18kcal/mol); 2) presence of miRNA* reads on 
the opposite stem of the hairpin; 3) presence of 3’ overhangs on the highest likelihood 
miRNA/miRNA* duplex; and 4) evidence of spliceosome-mediated precursor processing 
based on alignment to intron-exon boundaries. 
Novel miRNA conservation. Homology searches were performed in eight 
species: M. mulatta, M. musculus, C.l. familiaris, L. africana, M. domestica, G. gallus, X. 
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tropicalis, and D. rerio. The novel miRNA precursor sequences, defined as the maximal 
extension of sequences bearing the stem-loop structure, were mapped to each species’ 
genome using blastn (http://blast.ncbi.nlm.nih.gov/Blast.cgi/) with a minimal word-size 
of seven. Blastn hits that were reported in any given species shared greater than 90% 
sequence similarity and had a ratio of alignment length to the precursor length greater 
than 0.9. Secondary structure of aligned sequences was determined with RNAfold. 
Aligned sequences were classified as conserved novel miRNAs if the following criteria 
were met: 1) the highest likelihood secondary structure was a hairpin with a minimum 
free energy less than -18kcal/mol, 2) the mature miRNA sequence was derived from the 
hairpin stem, and 3) the miRNA seed region (nt 2-7) was perfectly conserved. 
miRNA qRT-PCR. qRT-PCR of mature miRNAs was performed with TaqMan 
miRNA assays according to manufacturer’s instructions (Life Technologies). Briefly, 5ng 
of total RNA was reverse transcribed in a 7.5ul reaction with the TaqMan MicroRNA 
Reverse Transcription Kit (Life Technologies). 0.67ul of cDNA was added to triplicate 
10ul PCR reactions. PCR was performed on a 7900HT thermocycler (Life Technologies). 
MiRNA expression was normalized to the endogenous snoRNA, Z30. Relative 
expression levels were calculated according to the 2-ΔΔCt method as follows: 100*2((Ct Z30)-
(Ct miRNA)) (133). Significance was determined with one way ANOVA and post-hoc two 
tailed t-tests. 
MiRNA expression constructs. MiRNA over-expression constructs were 
generated from the pEP-miR cloning and expression vector (Cell Bio Labs). Briefly, 
miRNA precursors ±100nt were amplified from genomic DNA. PCR products were 
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cloned into the BamHI and NheI sites of the vector. Transformants were selected on 
1ug/ml ampicillin and selected transformants were validated by Sanger sequencing. 
Transfections. HEK293 cells were cultured in DMEM supplemented with 2mM 
L-glutamine, 10mg/ml penicillin-streptomycin, and 10% fetal bovine serum at 37°C and 
5% CO2. Transfections were performed in triplicate. 24 hours prior to transfections, 
1x105 cells were plated in each well of a 24-well plate. Transfections were performed 
with TransIT-LT1 transfection reagent according to manufacturer’s instructions (Mirus). 
Briefly, 750ng pEP-miR and 3.75ul LT-1 were incubated in 46.25ul RPMI for 30 min at 
22°C before treatment. Cells were collected 48 hours post-treatment. 
miRNA northern blots. 30ug of total RNA was mixed with formamide loading 
dye and incubated at 65˚C for 20 min. Samples were loaded on a pre-warmed 12% 
denaturing polyacrylamide gel (Sequagel), and run at 100V until bromphenol blue 
reached the bottom of the gel. RNA was transferred onto a Genescreen Plus membrane 
(Perkin Elmer) with a Trans-Blot SD semi-dry transfer cell (Bio-Rad) at 250mA for 15 
min. The membrane was baked for one hour at 80˚C, pre-hybridized for two hours in 
PerfectHyb Plus (Sigma) at hybridization temperature, and hybridized overnight with a P-
32 labeled DNA probe. miR-203-AS probe sequence: 5’-
CCAGTGGTTCTTAACAGTTCAA-3’. The membrane was washed three times in 0.1X 
SSC, 0.1% SDS at hybridization temperature, and exposed for three days. For input 
control, the membrane was stripped with two 20 min applications of boiled 0.1% SDS 
with gentle agitation at 22˚C, and re-hybridized with a P-32 labeled U6 snRNA LNA 
probe (Exiqon). 
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RNA binding protein immunoprecipitation-PCR (RIP-PCR). HEK293 cells 
were transfected with pEP-miR-null or pEP-miR-novel #117 constructs as described 
above, except that transfections were scaled up to generate one 10cm plate per 
immunoprecipitation. Cells were washed three times in 1X PBS and UV crosslinked once 
for 400mJ/cm2 and again for 200mJ/cm2, with gentle agitation in between. Cells were 
pelleted by centrifugation at 4000 rpm for 5 min at 4°C. Cell pellets were washed once in 
1X PBS and resuspended in 200ul 1X PBS, 0.1% SDS, 0.5% deoxycholate, 0.5% nonidet 
P-40, supplemented with 1U/ul RNasin (Promega) and 1X Complete Protease Inhibitor 
Cocktail (Roche). Lysates were incubated on ice for 10 min, and cleared by 
centrifugation at 10000 rpm for 10 min at 4°C. Each cleared lysate was added to 50ul 
protein G-coated Dynabeads (Invitrogen) which had been previously bound to 5ug anti-
mouse Ago2/eIF2C2 monoclonal antibody (Abcam) or normal rabbit IgG (Cell Signaling 
Technology), according to the manufacturer’s protocol, and incubated for 4 hours at 4°C 
with rotation. Beads were washed three times with 1X PBS, 0.1% SDS, 0.5% 
deoxycholate, 0.5% nonidet P-40 and three times with 5X PBS, 0.1% SDS, 0.5% 
deoxycholate, 0.5% nonidet P-40. RNA extraction and qRT-PCR were performed as 
described above, except that relative abundance of novel #117 in the Ago2 IP sample was 
calculated relative to the IgG IP sample, in lieu of an endogenous control. 
Western blots. 10ul of 2X SDS reducing buffer was added directly to washed 
beads following immunoprecipitation, and incubated at 95°C for 5 min. Samples were 
loaded on a pre-warmed 4-20% polyacrylamide gel, run at 200V for 30 min, and wet 
transferred for 1 hour at 100V onto a 0.45um nitrocellulose membrane. The membrane 
was blocked in 1X TBST, 5% milk at 22°C for 1 hour. A 1:500 dilution of Ago2/eIF2C 
 43 
monoclonal antibody (Abcam) in 1X TBST, 5% milk was applied to the membrane, and 
incubated at 22°C for 3 hours. The membrane was washed three times for 10 min in 1X 
TBST, 5% milk. A 1:5000 dilution of HRP-conjugated secondary antibody in 1X TBST, 
5% milk was applied  to the membrane, and incubated at 22°C for 1 hour. The membrane 
was washed three times for 10 min in 1X TBST, 5% milk. The blot was developed with 
1ml of Supersignal West Femto Chemiluminescent substrate (Thermo Scientific). 
MiRNA editing analysis. Reads that aligned to mature miRNAs with one 
mismatch were subjected to filters prior to editing analysis. Reads containing a low 
quality mismatch (p[sequencing error]>0.05) based on the single base Illumina quality 
score were removed. 3’ terminal NàA or NàT mismatches were also removed. From 
the remaining pool of one mismatch reads, the relative frequencies of all possible 
substitutions at positions 1-20 of the miRNA relative to the 5’ end were calculated. 
Significance was determined with Pearson’s chi-squared test. 
Data deposition. All 76 small RNA sequencing libraries from psoriatic lesion and 
normal human skin biopsy samples have been deposited into NCBI/GEO databases under 
GEO31037. 
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Table 2-6. Distribution of novel and known miRNA loci with respect to overlapping 
genomic elements. 
 
 
 
 
 
 
 
 
 
 
Genomic element No. of novel loci % Novel loci % Known loci
Intergenic 53 18.66 34.56
Intronic- center 105
Intronic- 3' boundary 68
Intronic- 5' boundary 0
MiRtron (<100bp intron) 10 64.44 50.53
3' UTR 14
5' UTR 2 5.63 4.04
Coding exon 7 2.46 1.93
Non-coding RNA 2 0.70 0.00
Intronic (antisense) 14
3' UTR (antisense) 2
5' UTR (antisense) 0
Coding exon (antisense) 1
miRNA (antisense) 6 8.10 8.95
Table 2-6. Distribution of novel and known miRNA loci with respect to 
overlapping genomic elements
 52 
 
Table 2-7. TargetScan Custom predicted targets of miR-203-AS. 
 
 
 
 
 
 
 
 
 
 
 
Predicted target Description PP/NNa,b
MECP2 methyl CpG binding protein 2 (Rett syndrome) --
SYNGR1 synaptogyrin 1 --
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 --
C1orf52 chromosome 1 open reading frame 52 --
DACH1 dachshund homolog 1 (Drosophila) -2.01
DNAJB12 DnaJ (Hsp40) homolog, subfamily B, member 12 --
ETF1 eukaryotic translation termination factor 1 --
FBXO11 F-box protein 11 --
FBXO21 F-box protein 21 --
GRM3 glutamate receptor, metabotropic 3 --
HIPK1 homeodomain interacting protein kinase 1 --
HOXA7 homeobox A7 --
IL13 interleukin 13 --
KLHL14 kelch-like 14 (Drosophila) --
LRRTM2 leucine rich repeat transmembrane neuronal 2 --
MTF1 metal-regulatory transcription factor 1 --
PLAG1 pleiomorphic adenoma gene 1 --
PRKCB1 protein kinase C, beta 1 --
RARA retinoic acid receptor, alpha --
SFRS1 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) --
THRAP2 thyroid hormone receptor associated protein 2 --
TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) -2.11
TOX3 TOX high mobility group box family member 3 --
UHMK1 U2AF homology motif (UHM) kinase 1 --
UNQ1887 signal peptide peptidase 3 --
ZC3H11A zinc finger CCCH-type containing 11A --
AGPAT3 1-acylglycerol-3-phosphate O-acyltransferase 3 --
ARID1A AT rich interactive domain 1A (SWI-like) --
ARID2 AT rich interactive domain 2 (ARID, RFX-like) --
BCL7A B-cell CLL/lymphoma 7A --
CALM1 calmodulin 1 (phosphorylase kinase, delta) --
CAST calpastatin --
CDON Cdon homolog (mouse) -2.06
CNTNAP2 contactin associated protein-like 2 --
COX8A cytochrome c oxidase subunit 8A (ubiquitous) --
CREBBP CREB binding protein (Rubinstein-Taybi syndrome) --
CREBZF CREB/ATF bZIP transcription factor --
CRTAP cartilage associated protein --
CTSC cathepsin C 2.04
DACT3 dapper, antagonist of beta-catenin, homolog 3 (Xenopus laevis) --
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) --
FOSB FBJ murine osteosarcoma viral oncogene homolog B --
GADD45G growth arrest and DNA-damage-inducible, gamma --
GGA2 golgi associated, gamma adaptin ear containing, ARF binding protein 2 --
GLS glutaminase --
GNAI1 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 --
GPR56 G protein-coupled receptor 56 --
HIP2 huntingtin interacting protein 2 --
HMGN2 high-mobility group nucleosomal binding domain 2 --
HRBL HIV-1 Rev binding protein-like --
LASS1 LAG1 homolog, ceramide synthase 1 (S. cerevisiae) --
LFNG LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase --
MAFG v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) --
MAPKAPK3 mitogen-activated protein kinase-activated protein kinase 3 2.01
MBNL1 muscleblind-like (Drosophila) --
MIPOL1 mirror-image polydactyly 1 --
MTMR14 myotubularin related protein 14 --
MTMR4 myotubularin related protein 4 --
NLRP3 NLR family, pyrin domain containing 3 --
NUP153 nucleoporin 153kDa --
PHF17 PHD finger protein 17 --
PICALM phosphatidylinositol binding clathrin assembly protein --
PTER phosphotriesterase related --
ProSAPiP1 ProSAPiP1 protein --
RIMS1 regulating synaptic membrane exocytosis 1 --
RNF139 ring finger protein 139 --
SCAMP1 secretory carrier membrane protein 1 --
SEPT3 septin 3 --
SEPT5 septin 5 --
 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 --
SHANK3 SH3 and multiple ankyrin repeat domains 3 --
SLC4A1AP solute carrier family 4 (anion exchanger), member 1, adaptor protein --
SNIP SNAP25-interacting protein --
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 --
STX5 syntaxin 5 --
TMEM91 transmembrane protein 91 --
TNF tumor necrosis factor (TNF superfamily, member 2) --
TRIM3 tripartite motif-containing 3 --
TRIM9 tripartite motif-containing 9 --
TRMT5 TRM5 tRNA methyltransferase 5 homolog (S. cerevisiae) --
ULK2 unc-51-like kinase 2 (C. elegans) --
XAB1 XPA binding protein 1, GTPase --
YPEL2 yippee-like 2 (Drosophila) --
ZNF512B zinc finger protein 512B --
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 --
ABHD2 abhydrolase domain containing 2 --
AKAP13 A kinase (PRKA) anchor protein 13 --
ANKRD15 ankyrin repeat domain 15 --
CIT citron (rho-interacting, serine/threonine kinase 21) --
FZD4 frizzled homolog 4 (Drosophila) --
GSC goosecoid --
HNRPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 --
INHBB inhibin, beta B (activin AB beta polypeptide) --
KPNA5 karyopherin alpha 5 (importin alpha 6) --
MAP3K4 mitogen-activated protein kinase kinase kinase 4 --
MNT MAX binding protein --
NHS Nance-Horan syndrome (congenital cataracts and dental anomalies) --
PAX3 paired box gene 3 (Waardenburg syndrome 1) --
PHF15 PHD finger protein 15 --
PTBP1 polypyrimidine tract binding protein 1 --
PTK2B PTK2B protein tyrosine kinase 2 beta --
RAI16 retinoic acid induced 16 --
RND2 Rho family GTPase 2 --
SCN1A sodium channel, voltage-gated, type I, alpha subunit --
SIX3 sine oculis homeobox homolog 3 (Drosophila) --
SLC24A3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 --
SLC9A1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 (antiporter, Na+/H+, amiloride sensitive) --
SMC1A structural maintenance of chromosomes 1A --
TFAP2A transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) --
THAP11 THAP domain containing 11 --
TMEM183A transmembrane protein 183A --
TMEM183B transmembrane protein 183B --
TSC22D1 TSC22 domain family, member 1 --
VEGFA vascular endothelial growth factor A --
YTHDF3 YTH domain family, member 3 --
bFrom Gudjonsson et al., 2010. "--" indicates that the transcript is not reported as differentially expressed in this study
aNormal skin, NN; Involved psoriatic skin, PP.
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Figure 2-1. Quality control for small RNA sequencing. A) Pairwise comparisons of 
normalized digital read counts in three technical replicates. RNA derived from a psoriatic 
skin biopsy  “Inv #17” was prepared and sequenced independently three times. Each 
pairwise comparison is plotted separately. Numerical axes represent normalized digital 
read counts for indicated sample. B) Length distribution of trimmed small RNA reads in 
normal, uninvolved psoriatic, and involved psoriatic skin. 
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Figure 2-2. Flowchart describing alignment of small RNA reads to human sequence 
databases. All reads aligned with zero mismatches, unless relaxed parameters are 
indicated (i.e. 1MM=one mismatch). MiRNA* refers to mature miRNAs generated from 
the minor strand of the double stranded miRNA precursor. ncRNA refers to non-coding 
RNAs, such as tRNAs, piwi-interacting RNAs, snoRNAs, etc. in the H. sapien functional 
RNA database (see Materials and Methods). 
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Figure 2-3. Example of small RNA reads aligning to a known miRNA precursor 
(miR-1-1). The mature miR-1-1 sequence, as annotated in miRBase, is underlined.  The 
minimum free energy secondary structure is denoted by dot-bracket notation, where “(“ 
and “)” represent complementary bases and “.” represent non-complementary bases. 
Numbers in the right column represent the abundance of digital read counts 
corresponding to each sequence. 
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Figure 2-4. miRNA strand selection in skin and other human tissues. A) Relative 
expression of selected miRNAs and their cognate miRNA*s in normal human skin. 
Relative expression of B) miR-431 and miR-431* and C) miR-675 and miR-675* in skin 
and other human tissues in which it was detected. Red lines indicate relative level 
miRNA strand/relative level miRNA* strand in each tissue type. Dotted lines indicate 
threshold at which the abundance of the miRNA* strand exceeds that of the miRNA 
strand. Normal skin, NN; Uninvolved psoriatic skin, PN; Involved psoriatic skin, PP. 
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Figure 2-5. Patterns of miRNA editing in normal, uninvolved psoriatic, and involved 
psoriatic skin. Global frequencies of single base pair substitutions detected in (A) full 
length miRNAs and (B) miRNA seed regions in NN, PN, and PP skin. Normal skin, NN; 
Uninvolved psoriatic skin, PN; Involved psoriatic skin, PP. 
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Figure 2-6. Experimental validation of novel miRNAs with qRT-PCR. (A) 
Endogenous expression of mature novel miRNAs in skin in the presence of RNA and 
reverse transcriptase, RNA only, or reverse transcriptase only. (B) Levels of mature novel 
miRNAs following ectopic expression of novel miRNA loci with “pep-miR” vectors in 
HEK293 cells (see Materials and Methods). Relative expression was calculated with 
respect to the endogenous snoRNA Z30 (see Materials and Methods). “X” refers to the 
fold change in mature miRNA expression following ectopic expression of the precursor. 
(C) Endogenous expression levels of novel miRNAs in 21 human tissues. Relative 
expression was calculated with respect to the endogenous snoRNA Z30 (see Materials 
and Methods). 
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Figure 2-7. Features of a validated antisense miRNA locus (miR-203/novel #117). 
(A) Alignment of the dominant known and novel small RNA reads derived from the miR-
203 locus. Forward strand sequence encoding miR-203 is indicated. The 3p and 5p arms 
of novel #117 correspond to the miRNA and miRNA* strands, respectively. (B) 
Predicted minimum free energy secondary structure of novel #117. Red circles represent 
the dominant mature miRNA sequence. Yellow circles represent the dominant mature 
miRNA* sequence. (C) Distribution of small RNA reads along the length of the novel 
#117 precursor. (D) Northern blot showing the accumulation of precursor and mature 
forms of novel #117 following ectopic expression of the #117 locus with a “pep-miR” 
 62 
vector in HEK293 cells (see Materials and Methods). The endogenous U6 snRNA served 
as an input control. (E) Co-immunoprecipitation (IP) of ectopically expressed novel #117 
with Argonaute 2 (Ago2). Left, western blot showing specificity of the Ago2 antibody. 
Top right, relative abundance of novel #117 in Ago2  IP compared to IgG control as 
indicated by qRT-PCR. Bottom right, RT-PCR bands corresponding to Ago2 and IgG IPs 
quantified in top right panel. (F) Correlation of miR-203 and novel #117 expression in 
NN (green circle), PN (yellow circle), and PP skin (red circle), and other human tissues 
(black circles). Relative expression was calculated with respect to the endogenous 
snoRNA Z30. 
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Differential expression of known and novel miRNAs in psoriatic skin 
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ABSTRACT 
 
 
 
Psoriasis is a chronic, inflammatory skin disease for which there is currently no 
cure. Transcriptome analyses have revealed ~1300 mRNA expression changes in 
psoriatic skin, but much less is known about the role of microRNAs (miRNAs). I 
generated small RNA libraries from human skin biopsies with Next Generation 
sequencing (as described in Chapter 2), and performed digital gene expression analysis 
on 253, 212 and 204 million qualified reads from normal, uninvolved psoriatic and 
involved psoriatic skin, respectively. Eighty known and 18 novel miRNAs were two- to 
42-fold differentially expressed in psoriatic skin, a subset of which were validated and 
further analyzed by qRT-PCR. Of particular significance was 1) the 2.7-fold upregulation 
of a validated novel miRNA derived from the antisense strand of the miR-203 locus 
(miR-203-AS), which plays a role in epithelial differentiation; 2) the differential 
expression of several intragenic miRNAs encoded within host genes that have been 
implicated in psoriasis; and 3) the response of some differentially expressed miRNAs to 
treatment with the TNF-alpha antagonist adalimumab. Overall, these analyses revealed 
dramatic changes in global miRNA expression, reflecting defects in keratinocytes, 
immune cells, and vasculature. 
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INTRODUCTION 
 
Psoriasis is a chronic, inflammatory skin disease that affects 2-3% of Caucasians, 
and is less common in other populations (7). In involved psoriatic skin, hyperproliferation 
and defective terminal differentiation of keratinocytes impair barrier formation, 
infiltration of activated immune cells leads to inflammation, and interactions between the 
two cell types perpetuate disease (5,134). There is currently no cure for psoriasis, 
although some patients respond well to treatment with systemic biologics, such as the 
TNF-alpha antagonist adalimumab (135,136,137). There are over 1,000 differentially 
expressed transcripts in involved psoriatic (PP) skin compared to normal (NN) skin; a 
small subset of these are also differentially expressed in uninvolved psoriatic (PN) versus 
NN skin(18,19). However, much less is known about the expression of miRNAs in 
psoriatic skin, which may serve important regulatory functions.  
 Early microarray-based microRNA (miRNA) profiling studies have implicated a 
small number of miRNAs in psoriasis pathogenesis based on their differential expression 
in psoriatic skin (96,97). However, such array-based approaches are insensitive to low 
abundance small RNA species and limited to miRNAs that were previously known in 
humans or other species. In chapter 2, I described the global landscape of known and 
novel miRNAs expressed in human skin as determined by Next Generation sequencing 
(NGS). Here, I describe the differential expression of miRNAs in PP, PN, and NN skin as 
assessed by digital gene expression (DGE) analysis of Next Generation sequencing 
(NGS) reads and quantitative real-time PCR (qRT-PCR). These analyses revealed 
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dramatic changes in global miRNA expression, reflecting defects in keratinocytes, 
immune cells, and vasculature.  
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RESULTS 
 
Altered expression of known and novel miRNAs in psoriatic skin   
I generated small RNA libraries from 20 normal (NN), 23 uninvolved (PN), and 
24 involved (PP) skin biopsies, as described in chapter 2. I detected expression of 893 
known mature miRNAs, and 306 novel or recently described miRNA loci in the skin. I 
performed DGE analysis on these miRNAs to compare their expression in NN, PN, and 
PP skin. First, I normalized the number of miRNA reads to the total number of reads that 
mapped to the reference sequence in each skin category. Next, I implemented a detection 
threshold of 268 raw reads in the cumulative dataset (an average of four reads per 
individual library), which was empirically adjusted to allow the lowest detection 
threshold while minimizing noise. This resulted in a set of 512 known, 13 recently 
described, and 47 novel, mature miRNAs and miRNA*s (222). 
Ninety-eight miRNAs, including 18 novel miRNAs, were significantly 
differentially expressed with a ±2-fold change in at least one comparison: PP/NN, PP/PN, 
or PN/NN (Bonferroni adjusted p<0.05; Table 3-1). Seventy-one miRNAs were 
upregulated while 27 were downregulated. This is substantially greater than the number 
of miRNAs previously shown to be ±2-fold differentially expressed in psoriatic skin from 
two previous microarray analyses (96,97). The majority of miRNA expression changes 
occurred in PP skin compared to both PN and NN (Figure 3-1). Thus, clustering of 
samples based on the expression of the top 98 differentially expressed miRNAs 
completely distinguished PP from PN and NN skin (Figure 3-1). Only five miRNAs were 
±2-fold differentially expressed between PN and NN skin: miR-31, miR-206, miR-509-
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5p, miR-675*, and novel #122. These findings are consistent with mRNA expression 
changes that have been described in psoriatic skin, in that there are more upregulated than 
downregulated transcripts and relatively few changes between PN and NN skin (18,19). 
Many additional miRNAs exhibited more modest fold changes in psoriatic skin. The fold 
changes for all of the known and novel miRNAs detected in skin are included in 
Appendices A and B. I observed only minor differences in the frequencies of AàG and 
CàT substitutions, (which would represent putative RNA editing events) between NN, 
PN, and PP skin (Figure 2-5). Still, the possibility remains that a small set of individual 
miRNAs are subject to differential editing in psoriatic skin. 
MiRNAs that were derived from the same precursor were frequently co-regulated. 
There were 66 differentially expressed miRNAs/miRNA*s for which a cognate 
miRNA*/miRNA also passed the detection threshold for DGE. Eighty percent of these 
cognate strands exhibited a similar expression trend in the DGE dataset (±1.4-fold cut-
off). One exception was miR-431/431*. miR-431 was upregulated in PN and PP skin 
compared to NN (3.2 and 3.9 fold, respectively) while miR-431* remained unchanged 
(1.2- and 1.0-fold). I subsequently validated this finding with stem-loop qRT-PCR 
(Figure 3-2). Thus, a subset of differentially expressed miRNAs may exhibit altered 
strand selection in psoriatic skin. 
 
qRT-PCR validation of a subset of differentially expressed miRNAs 
I selected 12 additional differentially expressed miRNAs for independent 
validation with stem-loop qRT-PCR, and confirmed that 7/9 known and 3/3 novel 
miRNAs were significantly differentially expressed in PP skin compared to PN or NN 
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(Figure 3-2). The two miRNAs that did not validate (miR-206 and miR-205*) showed 
similar trends as the DGE analysis, but the differences were not significant (p=0.10 and 
0.09, respectively). Changes between NN and PN skin also validated poorly, presumably 
because the fold changes were typically smaller. Overall, qRT-PCR levels and 
normalized digital read counts for the differentially expressed miRNAs were highly 
correlated (R2=0.979). 
 
Functional annotation of miRNAs that are differentially expressed in psoriatic skin 
Some of the most dramatically upregulated miRNAs in psoriatic skin included the 
abundant miRNAs miR-21, miR-31, and miR-378, which belong to a class of pro-
angiogenic miRNAs termed “angiomiRs”; miR-155, miR-142-3p, and miR-146a, which 
regulate various hematopoietic cell fate decisions (89); miR-211, which inhibits 
melanoma metastasis (91,95); and the novel miR-203-AS, which was described in 
Chapter 2 (Figure 2-7). Downregulated miRNAs included miR-675* and miR-483-3p, 
which lie in the imprinted H19-IGF2 locus for which our lab has observed small but 
reproducible methylation increases in psoriatic skin (138,139); and miR-124, which is 
frequently epigenetically silenced in cancer (140,141). The downregulation of miR-483-
3p is particularly significant because of its known role in the termination of wound 
healing in the skin (142). None of the differentially expressed miRNA genes overlapped 
with previously described psoriasis susceptibility loci (29,143), suggesting that miRNAs 
are more likely to function as downstream factors in disease pathogenesis. 
 
Host gene expression for differentially expressed intronic miRNAs  
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Many differentially expressed miRNAs were intragenic, and these miRNAs may 
be under partial or full control of their host gene promoters. Several of these miRNAs are 
derived from genes that are likely to be involved in psoriasis pathogenesis (Table 3-2). 
Most notably, there were six differentially expressed intragenic miRNAs that were 
encoded within host genes that are differentially expressed in psoriasis (19). The 
upregulated miRNA, miR-147b, is located within the 3’UTR of NMES1, which is 
upregulated in PP versus NN skin. The downregulated miRNAs, miR-10a, miR-100 (and 
miR-125b, which just narrowly missed our two-fold cut-off), and novel #342 lie within 
introns of HOXB3, LOC399959, and KRT15, respectively, which are downregulated in 
PP versus NN skin. LOC399959 encodes an uncharacterized ncRNA, and my findings 
suggest that this ncRNA likely functions as a polycistronic miRNA precursor. Novel #23 
lies within intron 2 of IFI27, which is upregulated in PP versus NN skin; this miRNA 
was omitted from global DGE analysis because of low abundance, but showed strong 
evidence for upregulation in PP versus NN skin. While some intragenic miRNAs have 
autonomous promoters, the co-regulation of these miRNAs and their host transcripts in 
psoriasis suggests that these miRNAs are largely dependent on their host gene promoters 
for transcription. Thus, these differentially expressed intronic miRNAs may be 
functioning cooperatively with their misregulated host transcripts to influence psoriasis 
pathogenesis. 
Other differentially expressed intragenic miRNAs lie within host genes whose 
known functions are related to psoriasis pathogenesis (Table 3-2). For example, the 
upregulated miRNA, miR-944, is located within an intron of the p63 gene, which is a 
transcription factor that regulates keratinocyte proliferation and differentiation (108,144); 
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the differential expression of p63 in psoriatic skin is complex in that it is isoform-specific 
and partially dependent on post-transcriptional mechanisms, such as miR-203 regulation 
(98,145,146). Two additional miRNAs that were omitted from global DGE analysis 
because of low abundance, but showed strong evidence for upregulation in PP versus NN 
skin, also fell into this category: miR-937 lies within a short intron of SCRIB, an 
adherens junction component and regulator of epithelial cell polarity (147); and miR-
1908 lies within an intron of FADS1, a fatty acid desaturase (148).  
In order to understand the relationships between miR-944, miR-937, and miR-
1908 and their respective host genes, I analyzed expression patterns of the mature 
miRNA (mat-miRNA), the primary miRNA transcript (pri-miRNA), and the host mRNA 
transcript with qRT-PCR in a panel of human tissues. In the case of miR-944, expression 
of pri-miR-944 was strongly correlated with expression of the p63 mRNA (R2=0.85), 
while expression of mat-miR-944 did not correlate well with either the pri-miR-944 or 
p63 (Figure 3-3A). For miR-937 and miR-1908, none of the species were highly 
correlated. Thus, there are complex and locus specific relationships between intragenic 
miRNAs and their host genes (Figure 3-3B,C). Specifically for miR-944,  it appears that 
such tissue specific regulation occurs at the level of miRNA processing, as mat-miRNA 
levels correlated poorly with pri-miR-944 and p63 levels. 
I next assessed whether the correlation between pri-miR-944 and p63 mRNA 
levels was evident in five NN, five PN, and five PP skin biopsies. Surprisingly, in NN 
and PN skin, mat-miR-944, but not pri-miR-944, levels were strongly correlated with p63 
mRNA levels (R2= 0.66 and 0.72, respectively, for NN and PN skin; Figure 3-3D). In 
contrast, neither miRNA species was strongly correlated with p63 in PP skin, but levels 
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of the pri-miRNA and mat-miRNA were correlated with each other (R2=0.55). These 
findings suggest that in NN and PN skin, mat-miR-944 is coordinately regulated with 
p63. Moreover, this coordinate regulation breaks down in PP skin, perhaps due to 
disease-related alterations in transcription of specific p63 isoforms, alternative splicing, 
or miRNA processing. 
 
miRNA responsiveness to adalimumab treatment  
I obtained skin biopsy samples from a group of patients treated with the TNF-
alpha antagonist adalimumab. Biopsies were taken from an involved site at zero and one 
month following treatment, and response to treatment was assessed by percent 
improvement in the Psoriasis Severity and Area Index (PASI) score at one and six 
months (Table 3-3). In order to determine whether miRNA expression is restored to 
normal following partial or complete resolution of psoriatic lesions, I assessed the levels 
of a subset of differentially expressed miRNAs by qRT-PCR in these samples. 
Differentially expressed miRNAs analyzed in these samples included some miRNAs with 
reported links to TNF-alpha pathways: miR-21, miR-31, miR-155, and miR-146a  are all 
induced in cells treated with TNF-alpha (149,150,151), and miR-124 is predicted to 
target the 3’UTR of TNF-alpha.  
For all of the miRNAs tested, their expression following one month of treatment 
either leveled off or worsened slightly in the majority of samples, which is consistent 
with the fact that lesions were only partially resolved after one month (21-65% 
improvement). Despite this, there were miRNAs for which the fold change at one month 
was correlated with treatment response at one or six months. Surprisingly, only one of the 
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TNF-alpha associated miRNAs, miR-31 (which was the most highly upregulated miRNA 
in PP and PN versus NN skin), exhibited a strong correlation with treatment response. 
The change in miR-31 levels at one month versus zero months was poorly correlated with 
treatment response at one month (R2=0.03), but was predictive of treatment response at 
six months (R2=0.61; Figure 3-4A). Changes in levels of other differentially expressed 
miRNAs- miR-7, miR-135b, miR-142-3p, and miR-203- at one month versus zero 
months were correlated with treatment response at one month, but not six months (R2= 
0.81, 0.60, 0.54, 0.65, and 0.57, respectively; Figure 3-4B). Changes in levels of miR-
486-5p, miR-378, miR-483-3p, miR-944, miR-203-AS, miR-21, miR-146a, miR-155, 
and miR-124 were not correlated with response to treatment at one or six months 
(R2<0.5). Overall, correlations between the relative values, log2 fold change and percent 
improvement in PASI score, were stronger than those assessed for absolute miRNA 
levels or PASI score at any single time point. 
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DISCUSSION 
 
I have performed DGE analysis on NGS reads from NN, PN, and PP skin, and 
shown extensive alterations to the psoriatic miRNAome, many of which have not been 
previously reported. Some differentially expressed miRNAs have known functions that 
reflect pathogenic features of psoriasis, such as hyperproliferation of keratinocytes, 
immune cell activation, and increased angiogenesis, while others are of unknown 
function. Of particular note is the differential expression of a novel antisense miRNA 
derived from the miR-203 locus.  
Reliability of miRNA profiling with NGS  
Small RNA sequencing may be subject to intrinsic bias introduced by 
mechanisms such as non-random adapter ligation or sequence-based differences in PCR 
efficiency (113,114). Such bias could result in skewing of absolute quantification of 
miRNAs, but should not affect the relative quantitation of singular miRNAs across 
samples. Consistent with this, I observed a close correlation between normalized digital 
read counts and qRT-PCR levels. Thus, I conclude that NGS of small RNAs is a reliable 
method for miRNA profiling and that digital read count is an adequate proxy for miRNA 
abundance. 
Significance of low abundance miRNAs 
A major advantage of deep sequencing of large cohorts is enhanced sensitivity 
and dynamic range. The known, recently described, and novel miRNAs I detected in skin 
produced between one and 130M reads, with the ten most abundant miRNAs accounting 
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for nearly 70% of all miRNA reads. This finding is consistent with other recently 
published NGS studies (119,152) and prompts the question of how important the myriad 
low abundance miRNAs are. Normal and psoriatic skin biopsies are largely composed of 
keratinocytes, but contain many other cell types as well, such as fibroblasts and 
specialized immune cells (153). Some of these are critical for the disease process, but are 
low in abundance. Consequently, important miRNAs expressed in rare cell types can be 
drowned out by signal from keratinocyte-derived miRNAs, even if they serve important 
regulatory functions that influence disease pathogenesis.  
Indeed, only two of the 98 differentially expressed miRNAs represented greater 
than 1% of miRNA reads in the cumulative dataset, indicating that miRNAs of moderate 
to low abundance account for most of the variation in the psoriatic miRNAome. 
Alternatively, bias introduced during library preparation may have led to an 
underestimate of miRNA abundance in some cases. It is unlikely that differential 
expression of these low abundance miRNAs was due to random fluctuations in digital 
read count because all of these miRNAs exhibited expression changes that were highly 
reproducible across individuals and statistically significant. Furthermore, several 
miRNAs that showed evidence for differential expression but did not meet my abundance 
threshold in the cumulative dataset were independently validated with qRT-PCR (data 
not shown), suggesting that accurate DGE data can be obtained for very low abundance 
miRNAs. 
According to a recent comparative genomics study, 269 known human miRNAs 
are primate-specific, and these miRNAs are generally expressed at low levels in adult 
tissues (154). Their computationally predicted targets show functional enrichment for 
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early developmental processes, cell cycle, and proliferation (154). Thus, the differential 
expression of poorly conserved novel miRNAs in psoriatic skin could reflect an innate 
developmental defect in skin barrier formation. I have reported the differential expression 
of 18 non-conserved novel miRNAs in psoriatic skin, presenting the intriguing possibility 
that some newly evolved novel miRNAs may serve human- or primate-specific functions 
with relevance to psoriasis pathogenesis. 
 
Comparison with previous studies 
I have shown extensive alterations to the psoriatic miRNAome, many of which 
have not been previously reported, including the differential expression of a novel 
antisense miRNA derived from the miR-203 locus. I also replicated several miRNA 
expression changes from two previous miRNA microarray studies which identified 23 
miRNAs as ±2-fold differentially expressed in psoriasis (96,97). Of these 23, I 
conclusively confirmed six: miR-21, miR-31, miR-142-3p, miR-146a, miR-223, and 
miR-378 (±2-fold change in our study). I tentatively confirmed an additional seven: miR-
17-5p, miR-30e-5p, miR-122a, miR-141, miR-142-5p, miR-146b, and miR-203 (±1.4 
fold change in our study). These 13 confirmed miRNAs included six out of eight 
miRNAs that were ±2-fold differentially expressed according to both microarray studies: 
miR-17, miR-21, miR-31, miR-142-3p, miR-146a/b, miR-200a, and miR-203. The 
remaining ten miRNAs that were previously reported as ±2-fold differentially expressed 
in psoriasis were detected by NGS in skin, but showed no evidence for differential 
expression. I also identified 67 known and 18 novel differentially expressed miRNAs that 
have not been previously implicated in psoriasis and have validated several of these by 
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stem-loop qRT-PCR. Many of the differentially expressed miRNAs reported in this study 
were likely to have been missed by previous studies because of their low abundance or 
because microarray platforms lacked probes that interrogated them. 
One tentatively validated miRNA was miR-203, which was reported to be 5.86- 
and 2.02-fold upregulated in PP versus NN skin, according to the two previous miRNA 
microarray studies in psoriasis (96,97). With the DGE analysis described here, miR-203 
exhibited a 1.6- and 1.4-fold upregulation in PP skin compared to NN and PN, 
respectively, which was lower than microarray-based fold changes. I confirmed these 
modest fold changes with qRT-PCR in my patient cohort (data not shown). The current 
model for miR-203 function is that its targeting of p63 in the suprabasal layers of the 
epidermis limits the proliferative potential of keratinocytes, which establishes a well-
defined boundary between proliferating and terminally differentiating keratinocytes (99). 
Given the hyperproliferative phenotype of psoriatic keratinocytes, the upregulation of the 
anti-proliferative miR-203 in psoriatic skin is puzzling. However, NGS revealed 
upregulation of a novel antisense miRNA derived from the miR-203 locus, which I have 
designated miR-203-AS. While miR-203-AS was much less abundant than miR-203 in 
skin, it was the most abundant novel miRNA in the cumulative dataset. Furthermore, it 
was 2.7- and 2.2-fold upregulated in PP and PN skin, respectively, compared to NN. 
Taken together, these findings more strongly support a role for miR-203-AS in psoriasis, 
but do not exclude the involvement of miR-203. Functional characterization of miR-203-
AS will likely help to reconcile apparent inconsistencies in the biological and pathogenic 
functions of miR-203.  
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Significance of intronic/intragenic miRNAs 
 Mounting evidence suggests that intragenic miRNAs, such as intronic miRNAs, 
functionally interact with their host genes. For example, miR-33, which lies in an intron 
of the sterol response element binding protein gene (SREBP), regulates cholesterol 
homeostasis (155). In other cases, a function that has been ascribed to a protein-coding 
gene may actually be mediated by an intragenic miRNA.  For example, the MLSN1 gene 
encodes a protein that was long thought to suppress motility and invasion of melanoma 
cells, but it has recently been recognized that the intronic miRNA miR-211  is actually 
responsible for this phenotype (95). In the case of psoriasis, several differentially 
expressed intragenic miRNAs lie within host genes that have been previously implicated 
into psoriasis. The upregulation of miR-944, which is encoded within an intron of p63, in 
PP skin is particularly intriguing, given the differential expression of miR-203, which 
directly targets p63, and the potentially related miR-203-AS in PP skin. Thus, taking into 
account host gene function of intragenic miRNAs could help to elucidate the pathways 
and specific targets they regulate.  
 
Altered expression of angiomiRs in involved psoriatic skin 
miR-21, miR-31 and miR-378 are three of the most abundant and differentially 
expressed miRNAs in PP skin and are members of a growing class of miRNAs termed 
“angiomiRs” (156). Pro-angiomiRs promote angiogenesis by targeting negative 
regulators in angiogenic signaling pathways, while anti-angiomiRs inhibit angiogenesis 
by targeting positive regulators of angiogenesis. The role of these and other differentially 
expressed angiomiRs in psoriatic skin is of interest, given its proclivity for 
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neovascularization. 
 Activated keratinocytes mediate angiogenesis through increased synthesis of 
VEGF, PDGF, and other endothelial cell mitogens, and inflammatory skin disease with 
some features of PS is induced by over-expression of VEGF in murine skin 
(157,158,159,160). miR-378 is proposed to promote VEGF expression by competing 
with miR-125 (which was modestly downregulated in PP skin) for the same binding site 
in the VEGF 3′ UTR (161). VEGF is upregulated in PP skin (162), and has been shown 
to induce expression of the upregulated miRNAs miR-18a, miR-31, and miR-155 (163).  
Interestingly, although a number of pro-angiomiRs were upregulated in PP skin, 
many miRNAs that would be predicted to inhibit angiogenesis by repressing VEGF were 
not differentially expressed. This includes miR-15b, miR-16, and miR-20a/b (156). One 
anti-angiomiR, miR-100, was downregulated in PP skin. miR-100 has been shown to 
inhibit angiogenesis by repressing the mammalian target of rapamycin (mTOR) in 
endothelial cells (164). Interestingly, the mTOR binding partner, regulatory associated 
protein of mTOR (RAPTOR), is encoded at 17q25, directly under a psoriasis association 
peak, pointing to mTOR upregulation in lesions through loss of RAPTOR activity or 
decreased levels of miR-100. These findings suggest that therapeutic application of anti-
angiomiR mimics might improve symptoms of psoriasis. 
 
Altered expression of oncogenic and tumor suppressive miRNAs  
Several miRNAs that were differentially expressed in psoriasis have been 
implicated in tumorogenesis, such as miR-21, miR-31 and the miR-17-92 cluster 
miRNAs miR-18a/19a/19b-1/92a-1 (165). These miRNAs have also been implicated in 
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other diseases such as cardiovascular disease (miR-21), Duchenne muscular dystrophy 
(miR-31), and systemic lupus erythematosus (miR-17-92) (166,167,168). Taken together, 
these findings suggest that these miRNAs do not function as classical oncogenes and 
tumor suppressors. Instead, their roles in cancer, psoriasis, and other diseases may be 
related to non-transformative pathways such as cell growth and survival, angiogenesis 
and inflammation. Alternatively, these miRNAs may be functioning pleiotropically by 
targeting distinct mRNAs in different tissues, developmental stages, or disease states. In 
one case, differential expression of a tumor suppressive miRNA may provide insight into 
psoriasis as a benign hyperplasia. miR-211 is a tumor suppressor in cutaneous melanoma, 
and its downregulation is correlated with increased metastasis (91,95). I found that miR-
211 was upregulated in PP versus PN and NN skin. Thus, upregulation of miR-211 may 
be one feature that distinguishes psoriatic skin from metastatic cutaneous tumors. 
 
miR-31 predicts response to treatment 
The angiomiR miR-31, which is induced by TNF-alpha in endothelial cells, was 
the most highly differentially expressed miRNA in PP and PN skin versus NN (42-fold 
and 14-fold upregulation, respectively). This miRNA was associated with 55,893 reads in 
the cumulative sequencing dataset, and ranks as the 136th most abundant miRNA in skin. 
The change in miR-31 level following one month of adalimumab treatment predicted 
response to treatment at six months. This finding is significant because patients who have 
a low likelihood of response could be identified early on during the course of treatment 
based on miR-31 levels. Since 20-47% of patients receiving high or low doses of 
adalimumab, respectively, in a randomized, double-blind, placebo controlled study did 
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not achieve 75% improvement in PASI score after 12 weeks, a substantial number of 
patients could be helped by early screening (137). One drawback is that miR-31 levels in 
the blood are uninformative (data not shown), so skin biopsies would need to be collected 
at zero and one month to complete this assessment. The lack of response of other TNF-
alpha-induced miRNAs to adalimumab treatment is curious, and suggests that positive 
feedback loops may be contributing to their sustained expression even in the absence of 
TNF-alpha signaling. 
 
Conclusions and future directions 
I have shown that at least 98 miRNAs are differentially expressed in psoriatic 
skin. These miRNAs are likely to influence many processes that are involved in psoriasis 
pathogenesis such as angiogenesis, epidermal differentiation, and inflammation. In terms 
of understanding the normal and pathogenic functions of these and other differentially 
expressed miRNAs, target identification is crucial. The identification of targets for the 
upregulated miRNAs, miR-203-AS and miR-944, would be of particular interest because 
of their connections to the p63 pathway. Overall, cutaneous diseases such as psoriasis are 
likely to be on the front line of miRNA-based diagnostics and therapeutics. The 
comprehensive profiling of the miRNAome in normal and psoriatic skin represents a 
critical first step towards such translational applications.  
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MATERIALS AND METHODS 
 
Digital gene expression analysis. Reads that aligned perfectly to mature known 
and novel miRNAs with 3nt extension were subjected to digital gene expression analysis. 
Reads that mapped to multiple mature miRNAs were attributed to all potential derivative 
miRNAs. Read counts in each skin category (NN, PN, and NN) were normalized to 
adjust for slight variation in total read count between categories. Let N be the number of 
qualified reads that aligned to hg19, C the number of categories, and M the number of 
qualified miRNA reads. Thus, the normalized number of reads for each miRNA in a 
given category is (Ntotal*Mcategory)/(C*Ncategory). A detection filter was applied such that 
miRNAs that were represented by fewer than 268 raw reads in the cumulative dataset 
were removed. Fold changes were calculated from normalized read counts, and Pearson’s 
chi-squared test with Bonferroni correction was applied to determine significance. 
miRNA qRT-PCR. qRT-PCR of mature miRNAs was performed as described in 
Chapter 2. 
mRNA qRT-PCR. Total RNA was reverse transcribed with the Superscript First 
Strand Synthesis System (Invitrogen). Briefly, 100ng-1ug of total RNA was primed with 
50ng random hexamer and reverse transcribed in a 20ul reaction with 50U SuperScript II 
reverse transcriptase. cDNA synthesis conditions were as follows: 25°C for 10 min, 42°C 
for 50 min, 70°C for 15 min, 4°C hold. PCR reactions were performed with Power SYBR 
Green master mix (Life Technologies). Briefly, 0.2ng of input cDNA was amplified in 
10ul PCR reactions. Final primer concentration was 0.25uM and primer sequences were 
as follows: p63 F 5’- and R 5’; SCRIB F 5’- and R 5’; and FADS1 F 5’- and R 5’. PCR 
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was performed on a 7900HT thermocycler (Life Technologies) under the following 
conditions: 50°C for 2 min; 95°C for 10 min; 40 cycles [95°C for 10 sec; 60°C for 1 
min]; 4°C hold. Raw expression values were normalized to 18S rRNA. Relative 
expression levels were calculated according to the 2-∆∆Ct method as follows: 2((Ct 18S)-(Ct 
mRNA)). 
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Table 3-2. Summary of differentially expressed intragenic miRNAs in psoriasis-
related genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-3. Adalimumab study patient data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA FC (NN v. PP) Host gene Intragenic position FC (NN v. PP) Host gene function
miR-147b 2.79 NMES1 3'UTR 2.50 Unknown
miR-10a -2.31 HOXB3 intron -2.08 Homeobox transcription factor
miR-100 -2.31 LOC399959 intron -2.22 Unknown
miR-125b -1.99 LOC399959 intron -2.22 Unknown
Novel #342 -2.94 KRT15 intron -2.47 Keratin 15
miR-211 2.60 MLSN1 intron ND Suppressor of melanoma metastasis
miR-937 6.15 SCRIB intron 1.34 Adherens junction subunit/regulator of cell polarity
miR-944 2.85 TP63 intron 1.72 Transcription factor involved in skin differentiation
miR-1908 -2.99 FADS1 intron -5.73 Fatty acid desaturase 
novel #23 8.80 IFI27 intron 8.00 alpha-interferon inducible protein
novel #47 3.78 IL18RAP intron ND IL18 receptor subunit
novel #123 2.11 CALR intron ND MHC class I peptide loading complex subunit
novel #116 2.38 TRAF3 3'UTR ND TNF receptor associated factor
novel #169 5.08 KRT72 intron ND High similarity to KRT6
Table 3-2. Summary of differentially expressed intragenic miRNAs in psoriasis-related genes
b Normal skin, NN; Involved psoriatic skin, PP.
Patient ID Sex BMI 0 month 1 month 6 months 1 month 6 months
UCSF5 M 28.1 12.1 9.5 2.0 21.49 83.47
UCSF22 M ND 12.9 7.0 2.4 45.74 81.40
UCSF1 M 27.9 15.8 8.4 2.0 46.84 87.34
UCSF30 M 28.4 15.2 6.9 0.9 54.61 94.08
UCSF26 M 28.7 13.3 5.2 0.9 60.90 93.23
UCSF4 M ND 8.0 2.8 2.2 65.00 72.50
UCSF14 F 25.4 8.5 2.9 2.0 65.88 76.47
Table 3-3. Adalimumab study patient data.
PASI % improvement
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Figure 3-1. Heat map showing hierarchical clustering of skin samples on the basis of 
98 differentially expressed miRNAs. Normal skin, NN; Uninvolved psoriatic skin, PN; 
Involved psoriatic skin, PP. 
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Figure 3-2. qRT-PCR validation of differentially expressed miRNAs. qRT-PCR 
levels of differentially expressed in ten normal controls and ten psoriasis patients. Lines 
indicate matched uninvolved and involved samples from the same patient (***p<0.001, 
**p<0.01,*p<0.05). Normal skin, NN; Uninvolved psoriatic skin, PN; Involved psoriatic 
skin, PP. 
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Figure 3-3. Analysis of intragenic miRNAs. (A) Relative expression of intragenic pri-
miRNAs, mat-miRNAs, and host genes in a panel of human tissues. (B) Relative 
expression of pri-miR-944, mat-miR-944, and p63 in five normal, five uninvolved, and 
five involved skin samples. Normal skin, N; Uninvolved psoriatic skin, “-“; Involved 
psoriatic skin, “+”. 
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Figure 3-4. miRNA expression changes in the skin are correlated with adalimumab 
treatment response. (A) Log2 fold change in miR-31 expression after one month of 
treatment plotted against % improvement in PASI score after one month or six months of 
treatment. (B) For miRNAs with R2>0.5, log2 fold change in expression after one month 
of treatment plotted against plotted against % improvement in PASI score after one 
month of treatment. Lower right panel, sum of log2 fold changes for each of the five 
miRNAs plotted against % improvement in PASI score after one month of treatment. 
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ABSTRACT 
 
Psoriasis is a chronic, inflammatory skin disease. Transcriptome analyses have 
revealed >1000 mRNA expression changes in psoriatic skin, and some of these gene 
expression changes may be driven by miRNAs. Indeed, involved psoriatic skin exhibits 
widespread misregulation of miRNAs: eighty known and 18 novel miRNAs are two- to 
42-fold differentially expressed. Myriad others exhibit more modest fold changes. In 
order to understand the normal and pathogenic functions of differentially expressed 
miRNAs in the skin, I analyzed cell-type specific expression and potential miRNA 
targets in psoriatic skin. In situ hybridization revealed stratified epidermal expression of 
an upregulated, keratinocyte-derived miRNA, miR-135b. I found that the upregulation of 
miR-135b and a second microRNA, miR-7 in psoriasis is likely to reduce translation of 
the late cornified envelope-1B (LCE1B) transcript. The LCE family gene products are 
structural components of the epidermal barrier and a copy number variant in the LCE3 
gene region is associated with psoriasis. I also found that the downregulation of miR-486 
in psoriasis is likely to lead to increased translation of the LCE family member, LCE3E. 
These findings are consistent with previously described downregulation of LCE1 family 
members and upregulation of LCE3 family members in psoriatic skin. The miRNA 
binding sites in LCE1B and LCE3E are poorly conserved, even among primates. Thus, 
newly evolved miRNA regulation of the LCE gene family may influence human skin 
barrier formation, and misregulation of miR-135b, miR-7, and miR-486 may contribute 
to psoriasis by altering the skin barrier. 
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INTRODUCTION 
 microRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally 
regulate gene expression (102). miRNAs function by directing the RNA silencing 
machinery to target mRNA transcripts. Target recognition is largely dependent on reverse 
complementarity between the 5’ miRNA seed region, defined as nt 2-8, and the 3’UTR of 
the transcript (72). It was initially thought that miRNAs inhibited their targets mainly at 
the level of translational inhibition (41,169). However, combined proteomic and 
transcriptomic analyses in mammalian cells has indicated that up to 85% of miRNA 
inhibition could be due to mRNA destabilization (81,106,107). Another key finding of 
such studies is that manipulation of a single miRNA in a given cell type can have 
widespread effects. For example, deletion of miR-223 in mouse neutrophils leads to 
inhibition of hundreds of proteins, likely through direct targeting of 3’UTRs (106). Most 
targets are modestly inhibited, and some, but not all, show concomitant downregulation 
in mRNA levels as well (106). Based on the modest but widespread expression changes 
observed for most miRNA targets, it has been postulated that miRNAs may serve as fine 
tuners of gene expression (170). Such fine tuning may be particularly important in the 
epidermis, where gene expression is spatially and temporally regulated to allow continual 
renewal of the barrier and dynamic responses to environmental stimuli. 
In chapter 3, I described the widespread misregulation of miRNAs in psoriatic 
skin. Some differentially expressed miRNAs have previously described roles in 
biological processes related to psoriasis pathogenesis, such as cell proliferation, 
differentiation, immunity, and inflammation, but many are of unknown function. Here, I 
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present evidence that a subset of differentially expressed miRNAs regulate components 
of the skin barrier. 
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RESULTS 
 
RNA in situ hybridization reveals cell-type specific miRNA expression 
I analyzed the expression of selected differentially expressed miRNAs in 
uninvolved (PN) and involved (PP) psoriatic skin with RNA in situ hybridization (RNA-
ish). I selected five miRNAs with previously described roles in keratinocyte or immune 
cell biology (miR-31, miR-205, miR-142-3p, miR-338-5p, and miR-31), and several of 
unknown function (miR-944, miR-135b, miR-124, miR-937, miR-1908, and novel #115). 
In general, signal intensity did not correlate well with digital read count or qRT-PCR 
(Table 3-1; Figure 3-2; Figure 4-1), indicating that RNA-ish is not suitable for analysis of 
miRNA abundance. This is likely due to probe-specific differences in sensitivity and 
specificity, or variation in the quality of skin sections. Consistent with variability in 
sample quality, no RNA-ish signal was observed for any miRNA in one normal (NN) 
biopsy included in this experiment. Thus, spatial miRNA expression was only compared 
in PP versus PN skin. 
miR-135b, miR-205 and miR-142-3p clearly labeled different cell types/skin 
layers. For example, miR-135b was upregulated in the suprabasal epidermis of PP skin, 
with highest expression just below the barrier, but was excluded from the basal layer 
(Figure 4-2). This pattern is consistent with the expression of miR-135b in cultured 
primary keratinocyte fractions where it is more highly expressed in transiently amplifying 
keratinocytes, compared to basal or terminally differentiated keratinocytes (87). In 
contrast, miR-205 was expressed primarily in the basal layer of PN skin, but in the basal 
and suprabasal layers of PP skin (Figure 4-2). This pattern is reminiscent of a number of 
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mRNAs such as integrins that are normally restricted to the basal layer of normal or 
uninvolved skin, but expressed in the suprabasal layer of involved skin (171). These 
staining patterns are strongly suggestive of roles for miR-135b and miR-205 in 
keratinocyte differentiation. miR-142-3p displayed evidence of immune cell staining, 
which is consistent with the previously described expression of miR-142-3p in 
hematopoietic tissues (Figure 4-2; 172). miR-142-3p exhibited dermal staining in PN 
skin, but was present in the dermis and epidermis of PP skin, suggesting it is expressed in 
immune cells that migrate to the epidermis in PP skin.  
 
Predicted targets of differentially expressed miRNAs 
In order to determine the potential functions of these and other differentially 
expressed miRNAs in psoriasis pathogenesis, I performed an in silico screen to identify 
their predicted targets. The pool of candidate targets was derived from a recent 
microarray-based transcriptome study, which reported differential expression of 1,089 
transcripts in PP versus NN skin (19). I screened the 3’UTRs of candidate targets for 
binding sites for differentially expressed miRNAs, and returned only those binding sites 
that were predicted by two independent algorithms: TargetScan and miRanda (Appendix 
A). 37/98 differentially expressed miRNAs were excluded from this analysis because 
some of the poorly conserved miRNAs, miRNA*s, and novel miRNAs that I identified 
were not present in the target prediction databases. These excluded miRNAs included 11 
of the top 20 differentially expressed miRNAs in PP versus NN skin. To identify their 
predicted targets I used TargetScan Custom to generate a global target profile. Their 
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predicted targets that are differentially expressed in psoriasis are also reported in 
Appendix A. 
The output from these analyses included transcripts that were predicted to be 
targeted exclusively by either up- or downregulated miRNAs or by both up- and 
downregulated miRNAs. In the former case, where a transcript was predicted to be 
targeted by either up- or downregulated miRNAs, there were targets that were positively 
correlated with their predicted miRNAs and those that were negatively correlated with 
their predicted miRNAs. Because miRNAs are typically thought to inhibit their direct 
targets, I focused on predicted targets that were negatively correlated with differentially 
expressed miRNAs, of which there were 19 up- and 105 downregulated transcripts (Table 
4-1). One notable observation was that the upregulated miRNA, miR-135b, which 
exhibited a suprabasally restricted expression gradient in PP epidermis, was predicted to 
target late cornified envelope-1B (LCE1B). This is a skin barrier constituent that is 2.1 
fold downregulated in PP versus NN skin (19,173). Moreover, a second upregulated 
miRNA, miR-7, was also predicted to target LCE1B. 
 
miRNA regulation of the LCE gene family 
The LCE gene family is divided into three groups (LCE1-3) that are physically 
linked and coordinately transcribed in response to environmental stimuli and keratinocyte 
differentiation (174). However no other LCE family members were flagged as predicted 
targets of differentially expressed miRNAs in my initial screen. This was due to two 
factors. First, while qRT-PCR analysis of individual family members has shown clear 
differential expression of most LCE family members in PP versus PN and NN skin (173), 
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only two LCE genes (LCE1B and LCE3D) were reported as differentially expressed in 
the microarray study from which I generated my candidate target pool (19). Secondly, the 
screen required that miRNA binding sites be predicted by two target prediction 
algorithms. To further investigate miRNA regulation of the LCE gene family, I manually 
analyzed the 3’UTRs of all LCE family members, and also considered miRNA binding 
sites that were predicted by only one algorithm (Table 4-2). This revealed several other 
family members that were predicted to be targets of differentially expressed miRNAs. 
Most of these miRNA:target pairs exhibited inversely correlated expression changes in 
psoriatic skin (Table 4-2). Differentially expressed miRNAs that regulate barrier 
components may exert pathogenic functions by impairing barrier development or 
remodeling in response to environmental stimuli. 
Some miRNAs that are abundant in the skin (top 20% of all expressed miRNAs), 
but are not differentially expressed in psoriasis, are also predicted to target LCE family 
members. Thus, it is likely that miRNAs also regulate barrier components in the context 
of the normal epidermis. A partial list of such miRNAs (limited to conserved miRNAs 
predicted by the miRanda algorithm) is provided in Table 4-3. However, since the current 
study pertains to the role of miRNAs in psoriasis, I have focused validation and follow up 
efforts on the differentially expressed miRNAs predicted to target LCE family members. 
 
miR-135b and miR-7 regulate LCE1B through direct interactions with the 3’UTR 
The upregulated miRNAs, miR-135b and miR-7, were predicted to target the 
downregulated transcript, LCE1B, by two independent algorithms. Predicted base pairing 
between the miRNAs and target sites within the LCE1B 3’UTR are shown in Figure 4-
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3A. I used heterologous reporter assays to validate the predicted interactions between the 
upregulated miRNAs, miR-135b and miR-7, and the downregulated transcript, LCE1B. I 
generated a series of mammalian luciferase reporter constructs containing wild-type 
(WT) or mutant LCE1B 3’UTR inserts (Figure 4-3B) and transfected these constructs 
into WT HEK293 cells or HEK293 cells overexpressing miR-135b and/or miR-7. In the 
case of miR-135b, the presence of the WT 3’UTR led to a 14.2% (SEM±1.8) reduction in 
luciferase activity in response to miR-135b overexpression, and deletion of the miR-135b 
seed binding region rescued WT luciferase activity (Figure 4-3C). Likewise, for miR-7, 
the presence of the WT 3’UTR led to a 19.8% (SEM±1.4) reduction in luciferase activity 
in response to miR-7 overexpression. This was rescued by deletion of the miR-7 seed 
binding region (Figure 4-3C). Concomitant overexpression of both miR-7 and miR-135b 
did not enhance repression beyond 20%, but rescue of WT luciferase activity in this 
strain required deletion of both miRNA seed binding regions in the LCE1B 3’UTR 
(Figure 4-3C), suggesting that both miRNAs contribute to repression of the reporter 
transcript in this context. The reduction in luciferase activity in response to miR-135b and 
miR-7 was not associated with any decrease in mRNA level (Figure 4-4), suggesting that 
translational repression is the underlying mechanism for regulation of LCE1B by these 
microRNAs. 
 
Recent origin of miR-135b and miR-7 binding sites 
The mature miR-135b and miR-7 sequences are perfectly conserved in primates 
and mouse, but the 3’UTR of LCE1B is poorly conserved beyond primates. It is 
conserved in chimps (99% max identity) and rhesus macaque (92% max identity), but is 
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highly divergent in the mouse reference genome (Figure 4-5A). If we consider the 
individual miRNA binding sites in primates, the miR-135b binding site is perfectly 
conserved in chimp, but contains multiple substitutions and deletions in all other primate 
species and mouse (Figure 4-5B). For all but one primate species (marmoset), there is at 
least one substitution within the seed binding region, which would be predicted to 
strongly influence miR-135b binding. In marmoset, five nucleotides adjacent to the seed 
binding region are deleted, which could abrogate miR-135b binding by disrupting 
multiple non-seed base pairings (Figure 4-5B). Thus, miR-135b regulation of LCE1B is 
likely to have evolved 8-5.4 million years ago in an interval that separates chimps and 
humans from orangutan, Old World, and New World monkeys. 
The miR-7 binding site initially appeared not to be conserved in chimps, as the 
first nucleotide in the 7-nt seed binding region, which is a G in the human reference 
sequence, is substituted to A in the chimp reference sequence (Figure 4-5C). I also 
identified one individual (unknown population) from the 1000 Genomes project carrying 
the A (chimp) allele of this variant (rs79341479, allele frequency in humans = 0.046%, 
2/4376; 175). Sanger sequencing of this region in ten chimpanzee samples revealed that 
this site is actually polymorphic in chimps, as 4/10 individuals were homozygous for the 
G allele. Further analysis of this SNP with a luciferase reporter assay showed that the A 
allele does not abrogate miR-7 repression of LCE1B, indicating that this site is likely to 
be a neutral polymorphism in humans and primates (Figure 4-3C). This is probably 
because the variant lies in the first nucleotide of the 7-nt seed binding region, leaving a 6-
nt seed binding region intact. This minimal 6-nt seed binding region is perfectly 
conserved in orangutan, rhesus, and baboon, while more distantly related primates such 
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as marmoset carry additional seed binding region substitutions that are likely to render 
the site non-functional. These results indicate that miR-7 regulation of LCE1B is likely to 
have evolved 30-40 million years ago, after separation from New World monkeys, in a 
common ancestor of Old World monkeys (rhesus and baboon), orangutan, chimps, and 
humans. 
miR-486 regulates LCE3E by binding a recently evolved site within the 3’UTR 
 I next used heterologous reporter assays to validate the predicted interactions 
between additional differentially expressed miRNAs and LCE family members listed in 
Table 4-2. Among the predictions I was able to test, I validated a single interaction 
between the downregulated miRNA, miR-486, and the upregulated transcript, LCE3E 
(Table 4-2; Figure 4-6A,B). The presence of the WT 3’UTR led to a ~10.6% (SEM±1.4) 
reduction in luciferase activity in response to miR-486 overexpression, and deletion of 
the miR-486 seed site rescued WT luciferase activity (Figure 4-6B). The reduction in 
luciferase activity in response to miR-486 was not associated with any decrease in 
mRNA level (Figure 4-4C), suggesting that translational repression is the underlying 
mechanism for regulation of LCE1B by these microRNAs. The mature miR-486 
sequence is perfectly conserved in primates and mouse. The LCE3E 3’UTR is present in 
chimps (98% max identity) and rhesus macaque (95% max identity), but is poorly 
conserved in mouse. The miR-486 binding site is perfectly conserved in chimp, but 
contains at least one internal seed binding region substitution in all other primate species 
(Figure 4-6D). The miR-486 seed region also exhibits variation in humans at position two 
of the 7-nt seed sequence (rs180816225); the ancestral G allele (allele frequency in 
humans = 99.863%) preserves the complementarity with miR-486, while the A allele 
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(allele frequency in humans = 0.137%, 6/4376) does not (Figure 4-6A,D; 175). Indeed, 
the presence of the A allele in the seed binding region abrogates miR-486 mediated 
repression of LCE3E (Figure 4-6B). This variant might lead to psoriasis susceptibility, 
but would not have been identified with GWAS, which cannot be used to analyze rare 
variants unless they are common in the one population being analyzed.  
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DISCUSSION 
 
The misregulation of miRNAs has emerged as a common theme among most 
human diseases, such as cancer, autoimmune disease, and psoriasis(84). However, the 
functional contributions of miRNAs in normal and diseased human tissues have been 
more difficult to assess. This is due to the subtle effects exerted by singular miRNAs on 
target expression, issues of cell- and tissue-type specificity, and sensitivity of 
miRNA:mRNA interactions to stoichiometry. In this chapter, I described one approach to 
target identification which took into account cell-type specificity and relevance of 
candidate targets to psoriasis pathogenesis. I have shown that three differentially 
expressed miRNAs in psoriasis directly regulate members of the LCE family, and that 
miRNA regulation of the LCE family evolved after the separation of Old from New 
World monkeys. 
 
miRNA regulation of LCE family members in the psoriatic epidermis  
 Members of the LCE gene family are encoded on chromosome 1 in the epidermal 
differentiation complex (EDC). This region contains many of the genes expressed during 
keratinocyte differentiation, such as filaggrin, loricrin, and the small proline rich proteins 
(SPRRs). The LCE group 1 and 2 gene products are normally expressed in the skin 
barrier, where they are constituents of the heavily crosslinked cornified envelope (176), 
and their expression is downregulated in the PP skin barrier (173). In contrast, the group 
3 LCE genes are not normally expressed in the barrier, but are turned on in the PP 
epidermis (173). Despite this overall group-wise regulation, there is variability in the 
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overall abundance and in the magnitude of differential expression between group 
members. Taken together, these observations suggest that the incorporation of specific 
LCE gene products into the barrier may be favorable under different conditions.  
miRNA-mediated regulation of LCE genes in the epidermis would be one way to 
achieve a fast and dynamic response to pathogenic or environmental stimuli. This is 
because small changes in miRNA expression can drastically influence their ability to 
regulate targets, due to their sensitivity to stoichiometry (177). Extending this model to 
psoriasis, the incorporation of LCE3 gene products into the barrier may be advantageous 
in the context of epidermal hyperproliferation and inflammation. Indeed, this is consistent 
with the finding that a deletion spanning the LCE3B/C genes is a psoriasis risk factor in 
European and Chinese populations (32,178). Thus, miRNAs that inhibit group 1 or 2 
LCEs are upregulated (i.e.: miR-7 and miR-135b), while miRNAs that inhibit group 3 
LCEs are downregulated (i.e.: miR-486) to promote barrier repair or remodeling. 
 
Transcriptional regulation of miR-135b, miR-7, and miR-486 
There are several conserved transcription factor binding sites within 2kb upstream 
of miR-135b (Chx10, SRF), miR-7 (miR-7-1: MEF2A, miR-7-2: ATF6, NKX25, 
POU3F2), and miR-486 (GATA). While none of these transcription factors have been 
reported as differentially expressed in psoriatic skin, transcription factors are not always 
detected on microarrays because of their overall low abundance. Interestingly, despite the 
fact that miR-135b and miR-7 regulate the same target, LCE1B, there were no conserved 
transcription factor binding sites present in both promoters. This may reflect the fact that 
the two miRNAs likely serve many non-redundant functions because their global target 
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profiles are largely distinct. An additional possibility, particularly in light of the recent 
evolution of the miRNA binding sites, is that the promoters contain non-conserved 
transcription factor binding sites or uncharacterized motifs that regulate their 
transcription in human skin. Also of note is the presence of a GATA site ~1kb upstream 
of the miR-486 gene. GATA-3 is required for establishment of the epidermal barrier in 
mice, and barrier-impaired skin from GATA-3 null mice exhibits increased levels of anti-
microbial and innate immunity genes (179). It would be intriguing to determine whether a 
failure to transcriptionally activate miR-486 contributes to this psoriasoform phenotype. 
 
Newly evolved miRNA regulation of LCE family members 
 Over the course of mammalian evolution, the epidermis has changed drastically. 
For example, the interfollicular epidermis in mice is much thinner and more resistant to 
scarring than in humans (112). Moreover, primates and humans have been exposed to the 
selective pressure of new environmental conditions, which could be particularly relevant 
to the skin. Thus, it is plausible that new mechanisms have arisen for the development 
and maintenance of the human/primate epidermis. Indeed, many genes involved in 
keratinization (including LCE1B and LCE3E) are under positive selection in primates 
and humans (180). Consistent with this, I have shown that recently evolved, functional 
miRNA binding sites exist in primates, and that these miRNA binding sites exhibit 
substantial variation between species and harbor rare variants in humans. This 
observation is particularly intriguing, considering that murine models typically fail to 
recapitulate all of the features of human psoriasis (112). 
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Significance of miRNA regulation in the normal epidermis 
 The majority of this chapter has focused on the pathogenic roles of three miRNAs 
that are differentially expressed in psoriatic skin. However, many barrier components 
(such as the LCEs) are predicted to be targeted by miRNAs that are abundant in the 
epidermis, but not differentially expressed in psoriasis. Thus, miRNAs are likely to play a 
role in establishment and maintenance of the skin barrier under normal conditions. One 
intriguing hypothesis is that the enucleated, terminally differentiated keratinocytes that 
populate the skin barrier have limited transcriptional capacity. Thus, barrier components 
must be transcribed prior to enucleation, and translationally repressed by miRNAs until 
keratinocytes reach the barrier.  
 
Future directions and conclusions 
Misregulation of miRNAs that target LCE family members may be one 
mechanism contributing to barrier dysfunction in PP skin. It remains to be seen whether 
the recent evolution of these regulatory interactions could underlie primate-specific 
features of the epidermis or influence differences in psoriasis susceptibility between 
species or individuals.  
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MATERIALS AND METHODS 
 
MiRNA in situ hybridization. MiRNA in situ hybridizations were performed as 
previously described (181). Briefly, fresh skin biopsies were fixed in 10% formalin for 
24-72h and paraffin embedded. 6um sections were mounted on glass slides, 
deparaffinized, and treated with 10ug/ml proteinase K for 20 min at 37°C. Slides were 
hybridized with 20-60nM double DIG-labeled LNA probes (Exiqon) overnight at 57°C  
(miR-135b, miR-205) or 50°C (miR-142). Slides were washed in 5X SSC, 1X SSC, and 
0.2X SSC for 10 min at hybridization temperature. Staining was performed with 
NBT/BCIP (Roche) for 90 min at 32°C followed by nuclear fast red counterstain (Vector 
Laboratories). An LNA probe with scrambled sequence was used as a negative control 
(Exiqon). 
Target prediction screen. Predicted miRNA targets were downloaded from the 
TargetScan (72,182) and miRanda (183,184) websites (http://www.targetscan.org/, 
http://www.microrna.org/microrna/home.do). The datasets were filtered against the 
differentially expressed transcripts (19) and miRNAs in psoriatic skin. Differentially 
expressed transcripts that were predicted to be targeted by one or more differentially 
expressed miRNAs with both target prediction algorithms were returned. Candidate 
targets were further sorted based on directionality of differential expression.   
3’ UTR reporter constructs. 3’UTR reporter constructs were generated from the 
si-CHECK2 vector (Promega). Briefly, 3’ UTRs of candidate target genes were amplified 
from genomic DNA. PCR products were cloned into the XhoI and PmeI sites of the 
vector, thus fusing the Renilla luciferase gene to the candidate 3’UTR. Transformants 
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were selected on 1ug/ml ampicillin and validated by Sanger sequencing. miRNA binding 
site mutagenesis was performed by deleting the seven nucleotide miRNA seed region 
from the 3’UTR with the QuikChange lightning targeted mutagenesis kit (Agilent), 
according to manufacturer’s protocol.  
Transfections. HEK293 cells were cultured in DMEM supplemented with 2mM 
L-glutamine, 10mg/ml penicillin-streptomycin, and 10% fetal bovine serum at 37°C and 
5% CO2. Transfections were performed in triplicate. 24 hours prior to transfections, 
1x105 cells were plated in each well of a 24-well plate. Transfections were performed 
with TransIT-LT1 transfection reagent according to manufacturer’s instructions (Mirus). 
Briefly, 250ng pEP-miR, 250ng psiCHECK2, and 250ng pUC18 (or pEP-miR for double 
overexpression treatments) were incubated in a solution of 46.25ul RPMI and 3.75ul LT-
1 for 30 min at 22°C before treatment. Cells were collected 24 hours post-transfection. 
Luciferase assays. Dual luciferase reporter assays were performed according to 
manufacturer’s instructions (Promega). Briefly, transfected cells were lysed in passive 
lysis buffer for 15 minutes at room temperature. Lysates were diluted 10-fold and 20ul of 
diluted lysate was added to each assay. Renilla luciferase activity was normalized to 
firefly luciferase activity to control for transfection efficiency. Significance was 
determined with one way ANOVA and post-hoc two tailed t-tests. 
mRNA qRT-PCR. mRNA qRT-PCR was performed as described in Chapter 3. 
Cells were collected 24 hours post-transfection. Primers sequences were targeted to the 
LCE1B and LCE3E 3’UTRs (173). 
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TABLES AND FIGURES 
 
Table 4-1. Differentially expressed targeted by inversely correlated, differentially 
expressed miRNAs. 
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Table 4-2. Differentially expressed miRNAs predicted to target LCE transcripts. 
 
 
 
 
 
 
 
 
 
 
Table 4-3. Abundant miRNAs predicted to target LCE transcripts by the miRanda 
algorithm. 
 
 
 
 
 
 
 
LCE miRNA predicted to binda miRSVR scoreb miRNA rank (NNc) miRNA read counts (NN)
LCE1B miR-24 -1.19 9 3375273
LCE1B miR-1 -0.34 51 228174
LCE1B miR-218 -0.21 121 25891
LCE1C miR-24 -0.58 9 3375273
LCE1C miR-182 -0.17 46 295736
LCE1E miR-32/92ab/363 familyd -0.17 39 368268
LCE1E miR-25 -0.17 80 77376
LCE1E miR-425 -0.57 92 58762
LCE1E miR-218 -0.18 121 25891
LCE1E miR-144 -0.32 161 9282
LCE2A let-7/miR-98  family -0.12 1 48065414
LCE2B let-7f/miR-98 -0.11 2 15566363
LCE2B miR-130a/b -0.35 94 54276
LCE2C let-7/miR-98  family -0.15 1 48065414
LCE2C miR-335 -0.13 155 10394
LCE2D let-7/miR-98  family -0.14 1 48065414
LCE3D miR-28-5p/708 family -0.79 93 54506
LCE5A miR-320a/b/c/d -0.11 79 77548
LCE6A miR-24 -0.33 9 3375273
LCE6A miR-185 -0.12 98 47631
aConserved miRNAs predicted to bind LCE 3'UTRs by miRanda algorithm
bMore negative miRSVR scores imply stronger probability of target inhibition
cNormal skin, NN
dFor miRNA families, rank and read count is reported for most abundant family member
Downregulated LCE miRNA (FC PP/NN,PP/PNa) Algorithm Position in 3'UTR miRSVRb/Context+c score Validated?d
LCE1B 135b (5.65,5.32) miRanda/TargetScan 150-156 -0.47/-0.14 Y
LCE1B 7 (3.05,2.31) miRanda/TargetScan 70-76 -0.28/-0.15 Y
LCE1B 206 (12.80,4.84) miRanda 301-306 -0.34/NA N
LCE1C 378 (2.68,2.11) miRanda 141-147 -0.41/NA N
LCE1E 31 (42.93,14.03) miRanda/TargetScan 71-77 -0.13/-0.17 N
LCE1E miR-590-3p (1.94,2.71) miRanda/TargetScan 699-705 -0.16/-0.15 N
LCE1E miR-590-3p (1.94,2.71) miRanda/TargetScan 739-745 -0.91-0.26 N
LCE1E 137 (-2.37,-1.87) miRanda 735-740 -0.21/NA N
LCE2B 19a (1.89,2.31) miRanda/TargetScan 138-144 -0.28/-0.13 --
LCE2B 19b (2.10,2.21) miRanda/TargetScan 138-144 -0.28/-0.13 --
Upregulated LCE miRNA (FC PP/NN,PP/PNa) Algorithm Position in 3'UTR miRSVRb/Context+c score Validated?d
LCE3E 486-5p miRanda/TargetScan 178-185 -0.87/-0.35 Y
bThe mirSVR score is given for miRanda predicted targets; more negative scores imply stronger probability of target inhibition
cThe context+ score is given for TargetScan predicted targets; more negative scores imply stronger probability of target inhibition
dmiR-19a/b interactions with LCE2B were not tested due to ineffective overexpression from the pEP-miR vector
miRNAs predicted to target 3'UTR
aNormal skin, NN; Uninvolved psoriatic skin, PN; Involved psoriatic skin, PP.
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Figure 4-1. miRNA in situ hybridization for selected differentially expressed 
miRNAs in involved skin sections. Panels are arranged in descending according to 
digital read count, with the negative control scramble miR in the bottom right. Formalin 
fixed paraffin embedded skin sections were hybridized with DIG-labeled LNA probes 
and stained with NBT/BCIP (purple) and nuclear fast red. Signal intensity is poorly 
correlated with digital read count. 
 
 
 
 
 
 
 115 
 
 
Figure 4-2. RNA in situ hybridization for skin expressed miRNAs in uninvolved 
psoriatic and involved psoriatic skin sections. Expression of miR-135b in the (A) PN 
and (B) PP epidermis. Expression of miR-205 in (C) PN and (D) PP epidermis. 
Expression of miR-142-3p in (E) dermal immune cells (arrowheads) in PN skin and (F) 
dermal/epidermal immune cells (arrowheads) in PP skin. Scramble-miR background 
signal in (G) PN and (H) PP skin. Uninvolved psoriatic skin, PN; Involved psoriatic skin, 
PP. 
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Figure 4-3. miR-135b and miR-7 inhibit LCE1B through direct interactions with the 
3’UTR. (A) miRNA:mRNA duplex for miR-135b and miR-7 sites, as predicted by 
miRanda algorithm. Identical binding sites were also predicted by TargetScanS. (B) 
Schematic representation of luciferase-LCE1B 3’UTR reporter constructs. “*” indicate 
miRNA binding seed regions. The G/A construct encodes the LCE1B 3’UTR with the 
minor A allele for SNP rs79341479. (C) Relative luciferase activity in HEK293 cells 
overexpressing the indicated miRNAs compared to wild-type (WT) cells. Bar colors 
correspond with construct colors in part A. *p<0.05, **p<0.01. 
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Figure 4-4. miR-135b and miR-7 have no effect on luciferase-LCE1B reporter 
transcript levels. Relative mRNA levels of the luciferase-LCE1B WT 3’UTR reporter in 
HEK293 cells overexpressing miR-135b and/or miR-7 compared to wild type (WT). 
Primers were targeted to the LCE1B 3’UTR (see methods). 
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Figure 4-5. Multi-species alignments for the LCE1B 3’UTR and miRNA binding 
sites. (A) LCE1B locus on chromosome 1, with miR-135b and miR-7 binding sites (black 
bars under BLAT search heading) and conservation in chimp, rhesus macaque, and 
mouse indicated. (B) Sequence and conservation of miR-135b binding site in human, 
chimp, rhesus macaque, and mouse; red bar indicates seed region. (C) Sequence and 
conservation of miR-7 binding site in human, various primate species, and mouse; red bar 
indicates seed region. 
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Figure 4-6. miR-486-5p inhibits LCE3E through a direct interaction with the 
3’UTR. (A) miRNA:mRNA duplex for miR-486-5p binding site, as predicted by 
miRanda algorithm. (B) Relative luciferase activity in HEK293 cells overexpressing 
miR-486-5p compared to wild-type (WT) cells. **p<0.01. The G/A construct encodes the 
LCE3E 3’UTR with the minor A allele for SNP rs180816225. (C) Relative mRNA levels 
of the luciferase-LCE3E WT 3’UTR reporter in HEK293 cells overexpressing miR-486 
compared to wild type (WT). Primers were targeted to the LCE3E 3’UTR (see methods). 
 (D) Sequence and conservation of miR-486 binding site in human, various primate 
species, and mouse; red bar indicates seed region. 
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Chapter 5. 
Expression of noncanonical miRNAs and endogenous siRNAs in normal and 
psoriatic skin 
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ABSTRACT 
 
Noncanonical microRNAs (miRNAs), which bypass part of the canonical miRNA 
biogenesis pathway, and endogenous small interfering RNAs (endo-siRNAs) are key 
gene regulators in eukaryotes. Mounting evidence suggests that these small noncoding 
RNAs (sncRNAs) can originate from a variety of genomic loci. These include snoRNAs, 
tRNAs and introns for noncanonical miRNAs, and repetitive regions and mobile elements 
for endo-siRNAs. However, the roles of such sncRNAs in complex disease have yet to be 
characterized. To investigate their potential expression and function in psoriasis, we 
carried out a comprehensive, genome-wide search for noncanonical miRNAs and endo-
siRNAs expressed in normal and psoriatic human skin with Next Generation sequencing 
of small RNAs. We identified 23 noncanonical miRNAs (3 snoRNA-derived and 2 
tRNA-derived miRNAs and 18 miRtrons) and 39 endo-siRNAs that were expressed in 
skin. The expression of four sncRNAs was validated by qRT-PCR of total RNA and 
Argonaute immunoprecipitates isolated from human skin. Fifteen noncanonical miRNAs 
and endo-siRNAs were significantly differentially expressed in psoriatic involved versus 
normal skin, including an Alu-SINE-derived siRNA which was 17-fold upregulated in 
involved skin. These and other differentially expressed sncRNAs may function as 
regulators of gene expression in skin and play a role in psoriasis pathogenesis. 
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INTRODUCTION 
 
MicroRNAs (miRNAs) and endogenous small interfering RNAs (endo-siRNAs) are 
classes of small noncoding regulatory RNAs (sncRNAs) that play critical roles in gene 
regulation for many biological processes in eukaryotic organisms (34). miRNAs in 
particular have been heavily studied in recent years and shown to be essential gene 
regulators that broadly contribute to disease pathogenesis.  
miRNAs are produced from short hairpin-forming primary transcripts (pri-miRNAs) 
which are typically processed through a canonical pathway involving the RNase III 
enzymes Drosha, Dgcr8 and Dicer (103). Besides these canonical miRNAs, there exist 
noncanonical miRNAs whose biogenesis requires Dicer but neither Drosha nor Dgcr8 
(185). The first example of noncanonical miRNA was the class of miRtrons, which arise 
from the splicing of 60-100nt introns, independent of Drosha. The debranched short 
introns may fold into stem-loop structures, which are then cleaved by Dicer to release 
miRNAs (104,105,186,187). Noncanonical miRNAs can also arise from local hairpin 
formation within larger noncoding RNA (ncRNA) species, such as small nucleolar RNAs 
(snoRNAs) and transfer RNAs (tRNAs; 118,188). While there have been several 
snoRNA-derived miRNAs described in eukaryotes, only one example of a tRNA-derived 
miRNA has been described. In this case, a murine tRNA, IleTAT can fold into an 
alternative secondary structure consisting of a stem-loop hairpin from which a miRNA is 
derived (189). 
In contrast to miRNAs, endo-siRNAs are generated from long double-stranded 
RNAs (dsRNA) that can originate from the transcription of repetitive sequences, 
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transposable elements, or Piwi-interacting RNA (piRNA) loci. These long dsRNAs are 
processed by Dicer, but do not require Drosha or Dgcr8. Endo-siRNAs have been 
described in plants (34,190), C. elegans (191), D. melanogaster (192,193,194,195), and 
murine oocytes (196,197,198). There is also evidence suggesting that endo-siRNAs may 
be expressed in murine embryonic skin (86). Like miRNAs, siRNAs exert their 
regulatory functions through association with the RNA induced silencing complex 
(RISC), which contains an Argonaute (Ago) protein. However, unlike miRNAs, pairing 
between siRNAs and their targets requires fewer than three mismatches and elicits direct 
cleavage of target mRNAs (196). 
In previous chapters, I have described the majority of known and novel miRNAs 
expressed in normal and psoriatic skin. In this chapter, I describe the identification of 
novel noncanonical miRNAs and endo-siRNAs expressed in skin, and their potential 
roles in psoriasis. This work has broadened current perspectives on the diversity of 
sncRNAs and their potential roles in gene regulation in human skin. This work was a 
collaborative effort between myself and Jing Xia, a graduate student in Weixiong 
Zhang’s lab at Washington University. 
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RESULTS 
 
Next Generation sequencing of small RNAs 
A total of 67 small RNA libraries were prepared from human skin biopsies: 24 
psoriatic involved skin (PP), 23 psoriatic uninvolved skin (PN), and 20 healthy controls 
(NN), as described in Chapter 2. Approximately 85% of the qualified reads from each 
category mapped perfectly to the human genome. Among these mappable reads, 55% 
originated from mature miRNAs or miRNA precursors; 39% originated from other 
noncoding RNAs and repeat regions; and 6% originated from other genomic loci such as 
coding sequence, untranslated regions, introns, and intergenic sequences (Table 5-1). 
The presence of small RNA read clusters at various non-miRNA loci may reflect 
expression of unannotated, functional sncRNAs. Alternatively, genomic small RNA reads 
could arise from degradation products of mRNAs or unannotated transcripts. To address 
this question, we embarked on a systematic study of these small RNA reads with 
computational and experimental approaches. We first focused on noncanonical miRNAs 
that originated from snoRNAs, tRNAs and introns and then analyzed putative endo-
siRNA loci. Reads derived from these loci are described in detail below and generally 
exhibited features of functional Dicer dependent sncRNAs, such as a 21-22-nt peak in 
length distribution, 5’ homogeneity, and 5’ nucleotide identity bias (Figure 5-1). Notably, 
ncRNA species that are not processed by Dicer, such as tRNAs and rRNAs, do not 
display these features. 
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Noncanonical miRNAs or miRNA-like RNAs expressed in human skin 
miRNAs derived from snoRNAs and tRNAs 
Some ncRNA species are substrates for Dicer-mediated miRNA production and 
eight human snoRNAs have been reported to produce miRNAs (118). Analysis of the 
small RNA reads from human skin revealed that 58 million reads (~8.8%) aligned to 
snoRNAs, including all eight of the previously described miRNA-producing snoRNAs 
(Table 5-2). The majority (86%) of these reads were 21 or 22-nt in length, and their 5’ 
nucleotides were predominately A and G (89.7% of the total). We searched for novel 
snoRNA-derived miRNAs in this pool of reads, and identified three novel loci (Table 5-
2). Remarkably, ~79% of snoRNA reads aligned to one C/D box snoRNA, U60, which 
has not been previously implicated as a miRNA locus. Of these reads, 98.9% were 21-
22nt long. Folding structure analysis revealed that the U60 snoRNA could form an 
alternative RNA secondary structure that resembled a miRNA precursor hairpin (Figure 
5-2A). Alignment of the most abundant small RNA reads to each arm of this hairpin 
resulted in a 22-nt RNA-RNA duplex with 3’ overhangs (Figure 5-2A,B). Remarkably, 
the 22-nt miRNA-like small RNA was ranked as the second most highly expressed 
miRNA in human skin, based on sequencing read counts.  However, the high abundance 
of U60 reads could result from established library preparation biases (113,114); indeed, 
qRT-PCR experiments were consistent with a more moderate expression level in the skin 
(see below).  
We next examined small RNA reads that aligned to tRNAs (Table 5-2). First, we 
recognized that the mature mmu-miR-1983 sequence, derived from murine tRNA-
IIeTAT (189), was conserved in humans and associated with 228 21-22nt small RNA 
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reads in our dataset (Figure 5-3A). A second tRNA candidate with short hairpin-forming 
potential, PseudoTTA, was associated with a cluster of 14 small RNA reads (Figure 5-
3B). Both of these putative tRNA-originated miRNAs were expressed at very low levels 
in human skin. In the case of tRNA-IIeTAT, only ~2% of the reads aligning to the tRNA 
were consistent with the sequence of mmu-miR-1983, as compared to 92% in mouse 
embryonic stem cells (mESCs; GSM314552; 189). The higher expression level of miR-
1983 in mESCs might indicate that the alternative hairpin structure is preferential to the 
original tRNA structure in this cell type or more generally, in the germ line. 
Alternatively, differences in sample preparation between the two studies may account for 
relative differences in abundance. 
Intronic miRNAs and miRtrons 
The miRNA subclass of miRtrons includes typical miRtrons that reside at the 
exon/intron boundaries of 60 to 100-nt introns, and tailed miRtrons that are generated 
from one end of longer introns (186,199). Fourteen typical miRtrons have been 
previously described in humans (104) and were also detected in the current study. Our 
analysis of small RNA reads from skin indicated that an additional 26 known human 
miRNAs were likely to have been processed by the miRtron biogenesis pathway (2 
typical miRtrons and 24 tailed miRtrons). The currently annotated precursors for the 
majority of these known miRNAs, e.g. miR-636, miR-936 and miR-3064, extend beyond 
their respective host intron regions. However, 80% of the reads aligning to the 
intron/exon boundary terminated within 2-nt of the AG splice acceptor site, which 
strongly indicated that these pre-miRNAs were derived directly from debranched introns 
(Figure 5-4).  
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In Chapter 2, I described a number of novel miRtron candidates. Re-examination of 
these 67 miRtron candidates confirmed that 94% of reads aligning to the intron/exon 
boundary terminated within 2-nt of the AG splice acceptor site on average (Table 5-3). 
To identify additional novel miRtrons that are expressed in human skin, we carefully 
searched a 160bp window of intronic sequence at all intron/exon boundaries in the human 
genome for hairpin forming potential and small RNA read clusters. This analysis resulted 
in the identification of additional 18 candidates, which were not previously reported in 
Chapter 2 due to low abundance and/or atypical folding structures (Table 5-3). The 
lengths of the host introns varied from 70 to several thousand bases, suggesting that long 
introns can also give rise to miRtrons. In sum, this analysis increased the total number of 
miRtron candidates to 125 (19 typical miRtrons and 106 tailed miRtrons) in the human 
genome.  
miRtrons are typically expressed at low levels (200), which is consistent with our 
observation in human skin. In the set of miRtrons we studied, the most highly expressed 
was the known miRtron, miR-877, with 4,827 reads. Interestingly, the recently described 
miRtrons, #80 and #103, and two newly annotated miRtrons, miR-1292 and miR-3605, 
were expressed at levels comparable to that of miR-877. Hairpin structures and read 
alignments for the two most abundant miRtrons, #80 and #103, are shown in Figure 5-5. 
The low abundance of miRtrons may be due to multiple factors: the presence of more 
bulges and unpaired bases in their hairpin structures than canonical miRNAs that lowers 
Dicer processing efficiency, susceptibility to endogenous lariat degradation pathways, 
and, in many cases, their recent evolution (see below).  
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Endogenous siRNAs expressed in human skin 
The expression of endo-siRNAs in adult human tissues is not well understood. Our 
dataset of deeply sequenced small RNAs allowed us to perform a genome-wide search 
for putative endo-siRNAs that were associated with small RNA sequencing reads in 
human skin. 
endo-siRNAs from repeats and transposable elements 
A total of 27M reads (~4% of the total qualified reads) from our human skin dataset 
mapped to a variety of repeat elements in the human reference genome, such as SINEs, 
LINEs, LTRs and DNA transposons (Table 5-1). The locus with the most aligned reads 
was on chromosome 1 (Figure 5-6A). This was within an intron of the gon-4-like 
(GON4L) gene where three Alu SINEs appear in tandem. A total of 5,534 reads (53.4% 
of which were 21-23nt) aligned to this locus, with a cluster of 2,800 reads (83.7% of 
which were 21-23nt) uniquely mapped to the first Alu SINE (highlighted in green in 
Figure 5-6A). This putative endo-siRNA was the most differentially expressed siRNA 
between PP and NN skin (see below). In contrast, the expression level of the host gene 
GON4L shows little variation between PP and NN skin (data not shown), indicating that 
the SINEs and the host gene may be transcribed or processed independently.  
To study the biogenesis of this putative endo-siRNA, we generated mammalian 
expression constructs with various combinations of the three Alu SINE elements (E1, E2, 
and E3) and transfected them into HEK293 cells. We found that transcription of the E1 
segment, which does not form an intrinsic hairpin structure, is sufficient for siRNA 
production (Figure 5-6B). Thus, it is plausible that the E1 transcript may anneal to closely 
related Alu-SINE element transcripts in the genome to form a dsRNA for siRNA 
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production. Alternatively, transcription of E1 and E2 together may produce a long 
hairpin-structured dsRNA for siRNA production (Figure 5-6C). This possibility is 
consistent with slightly enhanced siRNA production from the E1+E2 fragment compared 
to the E1 fragment alone (Figure 5-6B). 
We also identified two less abundant putative endo-siRNAs derived from other 
repetitive elements (Figure 5-7). In the first case, a cluster of 12 reads (83.3% were 21-
23nt in length) uniquely mapped to inverted repeats of tandem L1 elements on 
chromosome 16. In the second case, a cluster of 72 reads (79.2% were 21-23nt in length) 
mapped to an LTR element on chromosome 4; however, 25% of the reads in this cluster 
did not map to this locus uniquely. Transcripts from these loci could form long hairpin 
structures of 98nt and 135nt, respectively. A clear 5’ homogeneity of the clustered 
sequencing reads originating from these two loci was observed, suggesting that the small 
RNAs are authentic endo-siRNAs rather than random degradation products.  
In addition, a striking ~11K reads uniquely mapped to Made1 elements, a human-
specific subclass of miniature inverted repeat transposable element (MITE), which 
encodes the large hsa-miR-548 family. We confirmed that 34 Made1 elements, which 
were not previously associated with miRNA production, can give rise to hairpin 
structures (Table 5-4; Figure 5-8). Mapping of small RNA reads to both 5’ and 3’ arms of 
these hairpins generally revealed putative Dicer-cleavage products with 3’ overhangs, 
which share sequence identity with individual members of the miR-548 family. Unlike 
most canonical miRNAs, the sncRNAs derived from Made1 elements have a large 
number of paralogs, including 58 annotated in miRBase (v.17) and 34 in this study. Thus, 
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based on its genomic origin within a common transposable element, we prefer to classify 
the miR-548 family members as siRNAs.  
endo-siRNAs from piRNA loci 
Analysis of reads aligned to piRNA-annotated loci uncovered two loci for which the 
length distributions of small RNAs had two dominant peaks at 21-23nt and at 27-30nt 
(Figure 5-9). This distribution would be indicative of expression of siRNAs and piRNAs, 
respectively. The two loci are within annotated Alu SINE elements and no hairpin 
structures could be detected by folding the corresponding flanking sequences. Hence, the 
origin of these siRNAs is unclear, but they could arise from annealing between closely 
related repetitive element-derived transcripts in the genome. Interestingly, the siRNAs 
from these two loci share sequences similar to miR-1285 and miR-1303 (Figure 5-9), two 
miRNA genes that overlap with Alu SINE elements. A search for paralogs of hsa-miR-
1285 and hsa-miR-1303 mature miRNAs revealed more than 80 loci with exact sequence 
identity in the human genome, indicating miR-1285 and miR-1303 may be more 
accurately classified as siRNAs.  
 
Conservation of noncanonical miRNAs and endo-siRNAs 
We performed a comparative genomic analysis of all 130 noncanonical miRNAs (5 
derived from tRNAs or snoRNAs and 125 miRtrons) and endo-siRNAs that were 
expressed in human skin (data not shown). To this end, we considered eight species: 
Macaca mulatta (rhesus), Mus musculus (mouse), Canis lupus familiaris (dog), 
Loxodonta Africana (elephant), Monodelphis domestica (opossum), Gallus gallus 
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(chicken), Xenopus tropicalis (frog) and Danio rerio (zebrafish). For 54/130 (41.5%) 
noncanonical miRNA loci we analyzed, the mature miRNA sequence was human 
specific.  For 50/130 noncanonical miRNAs (38.5%), the mature sequence was present in 
Macaca mulatta but not in Mus musculus, suggesting that they might be primate specific. 
For the final 26/130 (20%) noncanonical miRNA loci (23 miRtrons, 1 snoRNA- and 2 
tRNA-derived miRNAs) the mature miRNA sequence was conserved in one or more 
species beyond Macaca mulatta. The presence of snoRNA- and tRNA-derived miRNAs 
in non-primate mammals suggested potential roles for small RNAs derived from snoRNA 
and tRNA transcripts in human and other mammalian species. The 39 endo-siRNA loci 
described herein were present only in human and Macaca mulatta, largely due to the 
conservation of the hosting repeat elements (Alu SINEs) in primates (201). The majority 
of the noncanonical miRNAs and endo-siRNAs we studied were not conserved beyond 
primates, suggesting that these recently evolved sncRNAs could perhaps serve primate-
specific functions.  
 
qRT-PCR validation of noncanonical miRNAs and endo-siRNAs 
We selected three noncanonical miRNAs and one endo-siRNA for validation with 
quantitative RT-PCR (qRT-PCR): the U60 snoRNA-derived miRNA, the pseudoTTA-
derived miRNA, the recently described miRtron #103, and the Alu SINE-derived siRNA. 
We first set out to validate the endogenous expression of these sncRNAs in skin. While 
all four produced a consistent qRT-PCR signal that was both RNA and reverse 
transcriptase dependent (Figure 5-10A,B), we were not able to obtain a visible product 
for miRtron #103 (Figure 5-10B). This is likely due to its low abundance and the 
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established discrepancy between small RNA abundance as determined by Next 
Generation sequencing (NGS) versus qRT-PCR (113,114). Notably, the pseudoTTA 
miRNA was detected at higher levels with qRT-PCR in the human embryonic kidney cell 
line, HEK293, compared to skin (data not shown). This finding is consistent with the 
enrichment of the pseudoTTA miRNA in mESC sequencing data, and further suggests 
that this miRNA may be more abundant in embryonic tissues than in adult tissues. 
We next determined whether the ectopic expression of genomic DNA encoding the 
putative sncRNA precursor was sufficient for the accumulation of sncRNAs. DNA 
fragments of ~200nt harboring these sncRNAs were cloned into a mammalian expression 
vector and transfected into HEK293 cells. For each of the four loci tested, there was a >5 
fold enrichment in sncRNA production when the appropriate genomic segment was 
ectopically expressed, suggesting that these loci are indeed sufficient to generate 
sncRNAs (data not shown). Finally, we used these expression constructs to determine 
whether the ectopically expressed sncRNAs were present in Ago2 or Ago3 
immunoprecipitates with RNA binding protein immunoprecipitation coupled with qRT-
PCR (RIP-PCR; Figure 5-10C). Indeed, ectopically expressed miRtron #103 was 
significantly enriched in both Ago2 and Ago3 immunoprecipitates compared to IgG; the 
pseudoTTA-derived miRNA and the Alu-SINE derived siRNA were significantly 
enriched in Ago2 immunoprecipitates; and the U60-derived miRNA was modestly 
enriched in Ago2 and Ago3 immunoprecipitates, but these enrichments were not 
significant. This suggested that these novel sncRNAs may function through association 
with Ago effectors. 
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Differential expression of noncanonical miRNAs and endo-siRNAs in skin and 
predicted targets 
In order to investigate the potential function of the newly identified noncanonical 
miRNAs and endo-siRNAs in skin, we performed digital gene expression (DGE) analysis 
on noncanonical miRNAs and endo-siRNAs in PP, PN and NN skin samples. A total of 
15 out of 169 (8.9%) noncanonical miRNAs and endo-siRNAs exhibited significant 
differential expression with at least a 1.5-fold change in one or more comparisons (PP vs. 
NN; PP vs. PN; or PN vs. NN), with p-values less than 0.001. Ten sncRNAs were 
upregulated in PP vs. PN and NN skin (Alu-SINE-siRNA, Made1_#1, hsa-miR-937, 
tRNAIle-miRNA, miRtrons #14, #72, #144, #323 and #375, and U60 miRNA-5p), 
whereas five (miRtrons #80, #252, #145-5p and #145-3p and Made1_#47) were 
downregulated in PP vs. PN and NN skin (Table 5-5; Figure 5-11A). Notably, the 
expression of the most abundant Alu-SINE-derived siRNA was more than 17-fold 
increased in the PP vs. NN comparison. The differential expression of this siRNA and 
hsa-miR-937 (newly annotated as a canonical miRtron) was confirmed by qRT-PCR, 
while the more modest differential expression of the U60-derived miRNA did not 
validate (Figure 5-11B). The failure of U60 to validate could be a result of heterogeneity 
in PN and NN samples that is not related to disease. The clustering of samples based on 
the expression of the 15 differentially expressed small RNAs distinguished the majority 
of PP samples from PN and NN samples (Figure 5-11A).  
We searched for potential mRNA targets of differentially expressed noncanonical 
miRNAs by TargetScan  (72,79) and starBase (202) and that of endo-siRNAs with an in-
house siRNA target finding method. We specifically focused on those targets that are 
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differentially expressed in psoriasis based on published microarray-based mRNA 
profiling data from PP, PN and NN skin and murine models of psoriasis (19,203) to help 
appreciate the potential roles of these sncRNAs in regulating the expression of their 
targets. Since miRNAs and siRNAs typically reduce the expression levels of targeted 
mRNAs, we focused on predicted targets for which the differential expression of the 
miRNA/siRNA was inversely correlated with the target expression. This analysis showed 
that 11 out of the 15 differentially expressed small RNAs were inversely correlated with a 
subset of their predicted target genes that were at least 1.5-fold differentially expressed in 
psoriasis (Table 5-6). These targeted genes included the p53 inhibitor, mouse double 
minute 4 homolog (MDM4; 204,205), and syndecan 4 (SDC4), which plays a role in 
wound repair (206). Such inverse expression patterns suggested that noncanonical 
miRNAs and endo-siRNAs might influence psoriasis pathogenesis by regulating the 
expression of target genes in the skin. 
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DISCUSSION 
 
Most small RNA profiling studies have focused on canonical miRNAs. In order to 
examine other small RNA species expressed in skin, we searched for novel noncanonical 
miRNAs and endo-siRNAs from diverse origins in the human genome. We reported 23 
novel noncanonical miRNAs derived from snoRNAs, tRNAs and intron lariats, and 39 
putative endo-siRNA loci in repetitive sequences, transposable elements, and piRNA 
hosting regions. These included a snoRNA-derived miRNA that was moderately 
abundant in human skin, the first example of a tRNA-derived miRNA in an adult human 
tissue, and an siRNA derived from an Alu SINE element that was highly upregulated in 
psoriatic skin. 
 
Common features of noncanonical miRNAs and endo-siRNAs from diverse genomic 
origins 
The noncanonical miRNAs and endo-siRNAs that we identified have several 
distinctive characteristics that set them apart from RNA degradation products and other 
transcription products. First, these sncRNAs exhibited a size distribution centered around 
21-22nt, which is distinct from other classes of small RNAs and degradation products. 
One exception to this is the Alu-SINE-derived siRNA we described in which potential 
bulges introduced by imperfect base pairings likely underlie the dominant read size of 
23nt.  
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The second characteristic of noncanonical miRNAs and endo-siRNAs was the 
typical 5’ homogeneity of read clusters. Dicer processing often produces small RNA 
isoforms that differ at the 3’-end, but 5’-end heterogeneity is much less common 
(110,111,207). In contrast, ncRNAs that are not generated by Dicer do not have this 
property. For example, reads that mapped to 3’-ends of tRNAs displayed dramatic 3’-end 
homogeneity, which is characteristic of cleavage activities of RNase Z, the endonuclease 
that releases tRNA sequences (207). One key exception to the typical 5’ homogeneity we 
observed was the U60-derived miRNA, which exhibited three dominant isoforms with 
variable 5’ ends. However, several of the previously described snoRNA-derived miRNAs 
also shared this feature (e.g. hsa-miR-1839/ACA45-derived miRNA), suggesting that the 
biogenesis of snoRNA-derived miRNAs is not fully characterized. 
Lastly, the distribution of 5’ nucleotide identities for noncanonical miRNAs and 
endo-siRNAs was non-random. For noncanonical miRNAs derived from snoRNAs and 
endo-siRNAs, the dominant 5’ nucleotide was A (47.1% and 72.8%, respectively).  
Consistent with this, the presence of a U or A nucleotide facilitates RNA-protein 
interactions within the middle (MID) domain of the human Ago2 protein (208). 
Interestingly, canonical miRNAs have a stronger bias towards a 5’ terminal U nucleotide 
(78.8%). 
 
Association with protein components of the small RNA biogenesis and RNA 
silencing machinery 
Noncanonical miRNAs and siRNAs both require Dicer but not Drosha nor Dgcr8 for 
their biogenesis. In agreement with this, the murine homologs of the ACA61- and 
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ACA25-derived miRNAs, the pseudoTTA-derived miRNA, and the newly annotated 
tailed miRtron, miR-3064, were present in deep sequencing datasets from Dgcr8-
knockout mice but absent from Dicer-knockout mice (189,200). The additional 
noncanonical miRNAs that have murine homologs were not detected in these datasets, 
presumably due to lesser sequencing depth in the murine studies. It is likely that other 
novel sncRNAs from this study are Dgcr8-independent, but we have not been able to 
interrogate them with this analysis since they are not conserved in mouse. 
miRNAs and siRNAs exert their functions through association with RISC 
complexes, which include an Ago protein. In humans, there are four Ago family 
members, but no direct evidence has been collected for the association of endo-siRNAs 
with particular Ago family members (209). Here we show that some noncanonical 
miRNAs and endo-siRNAs associate with Ago2 and Ago3 proteins, indicating that many 
of the noncanonical miRNAs and endo-siRNAs we have described potentially function 
through incorporation into Ago effector complexes. These findings are largely consistent 
with recently published deep sequencing data from human Ago1/2/3/4 
immunoprecipitates (GSE21918) (210). Analysis of this dataset indicated that the 
pseudoTTA-derived miRNA, 50/125 miRtrons, 6/34 MADE1-derived siRNAs, the Alu-
SINE-derived siRNA, and the piRNA-locus-derived siRNAs all associated with one or 
more Ago proteins. Interestingly, sequences derived from the U60 snoRNA were present 
in the Ago immunoprecipitates, but there were no exact matches to the abundant 22nt 
species we detected; these reads were consistent with the 5’ terminus of the 22nt species 
but were typically 28nt in length. Also, the most abundant miRtron, #103, was not 
present in Ago1/2/3/4 immunoprecipitates. However, we found that this miRtron is not 
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endogenously expressed in the HEK293 cell line from which the Ago 
immunoprecipitation data was derived (data not shown). Thus, it is likely that cell-type 
specific expression underlies the absence of miRtron #103 and perhaps other sncRNA 
species from the Ago immunoprecipitation dataset as well.  
 
Distinction between siRNAs and miRNAs 
While miRNAs and siRNAs associate with many of the same cellular proteins for 
their biogenesis and function, they are thought to differ in their genomic origins. miRNAs 
tend to arise from non-repetitive regions of the genome encoding short, intramolecular 
hairpin sequences whereas siRNAs tend to originate from repetitive regions and 
transposable elements with long hairpin formation capability. Despite this, repetitive 
regions have been recently reported to give rise to both miRNAs and siRNAs in mouse, 
and now humans (189,211). This brings up the question: are there differences in the 
architecture of repetitive elements that encode siRNAs and miRNAs? One observation 
we made is that the L2 LINEs encoding canonical miRNAs, such as miR-28, are much 
shorter than typical L2 LINE consensus. Moreover, these short LINEs diverge from the 
L2 LINE consensus at a high rate, leading to the production of distinct small RNA 
species that map uniquely to the genome. Thus, we postulate that longer and less 
divergent transcripts, which have more paralogs, preferentially give rise to siRNAs, while 
shorter and divergent transcripts often produce miRNAs. This may be one reason that the 
number of annotated miRNAs greatly exceeds siRNAs; if, by definition, siRNAs 
originate from less divergent repetitive regions, many legitimate siRNA reads may be 
discarded during analysis due to promiscuous mapping. 
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Based on the distinct genomic origins of miRNAs and siRNAs, our findings 
suggested a small subset of annotated miRNAs should be annotated as siRNAs. One 
example is the miR-548 family, whose many members are derived from Made1 
transposable elements. The characterization of the miR-548 family members as siRNAs 
would also be consistent with the finding that Tcl1 elements, of which Made1 elements 
are a human-specific subclass, are known to derive siRNAs in C. elegans (212). 
Interestingly, a model of evolution of miRNAs from tandem repeats in plants has been 
proposed (213). The model suggests an evolutionary pathway in which inverted repeats 
spawning siRNAs, under certain constraints, evolve to generate miRNAs. In mammals, it 
has been proposed that the insertion of transposable elements into new genomic sites 
could be one of the driving forces that create new miRNAs during mammalian evolution 
(211). Thus, we may have captured some evolutionarily transient sncRNA species with 
our NGS-based approach and systematic analysis. 
miRNAs and siRNAs also differ in their mechanism of action. miRNAs typically 
bind imperfectly to target genes and induce translational repression or cause mRNA 
destabilization while siRNAs bind with near-perfect complementarity and lead to direct 
cleavage of target transcripts (196,214). We have begun the process of target prediction 
with computational methods, based on the proposed mechanisms of miRNA and siRNA 
function. However, it will be important in the future to validate the regulatory effects of 
the novel noncanonical miRNAs and endo-siRNAs on their targets. Such studies will 
improve our understanding of sncRNA regulation and also inform classification of 
sncRNAs as miRNAs or siRNAs. 
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Implications for psoriasis and other human diseases 
For 11/15 differentially expressed noncanonical miRNAs and endo-siRNAs, we 
observed inversely correlated expression with a subset of their predicted targets that are 
differentially expressed in psoriasis. In several cases, these predicted targets were also 
predicted to be regulated by canonical miRNAs that are differentially expressed in 
psoriasis, as described in Chapter 3, suggesting that multiple sncRNAs may contribute to 
psoriasis pathogenesis through their interactions with a single target.  
While all of these predicted targets have been implicated in psoriasis pathogenesis by 
their differential expression in PP skin, many are expressed at low levels in human skin, 
and their fold changes in PP versus NN skin are relatively low. Moreover, these targets 
have not yet been strongly implicated in psoriasis pathogenesis. Despite this, a few have 
particular functional relevance. First, the single predicted target for the highly 
upregulated Alu-SINE-derived siRNA was MDM4. This gene is an inhibitor of p53 that 
is frequently upregulated in cancers (204,205), but modestly downregulated in psoriasis 
(19,203). Thus, the down-regulation of MDM4 in psoriasis, which may be mediated by 
the novel Alu-SINE-derived siRNA we identified, might be one factor that distinguishes 
the benign hyperplasia in psoriatic involved skin from cancerous tumors. Another 
intriguing hypothesis about the function of the Alu-SINE siRNA is that it may bind and 
regulate transcription of genes that contain Alu elements. A second target with particular 
relevance to psoriasis pathogenesis was SDC4, which was predicted to be targeted by the 
tailed miRtron #72. SDC4 knockout mice display delayed wound healing and impaired 
angiogenesis (206). Thus, down-regulation of SDC4, which may be mediated by miRtron 
#72, might contribute to the chronic regenerative phenotype observed in psoriatic 
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involved skin. Both MDM4 and SDC4 are also predicted targets of canonical miRNAs 
that are upregulated in psoriasis.  
We have shown that the sncRNAs described here may regulate genes that are 
differentially expressed in psoriatic lesions. However, some sncRNA species, such as 
piRNAs and endo-siRNAs, tend to exhibit developmentally-restricted expression 
patterns. Other sncRNAs described here may also exhibit this property, which would be 
consistent with their low expression in adult skin. Thus, it is important to consider the 
possibility that aberrant expression of certain sncRNAs during development may underlie 
innate skin barrier or immune defects that contribute to disease susceptibility. 
 
Conclusions and future directions 
In the future, the functionality of the small RNAs described in this chapter should be 
confirmed by RISC loading assays, and their predicted targets in psoriatic skin should be 
validated. Target identification for the Alu-SINE siRNA that is strongly upregulated in 
involved skin would be of particular interest. Overall, our discovery and analysis of 
noncanonical miRNAs and endo-siRNAs from a variety of genomic loci have 
substantially increased our appreciation for the diversity and prevalence of sncRNA 
expression in adult human tissues, provided insights into their biogenesis, and identified 
additional sncRNAs that are differentially expressed in psoriasis. 
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METHODS 
 
Small RNA library preparation, sequencing, and read processing. These 
methods were described in Chapter 2. 
Identification of noncanonical miRNA. Qualified reads that aligned to every 
locus of human snoRNAs, tRNAs and intro-exon boundaries were subjected to our novel 
miRNA prediction method, which was tailored for identifying noncanonical miRNAs. 
Any reads that mapped to previously specified miRNA loci were removed. For each 
snoRNA and tRNA, 50nt extensions on both sides were added for secondary structure 
analysis with RNAfold and mFold (131,132). Since the two programs can predict 
multiple secondary structures, many of which are different, we merged all the predictions 
from both programs for downstream analysis. Structures lacking stems of at least 18nt 
and lacking reads that mapped to any of their stems were excluded. To accommodate 
atypical stem structures that often appear in noncanonical miRNAs, more unpaired based, 
in some cases up to 9bp, were allowed. Candidate miRNAs were then prioritized based 
on 1) occurrence of sequencing reads on the stem of a predicted hairpin structure with 
minimum free energy less than -18kcal/mol; 2) possible presence of miRNA* reads on 
the opposite stem of the hairpin; 3) presence of ~2nt 3’ overhangs on the highest 
likelihood miRNA/miRNA* duplex; and 4) reads length distribution peaks around ~22nt. 
To identify miRtrons, 160nt intronic sequence segments adjacent to exon/intron 
boundaries were extracted for introns analyzed. The same procedure as described above, 
without a sliding window, was then followed to identify miRtrons. In addition, we 
examined the presence of sequencing reads ending with AG dinucleotides as a 
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characteristic feature of miRtron. We also applied RNALfold (131) and manual analyses 
to find local secondary structures. 
Identification of endogenous siRNAs from multiple genomic origins. We 
applied EINVERTED (215) on each 10kb segment of DNA sequences of whole human 
genome (hg 19 build) to search for inverted repeats and long hairpin structures they can 
fold into. We chose inverted repeats by setting a minimum score threshold of 70. Next, 
we filtered out those predicted inverted repeats that have no more than 10 mappable 
reads. We also analyzed the genomic annotation of the predicted inverted repeats, i.e. 
checking them if overlap with SINEs, LINEs or pseudogenes. We next blasted these 
mappable reads to the annotated human noncoding RNAs to rule out the possibility that 
such sequencing reads were byproducts of other types of noncoding RNAs. Finally, we 
examined genomic regions in which the mappable reads have lengths of dominantly 
21~23nt, expected for the length of siRNAs. The amount of the normalized reads having 
unique genomic loci represented the expression levels of such inverted repeats in each 
skin category. 
Conservation analysis of sncRNAs. We retrieved from the UCSC genome 
browser (216) the multiple alignments of nine species – Homo sapiens (human), Macaca 
mulatta (rhesus), Mus musculus (mouse), Canis lupus familiaris (dog), Loxodonta 
Africana (elephant), Monodelphis domestica (opossum), Gallus gallus (chicken), 
Xenopus tropicalis (frog) and Danio rerio (zebrafish) – for each novel miRNA and 
siRNA. We calculated the number of insertions, deletions and mismatches when each 
non-human sequence was compared with a human sncRNA based on the multiple 
alignments of the nine species. An sncRNA was considered conserved in one species if 
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the sequence in that species had no variation (insertions, deletions and mismatches) in the 
seed region for a miRNA or less than 2 variations in the whole region for a siRNA.  
qRT-PCR. qRT-PCR of sncRNAs was performed with custom TaqMan small 
RNA assays (Life Technologies), as described in Chapter 2.  
Cell culture. The cloning of sncRNAs into pEP-miR cloning and expression 
vectors (Cell Bio Labs) and transfections of HEK293 cells were performed as described 
in Chapter 2. 
RIP-PCR. RIP-PCR was performed as described in Chapter 2 for Ago2. The same 
protocol was applied with a rabbit polyclonal antibody for Ago3 (Sigma-Aldrich). 
Significance was determined by one-way ANOVA and post-hoc two tailed t-tests. 
Digital gene expression analysis. Digital gene expression analysis was performed as 
described in Chapter 2, except that no detection filter was applied, to allow for analysis of 
low abundance sncRNA species. 
Putative targets of miRNAs and siRNAs. miRNA target genes were predicted by 
TargetScan (72,79) and starBase (202). We used the common target genes predicted by 
both programs. For predicting targets of siRNAs, human cDNA sequences were 
downloaded from UCSC genome browser (hg19 build) and the reverse complementary 
sequences of siRNAs were mapped to the cDNA sequences by BLAST (217). Hits with 
fewer than four mismatches were considered as putative targets of siRNAs.  
mRNA gene expression analysis. Microarray data of mRNA genes of psoriatic and 
normal skin of human were downloaded from Gene Expression Omnibus (GEO) 
accession number GSE13355, which has a total of 122 samples containing 58 psoriatic 
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patients and 64 normal healthy controls. Differentially expressed genes were identified 
using Rank Product (218). We selected differentially expressed genes with a false 
discovery rate less than 0.05 for 1,000 permutations. Differentially expressed probe sets 
were aligned to corresponding genes according to the annotation of Affymetrix Human 
Genome U133 Plus 2.0 Array. 
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Table 5-3. Summary of miRtrons expressed in human skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#8 chr1 161196984 161197047 + 875 tailed miRtron TOMM40L 303 100 1,3,4
#14* chr1 37945827 37945890 + 36 tailed miRtron ZC3H12A 4351 83
#20 chr12 48526580 48526650 + 341 tailed miRtron PFKM 1475 94 1,4
#43 chr19 58846055 58846124 + 255 tailed miRtron ZSCAN22 7638 100
#64 chr1 201972254 201972364 + 42 tailed miRtron RNPEP 1470 94 1,3
#67 chr12 48131469 48131537 - 42 tailed miRtron RAPGEF3 337 65 1,3,4
#72 chr2 219144850 219144913 - 872 tailed miRtron TMBIM1 1814 100
#74* chr11 62334483 62334540 - 32 tailed miRtron EEF1G 389 91
#75* chr10 102798336 102798399 + 37 tailed miRtron SFXN3 1212 85
#77* chr2 61008950 61009019 + 16 tailed miRtron PAPOLG 1106 100
#80 chr17 39673418 39673471 - 4729 tailed miRtron KRT15 1165 99
#91* chr16 28735574 28735642 + 36 tailed miRtron EIF3C 771 100
#103 chr5 150901648 150901715 - 2606 tailed miRtron FAT2 3682 100
#114 chr11 62560174 62560243 - 440 tailed miRtron NXF1 1557 100 3,4
#118 chr1 43830304 43830394 - 243 tailed miRtron ELOVL1 91 87
#119 chr15 75132983 75133046 - 317 tailed miRtron ULK3 764 100
#129 chr10 103870890 103870973 - 27 tailed miRtron LDB1 112 100 1
#130 chr10 104139213 104139277 + 15 tailed miRtron GBF1 87 92
#141 chr1 1231489 1231547 - 47 tailed miRtron ACAP3 102 100 1
#142 chr11 1857595 1857654 + 52 tailed miRtron SYT8 141 100
#144* chr7 123329205 123329266 - 180 tailed miRtron WASL 3197 100
#145 chr17 40666218 40666306 + 388 tailed miRtron ATP6V0A1 311 91 1,3,4
#150* chr19 13063440 13063502 + 47 tailed miRtron RAD23A 3281 97 3
#152 chr11 85989377 85989440 + 170 tailed miRtron EED 408 100 3
#158 chr12 121442296 121442365 - 82 tailed miRtron C12orf43 514 66
#159 chr22 38363570 38363631 + 141 tailed miRtron POLR2F 455 99 3
#168 chr1 25245836 25245902 - 72 tailed miRtron RUNX3 8230 100
#174 chr13 42142435 42142518 - 18 tailed miRtron KIAA0564 2163 93
#175* chr22 30737875 30737948 - 31 tailed miRtron SF3A1 315 80 3
#179 chr1 43914209 43914289 + 105 tailed miRtron SZT2 128 77 1,3,4
#186 chr3 52557358 52557442 + 114 tailed miRtron STAB1 86 96
#203 chr17 74094090 74094160 - 64 tailed miRtron EXOC7 3253 98
#204 chr17 8048311 8048384 - 38 tailed miRtron PER1 965 97
#206 chr18 10759582 10759642 - 63 tailed miRtron PIEZO2 122 97
#210 chr19 3201454 3201531 + 26 tailed miRtron NCLN 2626 100
#211 chr7 143079629 143079685 + 40 tailed miRtron ZYX 146 100 3
#212 chr19 35613605 35613671 + 101 tailed miRtron FXYD3 1520 100
#214 chr19 40486136 40486193 + 15 tailed miRtron PSMC4 140 0**
#215 chr19 41175925 41175995 - 17 tailed miRtron NUMBL 3324 94 3
#217 chr19 48981457 48981542 + 23 tailed miRtron CYTH2 130 95
#218* chr19 11333582 11333668 - 43 miRtron DOCK6 88 100 3
#219 chr19 49513167 49513229 + 16 tailed miRtron RUVBL2 91 100
#220 chr19 55751279 55751340 - 173 tailed miRtron PPP6R1 88 92 3
#221* chr17 73775045 73775127 - 20 miRtron H3F3B 84 100 1,3
#222 chr19 6389649 6389712 - 61 tailed miRtron GTF2F1 2265 100 1,3
#228 chr20 60913663 60913725 - 21 tailed miRtron LAMA5 7210 94
#231 chr21 46898180 46898240 + 101 tailed miRtron COL18A1 362 100
#232 chr2 160043351 160043412 + 21 tailed miRtron TANC1 1003 100
#237 chr2 219206639 219206704 + 34 tailed miRtron PNKD 355 100
#239 chr22 30403042 30403102 + 76 tailed miRtron MTMR3 4121 57
#240 chr2 232658900 232658972 + 28 tailed miRtron COPS7B 2455 100
#246 chr2 69053052 69053118 + 27 tailed miRtron ARHGAP25 3115 96
#247* chr11 118514732 118514789 + 298 tailed miRtron PHLDB1 132 82
#252* chr6 32137816 32137887 - 170 tailed miRtron AGPAT1 127 0** 3
#253 chr3 148601339 148601399 + 28 tailed miRtron CPA3 1018 100
#256 chr3 49843594 49843663 - 33 tailed miRtron UBA7 1571 93
#257 chr3 52437314 52437388 - 30 tailed miRtron BAP1 118 100
#258 chr6 32147595 32147653 + 41 tailed miRtron RNF5P1 114 100
#260 chr4 55956244 55956299 - 29 tailed miRtron KDR 2539 100
#271* chr19 55756554 55756632 - 77 tailed miRtron PPP6R1 80 97 3
#275 chr6 6152180 6152243 - 27 tailed miRtron F13A1 15509 100
#277 chr7 2297150 2297207 - 25 tailed miRtron SNX8 221 100
#279 chr7 44091368 44091428 + 52 tailed miRtron DBNL 1550 75
#281 chr7 64139446 64139555 + 319 tailed miRtron ZNF107 9999 100
#284* chr19 55899552 55899610 + 29 tailed miRtron RPL28 195 100 3
#285* chr9 34709425 34709496 - 11 miRtron CCL21 73 100
#286 chr8 125579420 125579474 - 80 tailed miRtron MTSS1 1201 100
#304 chr9 33467863 33467931 - 47 tailed miRtron NOL6 162 100
#306 chr9 35732924 35732993 + 38 tailed miRtron CREB3 95 100
#309 chrX 153209603 153209674 - 22 tailed miRtron RENBP 154 95
#314 chr17 4872997 4873061 - 21 tailed miRtron CAMTA2 201 0** 3
#318 chr8 62460768 62460813 - 26 tailed miRtron ASPH 4823 0**
#321 chr11 122928628 122928693 - 86 tailed miRtron HSPA8 333 91
#328 chr1 149937804 149937875 - 62 tailed miRtron OTUD7B 1416 50
#335 chr12 88193 88256 + 154 tailed miRtron LOC100288778 240 87 1,3
#338 chr16 16418445 16418511 + 960 tailed miRtron PKD1P1 128 96 1,3,4
#341 chr17 38318189 38318256 + 109 tailed miRtron CASC3 91 100
#344 chr17 40860101 40860165 - 72 tailed miRtron EZH1 793 80
#350* chr3 127294109 127294173 - 30 tailed miRtron TPRA1 138 0** 3
#354* chr22 38165195 38165268 + 16 miRtron TRIOBP 75 100 1,3,4
#359 chr6 42071617 42071692 - 72 tailed miRtron C6orf132 585 100 3
#363 chr9 132631885 132631950 + 71 tailed miRtron USP20 247 97 1,3,4
#371* chr17 43011986 43012047 - 105 tailed miRtron KIF18B 214 100 1,3,4
#375 chr19 13051296 13051354 + 328 tailed miRtron CALR 89 100 1,3
#378 chr8 125520755 125520843 - 18 miRtron TATDN1 89 100 2,4
aAGO immunoprecipitate data sets in which the mature miRtron sequence was present (Hafner et al., 2010).
% 
terminating  AGO
a
* Low abundance or atypically folded miRtrons discovered by re-analysis
** No miRNA* reads terminating at splice sites were sequenced. 
Table 5-3. Summary of 85 novel miRtrons expressed in skin
ID Chr Start End Strand No. reads Type Host gene Intron length
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Table 5-4. Summary of MADE1 elements associated with small RNA reads. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID Chr Start End Strand Annotation No. reads AGOa
Made1_#1 chr1 82174864 82174941 - DNA transposon 2025
Made1_#2 chr1 183752471 183752547 - DNA transposon 11
Made1_#3 chr1 235107531 235107603 - DNA transposon 11
Made1_#4 chr10 24007027 24007109 - DNA transposon 5 1
Made1_#5 chr10 68389161 68389229 - DNA transposon 15
Made1_#6 chr10 125670996 125671075 + DNA transposon 19 3
Made1_#7 chr11 20033822 20033901 + DNA transposon 15
Made1_#8 chr12 72267908 72267986 + DNA transposon 340
Made1_#9 chr14 96672883 96672962 - DNA transposon 24
Made1_#10 chr14 102828042 102828118 + DNA transposon 67 1
Made1_#11 chr15 94624333 94624411 - DNA transposon 19
Made1_#12 chr16 47708265 47708339 - DNA transposon 26
Made1_#13 chr16 79750312 79750392 + DNA transposon 49
Made1_#14 chr17 40646790 40646858 - DNA transposon 29 3
Made1_#15 chr17 66383129 66383208 + DNA transposon 14
Made1_#16 chr2 49286730 49286810 - DNA transposon 422
Made1_#17 chr2 54806171 54806249 - DNA transposon 20
Made1_#18 chr2 72878633 72878708 - DNA transposon 9 3
Made1_#19 chr2 96656055 96656137 + DNA transposon 12
Made1_#20 chr2 137402682 137402759 - DNA transposon 25
Made1_#21 chr21 36253203 36253279 + DNA transposon 14
Made1_#22 chr4 175636930 175637008 - DNA transposon 22
Made1_#23 chr5 31470534 31470597 - DNA transposon 23
Made1_#24 chr5 55858293 55858360 - DNA transposon 24
Made1_#25 chr5 150485436 150485514 + DNA transposon 14
Made1_#26 chr6 38630466 38630545 - DNA transposon 10 2,3
Made1_#27 chr6 108097497 108097575 - DNA transposon 40
Made1_#28 chr6 119499447 119499519 + DNA transposon 19
Made1_#29 chr8 27082383 27082437 + DNA transposon 13
Made1_#30 chr8 41128575 41128654 + DNA transposon 20
Made1_#31 chr9 96357111 96357181 + DNA transposon 30
Made1_#32 chr2 60343031 60343108 + DNA transposon 10
Made1_#33 chr8 68965595 68965658 - DNA transposon 8
Made1_#47 chr9 135821094 135821159 - DNA transposon 2198
aAGO immunoprecipitate data sets in which the mature miRtron sequence was present (Hafner et al., 2010).
Table 5-4. Summary of MADE1 elements associated with sncRNA reads
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Figure 5-1. Length distribution and 5’ nucleotide identity for all qualified reads 
aligned to (A) annotated miRNAs (miRbase version 17), (B) endo-siRNA loci identified 
in current study, (C) snoRNAs, (D) tRNAs and (E) rRNAs (Ensembl noncoding RNA 
version 61). 
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Figure 5-2. A miRNA derived from C/D box snoRNA U60. (A) The stem-loop hairpin 
structure of U60, with bases of the putative miRNA colored in red.  (B) Read alignments 
with the number of sequencing reads, length of read and the number of genomic loci to 
which the read can be mapped with no mismatches.  
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Figure 5-3. Noncanonical miRNAs derived from tRNAs. (A) miRNA derived from 
tRNA candidate pseudoTTA. Top panel, tRNA folding structure with a presumed tRNA 
fragment highlighted in red, and the alternative miRNA hairpin structure with the 
miRNA and miRNA* highlighted in green and blue respectively. Bottom panel, read 
alignments, with the number of reads, length of read, and the number of genomic loci to 
which the read can be mapped with no mismatches. The red vertical lines represent the 5’ 
and 3’ ends of the tRNA. (B) miRNA derived from pseudo-TTA. Top panel, tRNA and 
predicted pre-miRNA hairpin structures. The putative mature miRNA sequence is 
indicated in red. Bottom panel, read alignments with the number of reads, length of read, 
and the number of genomic loci to which the read can be mapped with no mismatches. 
The pseudoTTA tRNA sequence is highlighted in blue. 
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Figure 5-4. Examples of newly annotated miRtrons. (A) hsa-miR-636, (B) hsa-miR-
936 and (C) hsa-miR-3064. The red vertical lines indicate exon/intron boundaries. Red 
bases represent intron sequences; blue bases represent exon sequences.   
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Figure 5-5. Features of novel tailed miRtrons, #80 and #103. (A) The hairpin 
structures with the putative mature miRNAs indicated in red. (B) Read alignments with 
the number of reads, length of read and the number of genomic loci to which the read can 
be mapped. The vertical lines indicate the intron/exon boundaries. Reads terminating 
within 1nt of intron 3’ acceptor splice sites end with bases in red.  
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Figure 5-6. endo-siRNA derived from tandem Alu SINE transposable elements in an 
intron of the gon-4-like (GON4L) gene on chromosome 1. (A) Alignment of 
sequencing reads to the human genome (hg19). The three Alu SINEs are represented as 
thick grey lines with “+” or “-” indicating the plus or negative orientation. The red box 
indicates the reads uniquely mapped to this locus.  (B)  Abundance of siRNAs in six 
constructs that include six combinations of the three Alu SINEs. The y-axis indicates the 
normalized expression relative to the wide-type. (C) Predicted folding structure of the 
first two Alu SINEs. The most abundant RNA species is highlighted in green. 
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Figure 5-7. Examples of endo-siRNAs derived from repetitive elements. Small RNA 
reads aligned to (A) an L1 LINE (B) an LTR. The repeats are represented as thick grey 
lines. Filled red and blue rectangles indicate reads aligning to the + and – strands, 
respectively. Open red rectangles represent the dominant read clusters from each locus. 
The most abundant read from these clusters are highlighted in green along the hairpin 
structures. 
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Figure 5-8. Example of endo-siRNAs derived from a MADE1 element. (A) Read 
alignments for a representative MADE1 locus on chromosome 1. (B) Predicted folding 
structure of the locus with a RNA/RNA duplex marked in green. (C) Distribution of reads 
within the locus. 
 
 
 
 
Figure 5-9. endo-siRNAs derived from two piRNA annotated loci. (A) Bimodal 
length distributions of reads mapped to the two piRNA loci. (B) Putative endo-siRNA 
sequences aligned to their respective paralagous known miRNAs. 
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Figure 5-10.  Endogenous expression of mature novel miRNAs in skin. (A) qRT-PCR 
amplification traces of sncRNAs from human skin biopsy RNA (black lines) and negative 
controls (grey lines). An arbitrary threshold used for relative quantitation of expression 
levels (not shown) is indicated in green. (B) qRT-PCR product bands from human skin 
biopsy RNA and negative controls. A band size of ~50bp corresponds to an ~21-nt RNA 
species due to the addition of arbitrary sequence during the reverse transcription step (see 
Methods). (C) Abundance of sncRNAs in Ago2 and Ago3 immunoprecipitates relative to 
IgG. (* p<0.05, **p<0.01, ***p<0.001). RT = reverse transcriptase. 
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Figure 5-11. Differential expression of sncRNAs in involved psoriatic skin. (A) qRT-
PCR levels of differentially expressed sncRNAs in ten normal (NN), ten uninvolved 
psoriatic (PN), and ten involved psoriatic (PP) skin samples. Lines indicate matched 
uninvolved and involved samples from the same patient. Relative expression was 
calculated with respect to the endogenous snoRNA Z30. (* p<0.05, **p<0.01, 
***p<0.001). (B) Heat map of 15 differentially expressed sncRNAs across 67 skin 
samples. 
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Chapter 6. 
Conclusions and future directions 
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SUMMARY 
 
It has long been appreciated that gene expression is widely altered in psoriatic 
skin due to impaired keratinocyte differentiation, inflammation, and immune cell 
activation. I hypothesized that differential expression of small noncoding regulatory 
RNAs (sncRNAs) might underlie some of the gene expression changes in psoriatic skin. 
Thus, I sought to characterize the global landscape of sncRNA expression in human skin, 
and to investigate the functional roles of sncRNAs with respect to psoriasis pathogenesis.  
In chapter two, I described the global microRNA (miRNA) landscape in human 
skin, as assessed by Next Generation sequencing (NGS). I detected nearly 900 known 
miRNAs and miRNA*s, a number of previously undescribed miRNA*s from known 
miRNA loci, variants of known miRNAs (isomiRs and putatively edited miRNAs), and 
nearly 300 novel miRNA loci expressed in skin. Chapters 3 and 4 focused on the 
contribution of miRNAs to psoriasis pathogenesis. I described the differential expression 
of 98 known and novel miRNAs in psoriatic skin, and showed that three differentially 
expressed miRNAs regulated components of the skin barrier. Lastly, in Chapter 6, I 
described the expression of noncanonical miRNAs and endogenous small interfering 
RNAs (endo-siRNAs) in normal and psoriatic skin, including the dramatic upregulation 
of a novel Alu SINE-derived siRNA in involved (PP) skin. 
In summary, this thesis details the generation and analysis of the largest small 
RNA dataset produced from any human tissue to date and the use of molecular genetic 
approaches to validate and follow up on NGS-based findings. Future work should include 
functional analysis of the three miRNAs that regulate barrier components in vivo; 
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characterization of regulatory networks in skin involving both mRNAs and miRNAs; and 
profiling of poly(A)- RNA species, such as long noncoding RNAs, in normal and 
psoriatic skin. 
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FUTURE DIRECTIONS 
 
  
Functional of miRNAs in the skin barrier 
 
 I have identified two members of the LCE gene family as direct targets of 
differentially expressed miRNAs in keratinocytes. This finding is significant because the 
LCE gene family has been strongly implicated in psoriasis, based on gene expression and 
GWAS studies. Moreover, LCE gene products are constituents of the skin barrier, which 
is dramatically impaired in psoriatic skin. It has also been suggested that innate barrier 
defects could predispose individuals to psoriasis later in life. Thus, it is important to 
characterize the phenotypic consequences of miRNA-mediated regulation of LCE family 
members. 
 Neither the miR-135b and miR-7 sites in LCE1B, nor the miR-486 binding site in 
LCE3E are conserved in mouse. Thus, primary human keratinocytes or epidermal 
equivalents provide the best system in which to study phenotypic effects of endogenous 
miRNA:LCE interactions. For primary keratinocytes, supplementation of medium with 
calcium induces differentiation over a period of seven days; for epidermal equivalents, 
the exposure of keratinocytes to an air-liquid interface induces stratification reminiscent 
of the native epidermis. In either case, it would possible to perturb miR-135b, miR-7, or 
miR-486 expression during the course of differentiation and screen for various 
phenotypes such as cell viability, proliferation, apoptosis, or gross morphology. 
Moreover, cells could be harvested at various time points and subjected to expression 
profiling or qRT-PCR for specific differentiation markers. These experiments would 
indicate whether perturbation of a single miRNA in keratinocytes is sufficient to induce a 
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differentiation defect in keratinocytes, and whether the misexpression of these miRNAs 
alters expression additional genes besides LCE that are related to keratinocyte 
differentiation. 
 An alternative means of studying the phenotypic effects of miR-135b, miR-7, and 
miR-486 in skin would be to generate transgenic mice expressing “humanized” LCE1B 
and LCE3E from their endogenous loci. This would render these genes susceptible to the 
miRNA regulation that I observed in humans. It would then be possible to assess whether 
the presence of human LCE1B or LCE3E affected characteristic features of the mouse 
epidermis (such as barrier thickness or hair follicle spacing), and whether such 
phenotypes were influenced by altered expression of miR-135b, miR-7, or miR-486. It 
might also be possible to perform these experiments in mouse models of psoriasis, to 
determine whether the presence of humanized LCE genes influences pathogenic features 
of the model. Such experiments could provide insight into innate differences between 
human and mouse epidermis and the functional impact of recently evolved miRNA:target 
interactions.  
I hypothesize that miR-135b, miR-7, and miR-486 influence barrier composition 
in PP skin by regulating the translation of LCE1B and LCE3E in the spinous and granular 
layers of the skin, prior to terminal differentiation. This hypothesis was partially based on 
the suprabasally restricted expression pattern of miR-135b in the epidermis, as 
determined by RNA in situ hybridization However, the spatial expression patterns of 
miR-7, miR-486, and LCE mRNAs remain unknown.  It would be extremely useful to 
visualize these species with RNA in situ hybridization in skin sections. In order for the 
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miRNAs to exert their proposed regulatory functions, I would expect that the miRNA and 
cognate LCE mRNA species would exhibit similar spatial expression patterns.  
 
 
Characterization of regulatory networks in psoriatic skin 
 
 Small RNAs are differentially expressed in psoriatic skin, and are likely 
contribute to disease pathogenesis. Specifically, I have shown that the differentially 
expressed miRNAs miR-7, miR-135b, and miR-486 regulate the barrier constituents, 
LCE1B and LCE3E. However, miRNAs function pleiotropically, and can influence a 
large number of direct and indirect targets within a cell. Thus, regulation of singular 
targets likely accounts for a small fraction of a given miRNA’s total activity, and it is 
important to characterize their regulatory impact on a larger scale. Indeed, I have shown 
that many of the differentially expressed transcripts in psoriatic skin are predicted to be 
targets of differentially expressed miRNAs. However, this approach relied on algorithms 
for target prediction that are not very accurate, and the transcript expression data was 
generated with array based techniques which are insensitive to low abundance species 
and exhibit a limited dynamic range.  
 In order to generate a more complete transcriptome profile from normal and 
psoriatic skin, our lab has generated poly(A)+ RNA libraries for deep sequencing from 
seven normal (NN), nine uninvolved (PN), and nine PP skin biopsy samples. Importantly, 
the set of skin biopsy samples we profiled overlap with small RNA sequencing samples, 
so that levels of small RNAs and mRNAs within a single biopsy can be directly 
compared. We are currently analyzing these data in order to characterize key gene 
expression networks that are perturbed in psoriatic skin. We will then perform sample-
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matched comparisons of mRNA and miRNA expression in skin to elucidate 
concentration dependent relationships between mRNAs and miRNAs, independent of 
target prediction algorithms. This type of analysis has been successfully applied for the 
melanoma tumor suppressor miR-211 (95). In that case, strong anti-correlations were 
observed for known miR-211 targets. Additionally, it was found that miR-211 directly 
targets two of three central node genes in the melanoma metastasis network, which 
accounts for its strong influence on cell migration and invasiveness of melanoma cells. 
 Based on these findings in melanoma, we expect that a small number of 
differentially expressed miRNAs will regulate central nodes of gene expression networks 
in psoriasis. The misexpression of such miRNAs may exert strong pathogenic effects due 
to their indirect influence on large numbers of downstream targets. Many other miRNAs 
may directly regulate downstream factors, and would be expected to yield more subtle 
effects on disease pathogenesis. Such effects could be combinatorial, such that multiple 
miRNAs converge on a single target (as in the case of miR-7 and miR-135b on LCE1B), 
or a single miRNA regulates multiple targets. Overall, this approach has been shown to 
yield powerful insights into the role of miRNAs in melanoma pathogenesis, and should 
be similarly effective in psoriasis. 
Despite the power of this analysis, it is important to note it does not assess the 
direct, physical association of miRNAs and their targets. Thus, the development and 
application of new techniques for the global identification of direct miRNA targets in situ 
or in vivo will be crucial in order to understand the full effect of miRNA regulation in the 
skin. 
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Non-polyadenylated noncoding RNAs 
  
 Polyadenylation of mRNAs is prevalent in eukaryotic cells, and associated with 
transcript stability. While the majority of expressed mRNAs are poly(A)+, poly(A)- 
transcripts account for the majority of expressed RNAs in the cell. These include classical 
examples, such as rRNA transcripts (which account for >90% of the RNA content in a 
cell) and histone transcripts, as well as some mRNAs and noncoding RNAs (219,220). 
Poly(A)- RNAs include those that are never adenylated, as well as those that are initially 
adenylated but later undergo regulated deadenylation (219,220).  
Common RNA sequencing methods use poly(A)+ selection as a method for 
depleting highly abundant rRNA transcripts from the library, but such selection also 
excludes other poly(A)- species that may be of functional importance. Thus, new 
techniques are being developed for the analysis of poly(A)- species. One example is the 
RiboMinus method developed by Invitrogen, which depletes rRNA transcripts by 
hybridizing total RNA to biotinylated LNA probes designed against rRNA sequences, 
and then removing the hybridized RNAs with magnetic streptavidin-conjugated beads. 
Application of such poly(A)- profiling techniques has provided new insights into 
poly(A)- populations in human cells. For example, poly(A)- fractions in Hela and H9 cell 
lines included stable, excised introns; small noncoding RNAs such as snoRNAs, 
scaRNAs, and miRNA precursors; and intergenic, intragenic, and antisense long 
noncoding RNAs (220). 
Based on the widespread expression changes in poly(A)+ and small noncoding 
RNAs in involved skin, we would expect that some species of poly(A)- RNA would also 
be misexpressed. Indeed, one long non-coding RNA, the psoriasis susceptibility-related 
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RNA gene induced by stress (PRINS), has been previously implicated in psoriasis 
susceptibility (221). PRINS is a ~7kb noncoding RNA that is transcribed by RNA 
polymerase II, and induced in keratinocytes under various stress conditions. PRINS is 
highly expressed in PN skin compared to NN and PP (221). While PRINS is 
polyadenylated, its connection to psoriasis highlights the potential contribution of long 
noncoding RNAs to disease susceptibility, thus motivating a more complete 
understanding of long noncoding RNA expression in psoriasis via deep sequencing of 
poly(A)- RNAs. Overall, deep sequencing of the poly(A)- fraction would complete the 
psoriasis transcriptome, and allow a full integrated analysis of regulatory networks 
comprised of mRNAs, sncRNAs, and long noncoding RNAs. 
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CONCLUDING REMARKS 
 
Psoriasis is a complex disease, with many genes contributing to disease 
susceptibility and pathogenesis. Psoriatic skin exhibits myriad mRNA expression changes 
and, based on the work described in this thesis, misexpression of sncRNAs such as 
miRNAs. Some differentially expressed miRNAs have previously described functions 
and are likely to regulate targets involved in keratinocyte differentiation, inflammation 
and immunity, or angiogenesis; many others, including several novel miRNAs, are of 
unknown function. I have characterized three miRNAs of unknown function as negative 
regulators of skin barrier components. This finding adds to the increasing body of 
evidence that, despite the large number of immune-related psoriasis susceptibility genes, 
barrier defects also contribute to psoriasis pathogenesis. Overall, the work described in 
this thesis has advanced our understanding of sncRNA expression in skin, and implicated 
many new sncRNAs in psoriasis pathogenesis. Integrated analysis of global miRNA and 
mRNA expression in normal and psoriatic skin will likely refine our understanding of 
regulatory networks affected by the disease, and inform the development of new 
therapies for psoriasis. 
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Table A-1. Differentially expressed miRNAs targeting differentially expressed transcripts in psoriasis 
DOWNREGULATED TARGETS OF DE MIRNAs (up and downreg miRNAs listed): 
Transcript PP/NN Targeting miRNA (PP/NN) 
>AKR1B10 57.64 hsa-miR-375(-2.41),hsa-miR-665(2.34) 
>SERPINB4 57.48 hsa-miR-542-3p(1.31) 
>SERPINB3 40.89 hsa-miR-7(3.05),hsa-miR-542-3p(1.31) 
>IL1F9 36.34 hsa-miR-155(2.7),hsa-miR-944(2.85) 
>C10orf99 31.76 hsa-miR-431(3.91),hsa-miR-33b(2.23),hsa-miR-665(2.34) 
>KYNU 25.46 hsa-miR-33b(2.23),hsa-miR-542-3p(1.31),hsa-miR-375(-2.41),hsa-miR-1307(1.97) 
>IL8 17.47 hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-665(2.34),hsa-miR-369-3p(2.31) 
>KRT16 16.98 hsa-miR-665(2.34) 
>ADAMDEC1 15.86 hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-1276(2.14),hsa-miR-628-3p(-1.87) 
>GDA 14.40 hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-33b(2.23),hsa-miR-212(2.08),hsa-miR-590-3p(1.94),hsa-miR-10a(-
2.31),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-665(2.34),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-33b(2.23),hsa-miR-487a(2.12),hsa-miR-1308(2.03),hsa-miR-628-3p(-
1.87),hsa-miR-1179(-2.02) 
>TMPRSS11D 12.18 hsa-miR-135b(5.65),hsa-miR-431(3.91),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-
944(2.85),hsa-miR-1308(2.03),hsa-miR-885-5p(-2.56) 
>SLC6A14 10.59 hsa-miR-21(3.95),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-1303(2.66) 
>OASL 9.88 hsa-miR-944(2.85),hsa-miR-548f(2.32) 
>KLK13 9.77 hsa-miR-206(12.8),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31) 
>RRM2 9.20 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-548f(2.32),hsa-miR-486-3p(-2.56) 
>OAS2 8.97 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-135b(5.65),hsa-miR-
155(2.7),hsa-miR-885-5p(-2.56) 
>CLEC7A 8.72 hsa-miR-135b(5.65),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-369-
3p(2.31),hsa-miR-487a(2.12),hsa-miR-628-3p(-1.87) 
>ATP12A 8.00 hsa-miR-1276(2.14),hsa-miR-885-5p(-2.56) 
>STAT1 7.98 hsa-miR-155(2.7),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-592(2.92),hsa-miR-
1303(2.66),hsa-miR-548f(2.32),hsa-miR-223(2.13) 
>ZC3H12A 7.73 hsa-miR-486-3p(-2.56) 
>GJB2 7.31 hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-665(2.34),hsa-miR-487a(2.12) 
>HERC6 7.04 hsa-miR-10a(-2.31),hsa-miR-1303(2.66) 
>RGS1 6.96 hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-376b(1.73),hsa-miR-
21(3.95),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-369-3p(2.31) 
>IL1F5 6.62 hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-548f(2.32) 
>SPRR3 6.61 hsa-miR-135b(5.65) 
>SPRR1A 6.41 hsa-miR-7(3.05),hsa-miR-542-3p(1.31),hsa-miR-509-5p(1.61) 
>CCL18 6.22 hsa-miR-33b(2.23) 
>CXCL9 6.06 hsa-miR-31(42.93),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-137(-2.37),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-1308(2.03) 
>CXCL13 6.01 hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-486-5p(-1.81) 
>CCNB1 5.97 hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-548f(2.32) 
>RGS20 5.93 hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-212(2.08),hsa-miR-188-5p(2.36) 
>A2ML1 5.88 hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-944(2.85),hsa-miR-211(2.6) 
>CXCL1 5.81 hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-487a(2.12),hsa-miR-135b(5.65),hsa-miR-
7(3.05),hsa-miR-212(2.08),hsa-miR-135b(5.65),hsa-miR-665(2.34),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-
miR-1179(-2.02) 
>GZMB 5.70 hsa-miR-378(2.68) 
>TGM1 5.64 hsa-miR-142-3p(2.52) 
>HAS3 5.62 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-377(1.81),hsa-miR-486-5p(-1.81),hsa-miR-10a(-
2.31),hsa-miR-375(-2.41),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-
1308(2.03),hsa-miR-509-5p(1.61) 
>SOD2 5.55 hsa-miR-211(2.6),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-
1276(2.14),hsa-miR-509-5p(1.61),hsa-miR-486-3p(-2.56) 
>OAS1 5.52 hsa-miR-31(42.93),hsa-miR-378(2.68),hsa-miR-1303(2.66) 
>EPSTI1 5.51 hsa-miR-944(2.85) 
>MXD1 5.45 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-137(-2.37),hsa-miR-1268(4.45),hsa-miR-21(3.95),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-628-3p(-1.87),hsa-miR-885-5p(-2.56) 
>CNFN 5.43 hsa-miR-7(3.05) 
>RSAD2 5.26 hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-548f(2.32) 
>WNT5A 5.02 hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32),hsa-miR-
369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-487a(2.12),hsa-miR-885-5p(-2.56) 
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>TGM3 5.00 hsa-miR-206(12.8),hsa-miR-1268(4.45),hsa-miR-486-3p(-2.56) 
>SAMD9 4.98 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-
5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-885-5p(-2.56) 
>EHF 4.91 hsa-miR-206(12.8),hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-142-3p(2.52),hsa-miR-212(2.08),hsa-miR-590-
3p(1.94),hsa-miR-377(1.81),hsa-miR-137(-2.37),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-
miR-377(1.81),hsa-miR-1179(-2.02) 
>UPP1 4.90 hsa-miR-590-3p(1.94) 
>ARSF 4.77 hsa-miR-206(12.8) 
>KCNJ15 4.75 hsa-miR-206(12.8),hsa-miR-223(2.13),hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46),hsa-miR-1276(2.14) 
>HAL 4.72 hsa-miR-155(2.7),hsa-miR-137(-2.37),hsa-miR-369-3p(2.31),hsa-miR-885-5p(-2.56) 
>LAMP3 4.65 hsa-miR-377(1.81),hsa-miR-375(-2.41),hsa-miR-944(2.85) 
>VNN3 4.52 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-486-5p(-1.81),hsa-miR-455-3p(2.46) 
>MX1 4.50 hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-188-5p(2.36) 
>FCHSD1 4.40 hsa-miR-1268(4.45),hsa-miR-188-5p(2.36),hsa-miR-885-5p(-2.56) 
>ALOX12B 4.37 hsa-miR-129-5p(-2.62) 
>SLC5A1 4.34 hsa-miR-135b(5.65),hsa-miR-211(2.6) 
>SPTLC2 4.34 hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-212(2.08),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-
211(2.6),hsa-miR-146a(2.36),hsa-miR-1179(-2.02) 
>WFDC12 4.33 hsa-miR-378(2.68),hsa-miR-377(1.81),hsa-miR-137(-2.37) 
>SH3PXD2A 4.26 hsa-miR-590-3p(1.94),hsa-miR-944(2.85) 
>KIAA0101 4.24 hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-940(2.79),hsa-miR-378(2.68),hsa-miR-1303(2.66),hsa-miR-
1276(2.14) 
>TMEM45B 4.19 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-10a(-2.31) 
>OAS3 4.08 hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-542-3p(1.31),hsa-miR-944(2.85),hsa-miR-
378(2.68),hsa-miR-188-5p(2.36),hsa-miR-665(2.34),hsa-miR-1276(2.14),hsa-miR-487a(2.12),hsa-miR-1179(-
2.02),hsa-miR-486-3p(-2.56) 
>CKS2 4.06 hsa-miR-7(3.05),hsa-miR-548f(2.32) 
>CARHSP1 4.05 hsa-miR-31(42.93),hsa-miR-155(2.7),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-
377(1.81) 
>KLK10 4.04 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-18a(2.43),hsa-miR-21(3.95),hsa-miR-486-3p(-2.56) 
>CHRNA9 4.02 hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85) 
>PLAT 3.97 hsa-miR-486-5p(-1.81),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32) 
>RAB27A 3.95 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-944(2.85),hsa-miR-
940(2.79) 
>CDKN3 3.95 hsa-miR-146a(2.36),hsa-miR-548f(2.32) 
>LRG1 3.90 hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-940(2.79),hsa-miR-1308(2.03) 
>KRT6B 3.87 hsa-miR-146a(2.36),hsa-miR-369-3p(2.31) 
>XDH 3.84 hsa-miR-496(3.02),hsa-miR-542-3p(1.31),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-455-3p(2.46) 
>ERO1L 3.78 hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-944(2.85),hsa-miR-487a(2.12) 
>PBK 3.70 hsa-miR-590-3p(1.94),hsa-miR-885-5p(-2.56) 
>MELK 3.69 hsa-miR-944(2.85) 
>FOXE1 3.66 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46) 
>C12orf5 3.66 hsa-miR-369-3p(2.31),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-146a(2.36),hsa-miR-369-3p(2.31) 
>PARP9 3.63 hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61),hsa-miR-628-3p(-1.87) 
>RTP4 3.63 hsa-miR-31(42.93),hsa-miR-885-5p(-2.56) 
>SLC26A9 3.62 hsa-miR-378(2.68),hsa-miR-590-3p(1.94) 
>CCNB2 3.59 hsa-miR-548f(2.32) 
>GBP1 3.58 hsa-miR-21(3.95),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-
944(2.85) 
>GJB6 3.57 hsa-miR-7(3.05) 
>CDH3 3.54 hsa-miR-665(2.34),hsa-miR-628-3p(-1.87),hsa-miR-1179(-2.02) 
>CEP55 3.49 hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1308(2.03) 
>HYAL4 3.49 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-211(2.6) 
>CCNA2 3.49 hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-146a(2.36),hsa-miR-548f(2.32) 
>ABCA12 3.45 hsa-miR-206(12.8),hsa-miR-377(1.81),hsa-miR-1276(2.14) 
>ZDHHC21 3.43 hsa-miR-206(12.8),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-
548f(2.32),hsa-miR-487a(2.12),hsa-miR-628-3p(-1.87),hsa-miR-1179(-2.02),hsa-miR-486-3p(-2.56) 
>DSC2 3.42 hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-
592(2.92),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-33b(2.23),hsa-miR-628-3p(-
1.87) 
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>ZIC1 3.42 hsa-miR-206(12.8),hsa-miR-146a(2.36),hsa-miR-542-3p(1.31),hsa-miR-375(-2.41),hsa-miR-944(2.85),hsa-miR-
1303(2.66),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>ACPP 3.41 hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-31(42.93),hsa-miR-486-3p(-2.56) 
>SERPINB1 3.40 hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-548f(2.32) 
>GGH 3.39 hsa-miR-944(2.85) 
>PPIF 3.38 hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-940(2.79),hsa-miR-665(2.34),hsa-miR-
548f(2.32),hsa-miR-486-3p(-2.56) 
>BIRC5 3.36 hsa-miR-135b(5.65),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-
377(1.81) 
>PRSS3 3.35 hsa-miR-509-5p(1.61) 
>KIF20A 3.34 hsa-miR-496(3.02),hsa-miR-369-3p(2.31) 
>VNN1 3.34 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-
223(2.13),hsa-miR-628-3p(-1.87) 
>FUT2 3.33 hsa-miR-431(3.91),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1308(2.03) 
>SLC7A5 3.32 hsa-miR-33b(2.23) 
>AURKA 3.32 hsa-miR-377(1.81),hsa-miR-1179(-2.02) 
>DDX58 3.30 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-146a(2.36),hsa-miR-377(1.81),hsa-miR-455-3p(2.46),hsa-miR-
628-3p(-1.87),hsa-miR-885-5p(-2.56) 
>IFI44 3.29 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-188-5p(2.36),hsa-miR-31(42.93),hsa-miR-
206(12.8),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-
548f(2.32),hsa-miR-1308(2.03),hsa-miR-509-5p(1.61) 
>CCR7 3.28 hsa-miR-21(3.95),hsa-miR-378(2.68) 
>MMP1 3.27 hsa-miR-188-5p(2.36),hsa-miR-590-3p(1.94),hsa-miR-455-3p(2.46) 
>LASS3 3.27 hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-592(2.92),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-509-5p(1.61) 
>CHAC1 3.25 hsa-miR-940(2.79) 
>SERPINA1 3.25 hsa-miR-212(2.08),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-33b(2.23) 
>SAMSN1 3.24 hsa-miR-206(12.8),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-1179(-2.02) 
>MKI67 3.22 hsa-miR-206(12.8),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-486-3p(-2.56) 
>GBP6 3.20 hsa-miR-21(3.95),hsa-miR-146a(2.36),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-146a(2.36),hsa-miR-628-
3p(-1.87),hsa-miR-1179(-2.02) 
>GM2A 3.19 hsa-miR-135b(5.65),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-
486-3p(-2.56) 
>VSNL1 3.18 hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-455-
3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>CRABP2 3.16 hsa-miR-486-3p(-2.56) 
>KLRC4 3.16 hsa-miR-223(2.13),hsa-miR-548f(2.32),hsa-miR-1308(2.03) 
>OTUB2 3.14 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-542-
3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-455-3p(2.46),hsa-miR-188-
5p(2.36),hsa-miR-487a(2.12) 
>RNASE7 3.13 hsa-miR-7(3.05),hsa-miR-1303(2.66),hsa-miR-1276(2.14),hsa-miR-486-3p(-2.56) 
>S100A2 3.11 hsa-miR-129-5p(-2.62),hsa-miR-665(2.34) 
>DSG3 3.11 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-137(-
2.37),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31) 
>PI15 3.10 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-
146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-135b(5.65),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>JMY 3.10 hsa-miR-155(2.7) 
>TTK 3.08 hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46) 
>TMC5 3.08 hsa-miR-431(3.91),hsa-miR-496(3.02),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-486-3p(-2.56) 
>CXCR4 3.08 hsa-miR-206(12.8),hsa-miR-211(2.6),hsa-miR-548f(2.32) 
>ATP10B 3.07 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-137(-
2.37),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-188-
5p(2.36),hsa-miR-1276(2.14),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02),hsa-miR-885-5p(-
2.56) 
>UHRF1 3.07 hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-378(2.68),hsa-miR-188-
5p(2.36) 
>ALDH1A3 3.04 hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-1179(-2.02) 
>LYZ 3.04 hsa-miR-206(12.8),hsa-miR-142-3p(2.52),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-369-3p(2.31) 
>SOCS3 3.03 hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>GRHL3 3.01 hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-129-5p(-2.62) 
>TMPRSS4 3.00 hsa-miR-496(3.02),hsa-miR-142-3p(2.52),hsa-miR-137(-2.37),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31),hsa-
miR-1179(-2.02),hsa-miR-486-3p(-2.56) 
>APOBEC3B 2.99 hsa-miR-7(3.05),hsa-miR-1303(2.66) 
>TOP2A 2.97 hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-548f(2.32) 
>SLAMF7 2.96 hsa-miR-378(2.68),hsa-miR-33b(2.23),hsa-miR-378(2.68) 
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>NFKBIZ 2.96 hsa-miR-31(42.93),hsa-miR-187(2.17),hsa-miR-376b(1.73),hsa-miR-486-5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-
940(2.79),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>TRIM14 2.95 hsa-miR-142-3p(2.52),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-18a(2.43) 
>MMP9 2.95 hsa-miR-211(2.6),hsa-miR-1303(2.66) 
>PTGER3 2.94 hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-
129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-369-3p(2.31),hsa-miR-33b(2.23),hsa-miR-
223(2.13),hsa-miR-487a(2.12),hsa-miR-628-3p(-1.87) 
>GK 2.93 hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>MAD2L1 2.93 hsa-miR-376b(1.73),hsa-miR-548f(2.32) 
>FAM43A 2.91 hsa-miR-146a(2.36),hsa-miR-542-3p(1.31),hsa-miR-146a(2.36) 
>CD47 2.91 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-
155(2.7),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-
2.62),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-665(2.34),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61),hsa-miR-885-5p(-2.56) 
>CDK5R1 2.90 hsa-miR-7(3.05),hsa-miR-142-3p(2.52),hsa-miR-33b(2.23),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32),hsa-miR-
1308(2.03),hsa-miR-10a(-2.31) 
>AMMECR1 2.90 hsa-miR-7(3.05),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-
940(2.79),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-188-5p(2.36),hsa-miR-885-5p(-2.56) 
>SELE 2.86 hsa-miR-31(42.93),hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-377(1.81),hsa-miR-
944(2.85),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>IVL 2.86 hsa-miR-665(2.34) 
>CARD6 2.85 hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-369-3p(2.31) 
>C14orf147 2.83 hsa-miR-31(42.93),hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-665(2.34),hsa-miR-
548f(2.32),hsa-miR-885-5p(-2.56) 
>GPX2 2.82 hsa-miR-18a(2.43) 
>CLCA2 2.82 hsa-miR-7(3.05),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-375(-
2.41),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-1308(2.03) 
>SELL 2.81 hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-1308(2.03),hsa-miR-885-5p(-2.56),hsa-miR-
486-3p(-2.56) 
>PLAC8 2.81 hsa-miR-369-3p(2.31) 
>DNASE1L3 2.79 hsa-miR-31(42.93),hsa-miR-1303(2.66) 
>NETO2 2.78 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-944(2.85),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-1276(2.14) 
>STEAP4 2.77 hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-137(-
2.37),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31),hsa-miR-33b(2.23),hsa-
miR-1276(2.14) 
>WWTR1 2.76 hsa-miR-590-3p(1.94),hsa-miR-486-3p(-2.56) 
>FCGR3B 2.75 hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-944(2.85),hsa-miR-369-3p(2.31) 
>PLA2G3 2.73 hsa-miR-10a(-2.31),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-1303(2.66) 
>IRAK2 2.72 hsa-miR-10a(-2.31),hsa-miR-940(2.79) 
>HSD17B1 2.70 hsa-miR-548f(2.32) 
>FAM83D 2.70 hsa-miR-142-3p(2.52),hsa-miR-486-5p(-1.81),hsa-miR-665(2.34),hsa-miR-1276(2.14) 
>IFIT3 2.69 hsa-miR-431(3.91) 
>NUSAP1 2.69 hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-10a(-2.31),hsa-miR-509-5p(1.61) 
>HK2 2.68 hsa-miR-590-3p(1.94) 
>PRKCQ 2.67 hsa-miR-31(42.93),hsa-miR-665(2.34) 
>HMMR 2.65 hsa-miR-590-3p(1.94),hsa-miR-944(2.85) 
>SFT2D2 2.64 hsa-miR-548f(2.32),hsa-miR-1308(2.03) 
>TK1 2.63 hsa-miR-18a(2.43),hsa-miR-1268(4.45),hsa-miR-486-3p(-2.56) 
>GNA15 2.63 hsa-miR-211(2.6),hsa-miR-542-3p(1.31),hsa-miR-486-3p(-2.56) 
>SLC16A6 2.63 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37) 
>WDR4 2.63 hsa-miR-486-3p(-2.56) 
>GPR68 2.63 hsa-miR-378(2.68),hsa-miR-885-5p(-2.56) 
>MYO5A 2.62 hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-
369-3p(2.31),hsa-miR-33b(2.23) 
>TYMS 2.62 hsa-miR-129-5p(-2.62) 
>BUB1B 2.62 hsa-miR-486-5p(-1.81) 
>LCK 2.62 hsa-miR-18a(2.43) 
>TPX2 2.61 hsa-miR-548f(2.32) 
>EPN3 2.61 hsa-miR-33b(2.23),hsa-miR-542-3p(1.31),hsa-miR-10a(-2.31),hsa-miR-486-3p(-2.56) 
>TMEM86A 2.61 hsa-miR-496(3.02),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-
496(3.02),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-211(2.6) 
>FBXO45 2.60 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-
542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-188-5p(2.36),hsa-miR-
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665(2.34),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-487a(2.12) 
>KRT17 2.59 hsa-miR-486-3p(-2.56) 
>CCNE1 2.59 hsa-miR-1179(-2.02) 
>CD2 2.58 hsa-miR-137(-2.37),hsa-miR-155(2.7),hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-137(-2.37),hsa-miR-129-5p(-
2.62),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>GPT2 2.57 hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-377(1.81),hsa-miR-548f(2.32),hsa-miR-1179(-2.02) 
>EREG 2.57 hsa-miR-496(3.02),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-
miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-628-3p(-1.87),hsa-miR-
1179(-2.02) 
>LIPG 2.56 hsa-miR-31(42.93),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-590-
3p(1.94),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>ARG2 2.55 hsa-miR-10a(-2.31),hsa-miR-137(-2.37) 
>EPHA2 2.55 hsa-miR-10a(-2.31) 
>ZWINT 2.54 hsa-miR-10a(-2.31),hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>IDH3A 2.54 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-592(2.92),hsa-miR-455-3p(2.46),hsa-miR-885-5p(-2.56),hsa-miR-486-
3p(-2.56) 
>HR 2.54 hsa-miR-369-3p(2.31),hsa-miR-486-3p(-2.56) 
>PGM2 2.53 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-431(3.91),hsa-miR-378(2.68),hsa-miR-223(2.13),hsa-miR-137(-
2.37),hsa-miR-1308(2.03) 
>TPBG 2.52 hsa-miR-212(2.08),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-548f(2.32) 
>TMEM40 2.52 hsa-miR-590-3p(1.94),hsa-miR-1303(2.66) 
>APOL6 2.52 hsa-miR-211(2.6),hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-665(2.34),hsa-miR-548f(2.32) 
>NT5C3 2.52 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-548f(2.32) 
>MPHOSPH6 2.51 hsa-miR-146a(2.36),hsa-miR-377(1.81),hsa-miR-146a(2.36),hsa-miR-369-3p(2.31) 
>YKT6 2.50 hsa-miR-212(2.08) 
>ZBED2 2.50 hsa-miR-377(1.81) 
>APOL1 2.50 hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-33b(2.23) 
>C15orf48 2.50 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37) 
>MOXD1 2.49 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-486-
5p(-1.81),hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-548f(2.32) 
>UBE2F 2.48 hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46) 
>AASS 2.48 hsa-miR-377(1.81),hsa-miR-944(2.85) 
>LGALS3BP 2.48 hsa-miR-590-3p(1.94) 
>OBFC2A 2.47 hsa-miR-496(3.02),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>APOBEC3A 2.46 hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-1303(2.66) 
>FUT3 2.46 hsa-miR-206(12.8),hsa-miR-431(3.91),hsa-miR-1303(2.66) 
>NEK2 2.45 hsa-miR-377(1.81),hsa-miR-486-5p(-1.81),hsa-miR-369-3p(2.31),hsa-miR-628-3p(-1.87) 
>DHRS9 2.44 hsa-miR-211(2.6),hsa-miR-376b(1.73),hsa-miR-486-3p(-2.56) 
>FAM83A 2.43 hsa-miR-206(12.8),hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-376b(1.73) 
>PDSS1 2.42 hsa-miR-590-3p(1.94) 
>IL7R 2.41 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-211(2.6) 
>CALML3 2.41 hsa-miR-486-3p(-2.56) 
>TMEM49 2.41 hsa-miR-206(12.8),hsa-miR-223(2.13),hsa-miR-542-3p(1.31),hsa-miR-592(2.92),hsa-miR-147b(2.79) 
>CCNE2 2.40 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-31(42.93),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31) 
>C20orf24 2.40 hsa-miR-7(3.05) 
>UGT1A6 2.39 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-486-3p(-2.56) 
>CCL2 2.39 hsa-miR-206(12.8),hsa-miR-33b(2.23),hsa-miR-369-3p(2.31),hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-590-
3p(1.94),hsa-miR-369-3p(2.31) 
>LDLR 2.39 hsa-miR-135b(5.65),hsa-miR-592(2.92),hsa-miR-455-3p(2.46),hsa-miR-188-5p(2.36) 
>SCO2 2.39 hsa-miR-509-5p(1.61) 
>HSD17B2 2.38 hsa-miR-211(2.6) 
>PCDH7 2.38 hsa-miR-496(3.02),hsa-miR-142-3p(2.52),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-
129-5p(-2.62),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
1276(2.14),hsa-miR-1308(2.03) 
>PRDM1 2.38 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-137(-2.37),hsa-miR-129-5p(-
2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-369-3p(2.31),hsa-miR-885-5p(-2.56) 
>GCH1 2.37 hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-223(2.13) 
>DUOXA1 2.36 hsa-miR-431(3.91) 
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>KIF4A 2.35 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-375(-2.41) 
>SLC16A1 2.35 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
21(3.95),hsa-miR-33b(2.23),hsa-miR-944(2.85),hsa-miR-1276(2.14),hsa-miR-487a(2.12) 
>ID1 2.35 hsa-miR-944(2.85) 
>TNFRSF21 2.35 hsa-miR-135b(5.65),hsa-miR-33b(2.23),hsa-miR-1179(-2.02) 
>TNIP3 2.34 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-509-5p(1.61) 
>GINS3 2.34 hsa-miR-7(3.05),hsa-miR-211(2.6),hsa-miR-212(2.08),hsa-miR-10a(-2.31),hsa-miR-129-5p(-2.62),hsa-miR-
147b(2.79),hsa-miR-1276(2.14),hsa-miR-1308(2.03),hsa-miR-628-3p(-1.87) 
>UBE2L6 2.33 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-146a(2.36),hsa-miR-455-3p(2.46),hsa-miR-146a(2.36) 
>INA 2.33 hsa-miR-142-3p(2.52),hsa-miR-212(2.08),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-1303(2.66),hsa-miR-
509-5p(1.61),hsa-miR-885-5p(-2.56) 
>PRC1 2.33 hsa-miR-146a(2.36) 
>SOX7 2.33 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-376b(1.73),hsa-miR-211(2.6),hsa-
miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-487a(2.12),hsa-miR-486-3p(-2.56) 
>EIF4EBP1 2.33 hsa-miR-486-3p(-2.56) 
>HBEGF 2.32 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-376b(1.73),hsa-miR-1303(2.66),hsa-miR-211(2.6) 
>SMOX 2.32 hsa-miR-940(2.79),hsa-miR-486-3p(-2.56) 
>KIF11 2.31 hsa-miR-431(3.91) 
>ATP11B 2.31 hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-137(-
2.37),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-
223(2.13),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>TRIM22 2.30 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-944(2.85),hsa-miR-486-3p(-2.56) 
>HN1 2.28 hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-455-3p(2.46),hsa-miR-665(2.34) 
>E2F8 2.28 hsa-miR-590-3p(1.94),hsa-miR-377(1.81) 
>ECT2 2.28 hsa-miR-496(3.02),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-
548f(2.32) 
>LRP8 2.27 hsa-miR-206(12.8),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-
1308(2.03) 
>SYNCRIP 2.27 hsa-miR-187(2.17),hsa-miR-590-3p(1.94),hsa-miR-375(-2.41),hsa-miR-187(2.17) 
>ENSA 2.27 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-
377(1.81),hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-18a(2.43),hsa-miR-369-3p(2.31),hsa-miR-
1276(2.14),hsa-miR-1308(2.03) 
>CDH26 2.27 hsa-miR-590-3p(1.94),hsa-miR-944(2.85) 
>C12orf29 2.27 hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-155(2.7) 
>SMPD3 2.27 hsa-miR-18a(2.43),hsa-miR-212(2.08),hsa-miR-548f(2.32) 
>USP6NL 2.27 hsa-miR-378(2.68),hsa-miR-142-3p(2.52),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-
miR-548f(2.32),hsa-miR-223(2.13),hsa-miR-1179(-2.02) 
>ANLN 2.27 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-369-3p(2.31),hsa-miR-
509-5p(1.61),hsa-miR-628-3p(-1.87) 
>AIM2 2.27 hsa-miR-944(2.85),hsa-miR-509-5p(1.61) 
>LTB4R 2.27 hsa-miR-1179(-2.02) 
>FBXO6 2.27 hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-486-3p(-2.56) 
>DEPDC1B 2.27 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-1179(-2.02) 
>PLSCR1 2.26 hsa-miR-496(3.02),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-369-3p(2.31) 
>TOP1 2.26 hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32),hsa-miR-
369-3p(2.31),hsa-miR-487a(2.12) 
>DCUN1D3 2.26 hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-212(2.08),hsa-miR-944(2.85),hsa-miR-
211(2.6),hsa-miR-548f(2.32),hsa-miR-223(2.13),hsa-miR-1308(2.03) 
>GINS2 2.25 hsa-miR-377(1.81) 
>RIT1 2.25 hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-486-
5p(-1.81),hsa-miR-129-5p(-2.62),hsa-miR-378(2.68),hsa-miR-665(2.34),hsa-miR-33b(2.23),hsa-miR-
1276(2.14),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61),hsa-miR-628-3p(-1.87) 
>TNFSF10 2.25 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32) 
>MX2 2.25 hsa-miR-542-3p(1.31),hsa-miR-188-5p(2.36) 
>FOXM1 2.24 hsa-miR-211(2.6),hsa-miR-509-5p(1.61) 
>CENPA 2.24 hsa-miR-211(2.6),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-
146a(2.36),hsa-miR-1276(2.14) 
>PLCXD1 2.24 hsa-miR-940(2.79),hsa-miR-665(2.34),hsa-miR-509-5p(1.61) 
>CCL22 2.23 hsa-miR-21(3.95),hsa-miR-10a(-2.31),hsa-miR-1268(4.45),hsa-miR-940(2.79),hsa-miR-369-3p(2.31) 
>AMPD3 2.23 hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-628-3p(-1.87) 
>OSMR 2.23 hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-486-5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-548f(2.32),hsa-miR-
369-3p(2.31) 
>KIAA1199 2.23 hsa-miR-146a(2.36),hsa-miR-486-5p(-1.81),hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-369-3p(2.31),hsa-miR-
486-3p(-2.56) 
>IL13RA1 2.23 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-431(3.91),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-129-
5p(-2.62),hsa-miR-31(42.93),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-188-5p(2.36),hsa-miR-1308(2.03) 
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>SHCBP1 2.22 hsa-miR-431(3.91),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-940(2.79),hsa-miR-211(2.6) 
>SERPINA3 2.22 hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-665(2.34) 
>N4BP1 2.22 hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-509-5p(1.61) 
>TLE3 2.21 hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-31(42.93) 
>PTP4A1 2.21 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-
548f(2.32),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>STS 2.21 hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-431(3.91),hsa-miR-
944(2.85),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-33b(2.23),hsa-miR-
377(1.81),hsa-miR-509-5p(1.61),hsa-miR-628-3p(-1.87) 
>KLHL18 2.21 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-509-5p(1.61) 
>PRRG4 2.21 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62) 
>SOST 2.19 hsa-miR-378(2.68),hsa-miR-665(2.34) 
>RAB38 2.19 hsa-miR-18a(2.43),hsa-miR-542-3p(1.31),hsa-miR-375(-2.41),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14) 
>MCM10 2.19 hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-548f(2.32) 
>TGFA 2.18 hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-129-
5p(-2.62),hsa-miR-944(2.85),hsa-miR-455-3p(2.46),hsa-miR-1179(-2.02) 
>SLC7A1 2.18 hsa-miR-212(2.08),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-592(2.92),hsa-miR-211(2.6),hsa-miR-590-
3p(1.94),hsa-miR-376b(1.73),hsa-miR-369-3p(2.31),hsa-miR-377(1.81) 
>IL4R 2.18 hsa-miR-211(2.6),hsa-miR-665(2.34) 
>LAD1 2.17 hsa-miR-431(3.91),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-431(3.91) 
>HMOX1 2.17 hsa-miR-377(1.81) 
>ELL2 2.17 hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-
223(2.13),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-885-5p(-2.56) 
>C1QB 2.17 hsa-miR-33b(2.23),hsa-miR-1179(-2.02) 
>ATP6V1C2 2.16 hsa-miR-135b(5.65),hsa-miR-146a(2.36),hsa-miR-944(2.85),hsa-miR-146a(2.36),hsa-miR-188-5p(2.36),hsa-miR-
885-5p(-2.56) 
>BDH1 2.16 hsa-miR-212(2.08),hsa-miR-10a(-2.31) 
>H2AFX 2.16 hsa-miR-455-3p(2.46) 
>CH25H 2.15 hsa-miR-376b(1.73),hsa-miR-1303(2.66) 
>LGALS8 2.15 hsa-miR-223(2.13),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-885-5p(-2.56) 
>THBD 2.15 hsa-miR-18a(2.43),hsa-miR-542-3p(1.31),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-455-3p(2.46),hsa-miR-
1276(2.14) 
>CYP2C18 2.15 hsa-miR-542-3p(1.31) 
>RAB10 2.15 hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-
2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-
miR-1276(2.14) 
>TMEM79 2.14 hsa-miR-188-5p(2.36),hsa-miR-1276(2.14),hsa-miR-486-3p(-2.56) 
>TSPAN4 2.14 hsa-miR-206(12.8),hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>POLE2 2.14 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32) 
>STAT3 2.13 hsa-miR-21(3.95),hsa-miR-33b(2.23),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-1303(2.66),hsa-miR-
665(2.34),hsa-miR-1308(2.03),hsa-miR-885-5p(-2.56),hsa-miR-486-3p(-2.56) 
>ELOVL7 2.13 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-
376b(1.73),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-1179(-2.02) 
>IRF8 2.13 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-1276(2.14) 
>ZC3HAV1 2.12 hsa-miR-206(12.8),hsa-miR-590-3p(1.94),hsa-miR-486-5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-
188-5p(2.36),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61),hsa-miR-885-5p(-2.56) 
>BIRC3 2.12 hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-
369-3p(2.31) 
>CEBPD 2.12 hsa-miR-885-5p(-2.56) 
>EZH2 2.12 hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-509-5p(1.61) 
>MCL1 2.12 hsa-miR-496(3.02),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46),hsa-miR-885-
5p(-2.56) 
>CYP7B1 2.12 hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-1303(2.66),hsa-miR-628-3p(-1.87) 
>LRRC8B 2.11 hsa-miR-590-3p(1.94) 
>EIF5 2.11 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-590-3p(1.94),hsa-miR-548f(2.32),hsa-miR-33b(2.23),hsa-miR-
1276(2.14) 
>HSPA4 2.11 hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-431(3.91),hsa-miR-486-5p(-1.81),hsa-miR-
548f(2.32) 
>SUB1 2.11 hsa-miR-135b(5.65),hsa-miR-377(1.81),hsa-miR-548f(2.32) 
>RALGPS2 2.11 hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>TAP2 2.11 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-486-5p(-1.81),hsa-miR-
137(-2.37),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03),hsa-miR-509-5p(1.61) 
>SILV 2.10 hsa-miR-7(3.05),hsa-miR-496(3.02) 
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>CHEK1 2.10 hsa-miR-7(3.05) 
>LYPD5 2.10 hsa-miR-129-5p(-2.62),hsa-miR-146a(2.36) 
>RASGRP1 2.10 hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-
376b(1.73),hsa-miR-1303(2.66),hsa-miR-885-5p(-2.56) 
>ST6GALNAC1 2.10 hsa-miR-21(3.95),hsa-miR-142-3p(2.52) 
>MAP3K9 2.10 hsa-miR-7(3.05),hsa-miR-223(2.13),hsa-miR-377(1.81),hsa-miR-940(2.79),hsa-miR-1276(2.14),hsa-miR-1179(-
2.02) 
>CENPF 2.10 hsa-miR-33b(2.23),hsa-miR-487a(2.12) 
>SERPINB9 2.10 hsa-miR-206(12.8),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-455-3p(2.46),hsa-miR-665(2.34),hsa-miR-
369-3p(2.31) 
>PTAFR 2.10 hsa-miR-146a(2.36),hsa-miR-455-3p(2.46),hsa-miR-188-5p(2.36) 
>CXCL11 2.10 hsa-miR-206(12.8),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-
1303(2.66),hsa-miR-665(2.34),hsa-miR-487a(2.12) 
>FOSL2 2.10 hsa-miR-135b(5.65),hsa-miR-486-3p(-2.56) 
>MPZL1 2.10 hsa-miR-206(12.8),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-211(2.6),hsa-miR-
18a(2.43),hsa-miR-665(2.34),hsa-miR-487a(2.12) 
>AURKB 2.10 hsa-miR-188-5p(2.36) 
>GART 2.09 hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-146a(2.36),hsa-miR-10a(-2.31),hsa-miR-137(-2.37) 
>SLC39A6 2.09 hsa-miR-137(-2.37),hsa-miR-1179(-2.02) 
>CD36 2.09 hsa-miR-155(2.7),hsa-miR-376b(1.73),hsa-miR-944(2.85),hsa-miR-1179(-2.02) 
>CDCA5 2.08 hsa-miR-146a(2.36) 
>CTPS 2.08 hsa-miR-135b(5.65),hsa-miR-137(-2.37),hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-1303(2.66),hsa-miR-
211(2.6),hsa-miR-509-5p(1.61) 
>MFHAS1 2.08 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-223(2.13),hsa-miR-486-5p(-1.81),hsa-miR-940(2.79),hsa-miR-
1276(2.14),hsa-miR-223(2.13) 
>GINS1 2.08 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-486-
5p(-1.81),hsa-miR-137(-2.37),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-1307(1.97) 
>CCL19 2.08 hsa-miR-377(1.81) 
>BID 2.08 hsa-miR-142-3p(2.52),hsa-miR-21(3.95) 
>PON2 2.08 hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62) 
>ABCG1 2.07 hsa-miR-10a(-2.31),hsa-miR-129-5p(-2.62),hsa-miR-378(2.68),hsa-miR-10a(-2.31) 
>PLA2G2F 2.07 hsa-miR-18a(2.43),hsa-miR-10a(-2.31) 
>IFI30 2.07 hsa-miR-940(2.79),hsa-miR-1308(2.03) 
>COTL1 2.07 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-1276(2.14) 
>IL1RN 2.07 hsa-miR-31(42.93),hsa-miR-223(2.13),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-509-
5p(1.61),hsa-miR-1179(-2.02),hsa-miR-486-3p(-2.56) 
>KCNK6 2.07 hsa-miR-211(2.6),hsa-miR-486-5p(-1.81),hsa-miR-378(2.68) 
>RDH12 2.07 hsa-miR-940(2.79),hsa-miR-1303(2.66) 
>GPR109B 2.06 hsa-miR-211(2.6),hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>FCGR1A 2.06 hsa-miR-31(42.93),hsa-miR-378(2.68),hsa-miR-223(2.13),hsa-miR-378(2.68) 
>DCTN5 2.06 hsa-miR-31(42.93),hsa-miR-146a(2.36),hsa-miR-376b(1.73),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-
665(2.34) 
>NUP50 2.06 hsa-miR-206(12.8),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32),hsa-miR-1179(-2.02),hsa-miR-885-5p(-
2.56) 
>SAR1A 2.05 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-590-
3p(1.94),hsa-miR-21(3.95),hsa-miR-455-3p(2.46),hsa-miR-18a(2.43),hsa-miR-1276(2.14),hsa-miR-487a(2.12),hsa-
miR-1308(2.03),hsa-miR-486-3p(-2.56) 
>NRBF2 2.05 hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-212(2.08),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1179(-
2.02) 
>ZWILCH 2.05 hsa-miR-211(2.6) 
>IL1B 2.05 hsa-miR-21(3.95),hsa-miR-211(2.6),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-455-3p(2.46) 
>LYN 2.05 hsa-miR-378(2.68),hsa-miR-212(2.08),hsa-miR-376b(1.73),hsa-miR-944(2.85),hsa-miR-31(42.93) 
>TUBB6 2.05 hsa-miR-628-3p(-1.87) 
>PTPRC 2.05 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-487a(2.12) 
>THAP2 2.05 hsa-miR-590-3p(1.94),hsa-miR-486-5p(-1.81),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6) 
>YOD1 2.05 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-
miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-369-
3p(2.31),hsa-miR-223(2.13) 
>NFE2L3 2.04 hsa-miR-548f(2.32) 
>SDCBP2 2.04 hsa-miR-1276(2.14) 
>CTSC 2.04 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-
miR-455-3p(2.46),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-885-5p(-2.56) 
>RABIF 2.04 hsa-miR-431(3.91),hsa-miR-1303(2.66) 
 205 
>FSCN1 2.04 hsa-miR-1268(4.45),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-1308(2.03) 
>PGLYRP4 2.04 hsa-miR-378(2.68) 
>SQLE 2.04 hsa-miR-548f(2.32) 
>TMEM33 2.04 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-548f(2.32),hsa-miR-885-5p(-2.56) 
>PPARD 2.04 hsa-miR-223(2.13),hsa-miR-18a(2.43),hsa-miR-369-3p(2.31),hsa-miR-223(2.13),hsa-miR-486-3p(-2.56) 
>EPHB2 2.04 hsa-miR-211(2.6),hsa-miR-212(2.08),hsa-miR-10a(-2.31),hsa-miR-211(2.6),hsa-miR-509-5p(1.61),hsa-miR-486-
3p(-2.56) 
>SAR1B 2.04 hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-548f(2.32) 
>UGCG 2.03 hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>PPP2R2C 2.03 hsa-miR-542-3p(1.31),hsa-miR-369-3p(2.31) 
>SFN 2.03 hsa-miR-431(3.91),hsa-miR-486-3p(-2.56) 
>TAP1 2.02 hsa-miR-590-3p(1.94),hsa-miR-211(2.6) 
>PSPH 2.02 hsa-miR-940(2.79),hsa-miR-665(2.34),hsa-miR-369-3p(2.31) 
>DIO2 2.02 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-
223(2.13),hsa-miR-487a(2.12) 
>GLUL 2.02 hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-188-5p(2.36) 
>MAP4K4 2.02 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-592(2.92),hsa-miR-211(2.6),hsa-miR-369-
3p(2.31),hsa-miR-628-3p(-1.87),hsa-miR-1179(-2.02) 
>HDHD1A 2.02 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-944(2.85) 
>SLC27A4 2.02 hsa-miR-486-3p(-2.56) 
>IRF1 2.02 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-377(1.81) 
>CASP7 2.02 hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-212(2.08),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-2.62),hsa-miR-
940(2.79),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-1276(2.14) 
>PGBD5 2.01 hsa-miR-18a(2.43) 
>ALDH3B2 2.01 hsa-miR-187(2.17),hsa-miR-542-3p(1.31),hsa-miR-940(2.79),hsa-miR-486-3p(-2.56) 
>WARS 2.01 hsa-miR-378(2.68),hsa-miR-542-3p(1.31),hsa-miR-592(2.92) 
>CCL8 2.01 hsa-miR-33b(2.23),hsa-miR-944(2.85),hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31) 
>MED8 2.01 hsa-miR-375(-2.41),hsa-miR-940(2.79),hsa-miR-211(2.6) 
>PANX1 2.01 hsa-miR-10a(-2.31),hsa-miR-137(-2.37),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>PLEK 2.01 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-1303(2.66),hsa-miR-486-3p(-2.56),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-375(-
2.41),hsa-miR-129-5p(-2.62),hsa-miR-31(42.93),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-487a(2.12) 
>PCSK6 2.01 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-21(3.95) 
>RAB27B 2.01 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-542-3p(1.31),hsa-miR-211(2.6),hsa-miR-
548f(2.32),hsa-miR-628-3p(-1.87) 
>CARD14 2.01 hsa-miR-18a(2.43),hsa-miR-509-5p(1.61) 
>TRIP13 2.01 hsa-miR-155(2.7),hsa-miR-129-5p(-2.62),hsa-miR-885-5p(-2.56) 
>SERPINB8 2.01 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-33b(2.23),hsa-miR-212(2.08),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-542-3p(1.31),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-455-3p(2.46),hsa-miR-33b(2.23) 
>MAPKAPK3 2.01 hsa-miR-18a(2.43),hsa-miR-377(1.81),hsa-miR-18a(2.43),hsa-miR-1179(-2.02) 
>HOMER1 2.01 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-
5p(-2.62),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-369-3p(2.31),hsa-miR-223(2.13),hsa-
miR-487a(2.12),hsa-miR-628-3p(-1.87) 
>MFN1 2.00 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>EXOSC3 2.00 hsa-miR-496(3.02),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-369-3p(2.31) 
>PPIL1 2.00 hsa-miR-375(-2.41),hsa-miR-1268(4.45) 
>CD83 2.00 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-
665(2.34),hsa-miR-1308(2.03),hsa-miR-377(1.81),hsa-miR-628-3p(-1.87),hsa-miR-885-5p(-2.56) 
   
DOWNREGULATED TARGETS OF DE MIRNAs (up and downreg miRNAs listed): 
>DIXDC1 -2.00 hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-
376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-
146a(2.36),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-1179(-2.02),hsa-miR-885-5p(-
2.56),hsa-miR-486-3p(-2.56) 
>LCE1B -2.00 hsa-miR-135b(5.65),hsa-miR-7(3.05) 
>GLDN -2.00 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-
146a(2.36),hsa-miR-1303(2.66),hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-665(2.34),hsa-miR-1276(2.14) 
>NAP1L2 -2.00 hsa-miR-135b(5.65),hsa-miR-33b(2.23),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-509-
5p(1.61) 
>RBM25 -2.00 hsa-miR-496(3.02),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-
665(2.34),hsa-miR-1276(2.14) 
>PPP1R1A -2.01 hsa-miR-31(42.93),hsa-miR-940(2.79),hsa-miR-509-5p(1.61) 
>TACC2 -2.01 hsa-miR-31(42.93),hsa-miR-590-3p(1.94),hsa-miR-31(42.93),hsa-miR-1303(2.66),hsa-miR-509-5p(1.61) 
 206 
>DACH1 -2.01 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-
miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-
211(2.6),hsa-miR-188-5p(2.36),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
487a(2.12),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>TFAP2B -2.01 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-369-
3p(2.31),hsa-miR-885-5p(-2.56) 
>LRFN5 -2.01 hsa-miR-212(2.08),hsa-miR-590-3p(1.94) 
>SERHL -2.01 hsa-miR-665(2.34) 
>C1orf21 -2.01 hsa-miR-944(2.85) 
>ARID1B -2.01 hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-
548f(2.32),hsa-miR-486-3p(-2.56) 
>FAM117A -2.01 hsa-miR-940(2.79),hsa-miR-486-3p(-2.56) 
>AR -2.01 hsa-miR-18a(2.43),hsa-miR-509-5p(1.61),hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-
592(2.92),hsa-miR-1276(2.14) 
>PECR -2.02 hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-509-5p(1.61) 
>CCND1 -2.02 hsa-miR-155(2.7),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-487a(2.12) 
>CREB5 -2.02 hsa-miR-206(12.8),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-212(2.08),hsa-miR-129-5p(-
2.62),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1276(2.14) 
>DST -2.02 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-188-5p(2.36),hsa-miR-665(2.34),hsa-miR-
369-3p(2.31),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61) 
>CYP2J2 -2.02 hsa-miR-944(2.85) 
>LRP4 -2.02 hsa-miR-31(42.93),hsa-miR-940(2.79),hsa-miR-487a(2.12),hsa-miR-885-5p(-2.56),hsa-miR-486-3p(-2.56) 
>SORBS1 -2.02 hsa-miR-431(3.91),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-542-
3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-378(2.68),hsa-miR-1303(2.66),hsa-miR-455-
3p(2.46),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-33b(2.23),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>TMEM97 -2.03 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-592(2.92),hsa-miR-
1303(2.66),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>SOX5 -2.03 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-142-3p(2.52),hsa-miR-33b(2.23),hsa-miR-212(2.08),hsa-miR-
146a(2.36),hsa-miR-1276(2.14),hsa-miR-885-5p(-2.56) 
>FRZB -2.03 hsa-miR-155(2.7),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-155(2.7),hsa-miR-542-3p(1.31),hsa-miR-
137(-2.37),hsa-miR-155(2.7),hsa-miR-885-5p(-2.56),hsa-miR-155(2.7),hsa-miR-885-5p(-2.56) 
>IL17RD -2.03 hsa-miR-137(-2.37),hsa-miR-146a(2.36) 
>DBN1 -2.03 hsa-miR-212(2.08),hsa-miR-137(-2.37) 
>RNF128 -2.03 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-1276(2.14),hsa-miR-
487a(2.12) 
>SGCG -2.03 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-486-3p(-2.56) 
>BCAR3 -2.03 hsa-miR-496(3.02),hsa-miR-18a(2.43),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-487a(2.12) 
>NUAK1 -2.03 hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-885-5p(-2.56) 
>MYH14 -2.03 hsa-miR-31(42.93) 
>NDFIP2 -2.03 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-378(2.68),hsa-miR-590-
3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-378(2.68),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-509-5p(1.61) 
>DPYSL3 -2.03 hsa-miR-7(3.05),hsa-miR-211(2.6),hsa-miR-212(2.08),hsa-miR-590-3p(1.94),hsa-miR-31(42.93),hsa-miR-548f(2.32) 
>ZNF573 -2.03 hsa-miR-31(42.93),hsa-miR-885-5p(-2.56) 
>MBNL2 -2.04 hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-137(-2.37),hsa-miR-135b(5.65),hsa-miR-944(2.85),hsa-miR-18a(2.43),hsa-miR-369-3p(2.31),hsa-
miR-223(2.13),hsa-miR-487a(2.12) 
>TCF7L1 -2.04 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46) 
>ZNF43 -2.04 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-
135b(5.65),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-487a(2.12) 
>OLFML3 -2.04 hsa-miR-155(2.7),hsa-miR-369-3p(2.31),hsa-miR-486-3p(-2.56) 
>SDC2 -2.04 hsa-miR-206(12.8),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32),hsa-miR-
369-3p(2.31),hsa-miR-509-5p(1.61),hsa-miR-486-3p(-2.56) 
>C14orf28 -2.04 hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-628-3p(-1.87) 
>PRELP -2.04 hsa-miR-31(42.93),hsa-miR-211(2.6),hsa-miR-486-5p(-1.81),hsa-miR-1268(4.45) 
>ALCAM -2.04 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-135b(5.65),hsa-miR-944(2.85),hsa-miR-
1303(2.66),hsa-miR-211(2.6),hsa-miR-1276(2.14) 
>EFEMP1 -2.04 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-628-3p(-1.87) 
>NR3C1 -2.04 hsa-miR-206(12.8),hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-542-
3p(1.31),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-1179(-2.02) 
>GAN -2.04 hsa-miR-211(2.6),hsa-miR-187(2.17),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-
5p(-2.62),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>PCDHB16 -2.05 hsa-miR-135b(5.65),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-369-3p(2.31) 
>PIK3C2G -2.05 hsa-miR-376b(1.73),hsa-miR-10a(-2.31) 
>CRISPLD1 -2.05 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-376b(1.73),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-
1303(2.66),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>TNS1 -2.05 hsa-miR-31(42.93),hsa-miR-33b(2.23),hsa-miR-665(2.34),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61) 
 207 
>C19orf2 -2.05 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32) 
>FASN -2.05 hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>CD1A -2.05 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-146a(2.36),hsa-miR-33b(2.23) 
>TMEM99 -2.05 hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-628-3p(-1.87) 
>P4HA2 -2.05 hsa-miR-377(1.81),hsa-miR-129-5p(-2.62) 
>PIK3R1 -2.05 hsa-miR-21(3.95),hsa-miR-431(3.91),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-376b(1.73),hsa-miR-542-
3p(1.31),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-2.62),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-455-
3p(2.46),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>PDZD2 -2.05 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-
18a(2.43),hsa-miR-146a(2.36),hsa-miR-187(2.17),hsa-miR-486-5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61),hsa-
miR-1179(-2.02) 
>VAPA -2.05 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-1276(2.14) 
>LOR -2.06 hsa-miR-135b(5.65) 
>TNMD -2.06 hsa-miR-940(2.79) 
>BCL2 -2.06 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-1303(2.66),hsa-miR-
211(2.6),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-1308(2.03),hsa-miR-486-3p(-
2.56),hsa-miR-1303(2.66),hsa-miR-1308(2.03),hsa-miR-885-5p(-2.56) 
>NCOR1 -2.06 hsa-miR-10a(-2.31) 
>BAG2 -2.06 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-
223(2.13),hsa-miR-628-3p(-1.87) 
>CDON -2.06 hsa-miR-206(12.8),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-223(2.13),hsa-
miR-1308(2.03),hsa-miR-509-5p(1.61) 
>ACACB -2.07 hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-486-3p(-2.56) 
>NSUN6 -2.07 hsa-miR-590-3p(1.94),hsa-miR-137(-2.37) 
>CEP68 -2.07 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-
223(2.13),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-
592(2.92),hsa-miR-944(2.85),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>GALNTL2 -2.07 hsa-miR-206(12.8),hsa-miR-376b(1.73),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-665(2.34),hsa-miR-885-5p(-
2.56) 
>SLC29A1 -2.07 hsa-miR-223(2.13),hsa-miR-940(2.79),hsa-miR-486-3p(-2.56) 
>EN1 -2.07 hsa-miR-211(2.6),hsa-miR-212(2.08),hsa-miR-944(2.85),hsa-miR-369-3p(2.31),hsa-miR-486-3p(-2.56) 
>ELN -2.07 hsa-miR-1303(2.66),hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>HOXB3 -2.08 hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-10a(-2.31),hsa-miR-375(-2.41),hsa-miR-940(2.79),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-10a(-2.31),hsa-miR-885-5p(-2.56) 
>ZNF395 -2.08 hsa-miR-7(3.05),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-187(2.17),hsa-miR-223(2.13),hsa-miR-
212(2.08),hsa-miR-129-5p(-2.62),hsa-miR-18a(2.43),hsa-miR-665(2.34),hsa-miR-369-3p(2.31) 
>PPAP2B -2.08 hsa-miR-129-5p(-2.62),hsa-miR-369-3p(2.31) 
>ASPN -2.08 hsa-miR-21(3.95),hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-
miR-487a(2.12),hsa-miR-1179(-2.02) 
>ITPR2 -2.08 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-
129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-
miR-33b(2.23),hsa-miR-509-5p(1.61) 
>SLC2A13 -2.08 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-18a(2.43),hsa-miR-590-
3p(1.94),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-
miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-223(2.13) 
>PDGFC -2.08 hsa-miR-31(42.93),hsa-miR-7(3.05),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-486-
5p(-1.81),hsa-miR-375(-2.41),hsa-miR-944(2.85),hsa-miR-1276(2.14) 
>SPRY2 -2.08 hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03),hsa-miR-
885-5p(-2.56) 
>SLC26A2 -2.08 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-223(2.13),hsa-miR-129-5p(-2.62),hsa-miR-455-
3p(2.46),hsa-miR-146a(2.36),hsa-miR-548f(2.32) 
>LPL -2.09 hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-miR-188-
5p(2.36),hsa-miR-548f(2.32),hsa-miR-487a(2.12),hsa-miR-1179(-2.02) 
>SUSD2 -2.09 hsa-miR-496(3.02),hsa-miR-940(2.79) 
>ZNF559 -2.09 hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-377(1.81),hsa-miR-1179(-2.02) 
>PLA2R1 -2.09 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-548f(2.32) 
>NEGR1 -2.09 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-10a(-
2.31),hsa-miR-137(-2.37),hsa-miR-135b(5.65),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46),hsa-
miR-548f(2.32),hsa-miR-628-3p(-1.87) 
>FRMD3 -2.09 hsa-miR-21(3.95),hsa-miR-129-5p(-2.62),hsa-miR-455-3p(2.46),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>FCGBP -2.10 hsa-miR-21(3.95) 
>ALDH3A2 -2.10 hsa-miR-206(12.8),hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-378(2.68),hsa-miR-
211(2.6),hsa-miR-665(2.34),hsa-miR-377(1.81) 
>ACOX2 -2.10 hsa-miR-590-3p(1.94) 
>TPM1 -2.10 hsa-miR-33b(2.23),hsa-miR-542-3p(1.31),hsa-miR-375(-2.41),hsa-miR-548f(2.32) 
>PCDH20 -2.10 hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-542-3p(1.31),hsa-miR-486-5p(-1.81),hsa-miR-375(-2.41),hsa-miR-211(2.6),hsa-miR-487a(2.12) 
>CCRL1 -2.10 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-
21(3.95),hsa-miR-944(2.85),hsa-miR-548f(2.32) 
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>PDZK1 -2.10 hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-487a(2.12) 
>PDGFD -2.10 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-
21(3.95),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32) 
>ZNF483 -2.10 hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-509-5p(1.61) 
>FKBP7 -2.10 hsa-miR-548f(2.32) 
>H3F3B -2.10 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-486-
5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-137(-2.37),hsa-miR-21(3.95),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32),hsa-
miR-369-3p(2.31),hsa-miR-223(2.13) 
>PNPLA3 -2.10 hsa-miR-146a(2.36),hsa-miR-212(2.08),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-146a(2.36),hsa-miR-
369-3p(2.31) 
>KLF8 -2.10 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-147b(2.79) 
>CTNNBIP1 -2.11 hsa-miR-211(2.6),hsa-miR-10a(-2.31),hsa-miR-188-5p(2.36),hsa-miR-486-3p(-2.56) 
>TIMP3 -2.11 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-665(2.34),hsa-miR-
548f(2.32),hsa-miR-509-5p(1.61),hsa-miR-486-3p(-2.56) 
>ACTA1 -2.11 hsa-miR-155(2.7),hsa-miR-223(2.13) 
>RHOB -2.11 hsa-miR-21(3.95),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-21(3.95),hsa-miR-1303(2.66),hsa-miR-
548f(2.32),hsa-miR-486-3p(-2.56),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-146a(2.36),hsa-miR-
33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-
944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-377(1.81) 
>ADCY2 -2.11 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-
146a(2.36),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-18a(2.43),hsa-miR-33b(2.23) 
>TM2D1 -2.12 hsa-miR-376b(1.73),hsa-miR-1276(2.14) 
>RHPN2 -2.12 hsa-miR-206(12.8),hsa-miR-496(3.02),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>SCGB2A2 -2.13 hsa-miR-431(3.91) 
>CNN1 -2.13 hsa-miR-10a(-2.31) 
>ABCA9 -2.13 hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-18a(2.43),hsa-miR-944(2.85),hsa-miR-18a(2.43),hsa-miR-
146a(2.36),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>COL3A1 -2.14 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-665(2.34),hsa-miR-
1276(2.14),hsa-miR-487a(2.12) 
>IGFBP5 -2.14 hsa-miR-146a(2.36),hsa-miR-33b(2.23),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62) 
>PELI2 -2.14 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-
129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-548f(2.32) 
>RORC -2.14 hsa-miR-31(42.93),hsa-miR-592(2.92),hsa-miR-665(2.34),hsa-miR-1276(2.14) 
>TARDBP -2.15 hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-18a(2.43),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-137(-2.37),hsa-miR-592(2.92),hsa-miR-455-3p(2.46),hsa-miR-188-5p(2.36),hsa-miR-509-
5p(1.61),hsa-miR-1179(-2.02) 
>EDIL3 -2.15 hsa-miR-135b(5.65),hsa-miR-496(3.02),hsa-miR-377(1.81),hsa-miR-137(-2.37),hsa-miR-375(-2.41),hsa-miR-129-
5p(-2.62),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>MAP1B -2.15 hsa-miR-31(42.93),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-542-3p(1.31),hsa-miR-
940(2.79),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-223(2.13),hsa-miR-487a(2.12) 
>HOXC6 -2.15 hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-147b(2.79),hsa-miR-
665(2.34),hsa-miR-377(1.81),hsa-miR-486-3p(-2.56) 
>CAMK2N1 -2.16 hsa-miR-18a(2.43),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-486-5p(-1.81),hsa-miR-
129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-628-3p(-
1.87),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>MASP2 -2.16 hsa-miR-31(42.93),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>TSPYL5 -2.16 hsa-miR-135b(5.65),hsa-miR-33b(2.23),hsa-miR-377(1.81),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-1179(-
2.02) 
>EFNB2 -2.16 hsa-miR-206(12.8),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31),hsa-miR-487a(2.12),hsa-miR-
377(1.81) 
>ZC3H6 -2.16 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-
369-3p(2.31),hsa-miR-487a(2.12) 
>WISP2 -2.16 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-940(2.79) 
>SNX1 -2.16 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-
944(2.85),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>ALS2CR4 -2.16 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-376b(1.73),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-146a(2.36),hsa-miR-188-5p(2.36) 
>ACADL -2.17 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-
1303(2.66),hsa-miR-548f(2.32) 
>CES1 -2.17 hsa-miR-211(2.6),hsa-miR-188-5p(2.36) 
>ZNF423 -2.17 hsa-miR-211(2.6),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61) 
>NFIB -2.17 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-137(-
2.37),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-
455-3p(2.46),hsa-miR-665(2.34),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61) 
>PDLIM4 -2.17 hsa-miR-223(2.13),hsa-miR-542-3p(1.31) 
>NCALD -2.17 hsa-miR-7(3.05),hsa-miR-212(2.08),hsa-miR-940(2.79),hsa-miR-1276(2.14) 
>FOS -2.17 hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-431(3.91),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
147b(2.79) 
>DNM1 -2.17 hsa-miR-496(3.02),hsa-miR-940(2.79) 
>FAM19A5 -2.17 hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-187(2.17),hsa-miR-486-3p(-2.56) 
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>RPL37 -2.17 hsa-miR-10a(-2.31),hsa-miR-455-3p(2.46),hsa-miR-487a(2.12),hsa-miR-10a(-2.31) 
>FNDC1 -2.18 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>SRGAP2 -2.18 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-
212(2.08),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-944(2.85),hsa-miR-
940(2.79),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1179(-2.02) 
>FBLN1 -2.19 hsa-miR-31(42.93),hsa-miR-1276(2.14),hsa-miR-486-3p(-2.56) 
>LIFR -2.19 hsa-miR-206(12.8),hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-155(2.7),hsa-miR-369-3p(2.31) 
>PKIB -2.19 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-548f(2.32),hsa-miR-33b(2.23) 
>ESR1 -2.20 hsa-miR-135b(5.65),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-211(2.6),hsa-miR-
18a(2.43),hsa-miR-369-3p(2.31) 
>COL1A2 -2.20 hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-1308(2.03) 
>TNXB -2.20 hsa-miR-486-5p(-1.81),hsa-miR-137(-2.37) 
>KLF9 -2.21 hsa-miR-21(3.95),hsa-miR-142-3p(2.52),hsa-miR-376b(1.73),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-
1276(2.14) 
>CCDC73 -2.21 hsa-miR-590-3p(1.94),hsa-miR-375(-2.41),hsa-miR-628-3p(-1.87) 
>MEOX2 -2.21 hsa-miR-206(12.8),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-592(2.92),hsa-miR-369-
3p(2.31),hsa-miR-33b(2.23) 
>MCOLN3 -2.22 hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-137(-2.37),hsa-miR-211(2.6) 
>OMD -2.22 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-1276(2.14) 
>DMD -2.22 hsa-miR-31(42.93),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-212(2.08),hsa-miR-542-
3p(1.31),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-
miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-223(2.13) 
>PER1 -2.24 hsa-miR-486-3p(-2.56) 
>DKK2 -2.24 hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-142-3p(2.52),hsa-miR-146a(2.36),hsa-miR-590-
3p(1.94),hsa-miR-486-5p(-1.81),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-
211(2.6),hsa-miR-369-3p(2.31),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02) 
>SORCS2 -2.24 hsa-miR-33b(2.23),hsa-miR-1268(4.45),hsa-miR-509-5p(1.61) 
>RNASE4 -2.25 hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-188-5p(2.36),hsa-miR-
628-3p(-1.87) 
>SCARA5 -2.25 hsa-miR-31(42.93),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-665(2.34),hsa-miR-1179(-2.02) 
>HMGCS2 -2.25 hsa-miR-21(3.95) 
>SCIN -2.26 hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62) 
>PPP1R1B -2.26 hsa-miR-455-3p(2.46),hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>TGFBR3 -2.28 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-18a(2.43),hsa-miR-21(3.95),hsa-miR-
18a(2.43),hsa-miR-548f(2.32) 
>NAP1L3 -2.28 hsa-miR-33b(2.23) 
>MYH11 -2.29 hsa-miR-21(3.95),hsa-miR-187(2.17),hsa-miR-129-5p(-2.62),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-miR-
187(2.17),hsa-miR-487a(2.12),hsa-miR-1179(-2.02) 
>LMOD1 -2.30 hsa-miR-665(2.34),hsa-miR-486-3p(-2.56) 
>LEP -2.30 hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-1276(2.14),hsa-miR-
31(42.93),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-187(2.17),hsa-miR-
223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-135b(5.65),hsa-miR-
21(3.95),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-665(2.34),hsa-miR-548f(2.32),hsa-
miR-369-3p(2.31),hsa-miR-187(2.17),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61),hsa-miR-135b(5.65),hsa-miR-
21(3.95),hsa-miR-7(3.05),hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-
miR-944(2.85),hsa-miR-378(2.68),hsa-miR-1303(2.66),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31) 
>RTN4 -2.30 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-542-3p(1.31),hsa-miR-1268(4.45),hsa-miR-944(2.85),hsa-miR-455-
3p(2.46) 
>HLF -2.30 hsa-miR-31(42.93),hsa-miR-431(3.91),hsa-miR-18a(2.43),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-486-5p(-1.81),hsa-miR-137(-2.37),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-
223(2.13),hsa-miR-628-3p(-1.87) 
>ADIPOQ -2.31 hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-10a(-2.31),hsa-miR-129-5p(-2.62),hsa-miR-378(2.68),hsa-miR-
1303(2.66),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>LPHN3 -2.31 hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-
155(2.7),hsa-miR-1303(2.66),hsa-miR-1179(-2.02) 
>PGM5 -2.32 hsa-miR-206(12.8),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-
592(2.92),hsa-miR-369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-377(1.81) 
>TCF7L2 -2.32 hsa-miR-548f(2.32) 
>NRN1 -2.33 hsa-miR-7(3.05),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-369-3p(2.31) 
>GATA6 -2.34 hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-10a(-2.31),hsa-miR-375(-
2.41),hsa-miR-944(2.85),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
10a(-2.31) 
>HOXC10 -2.34 hsa-miR-590-3p(1.94),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62) 
>ADRB2 -2.34 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32) 
>CD34 -2.35 hsa-miR-431(3.91),hsa-miR-1303(2.66),hsa-miR-548f(2.32) 
>CYP4B1 -2.35 hsa-miR-206(12.8),hsa-miR-944(2.85) 
>CORO2B -2.35 hsa-miR-146a(2.36),hsa-miR-509-5p(1.61) 
 210 
>PDE4DIP -2.36 hsa-miR-31(42.93),hsa-miR-206(12.8),hsa-miR-431(3.91),hsa-miR-455-3p(2.46),hsa-miR-665(2.34),hsa-miR-1179(-
2.02) 
>SSPN -2.36 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-378(2.68),hsa-miR-590-3p(1.94),hsa-miR-21(3.95),hsa-miR-
944(2.85),hsa-miR-378(2.68),hsa-miR-548f(2.32) 
>PLCB4 -2.36 hsa-miR-431(3.91),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-
1303(2.66),hsa-miR-1276(2.14),hsa-miR-628-3p(-1.87) 
>DDAH1 -2.36 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-223(2.13),hsa-miR-
377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-
146a(2.36),hsa-miR-509-5p(1.61) 
>GSTA3 -2.36 hsa-miR-431(3.91) 
>SH3D19 -2.36 hsa-miR-155(2.7),hsa-miR-10a(-2.31),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1308(2.03) 
>RAI14 -2.37 hsa-miR-146a(2.36),hsa-miR-129-5p(-2.62),hsa-miR-147b(2.79),hsa-miR-155(2.7),hsa-miR-1276(2.14),hsa-miR-
1179(-2.02),hsa-miR-486-3p(-2.56) 
>FOXC1 -2.38 hsa-miR-31(42.93),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-188-5p(2.36),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31) 
>CHL1 -2.38 hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-10a(-2.31),hsa-miR-
21(3.95),hsa-miR-369-3p(2.31),hsa-miR-487a(2.12),hsa-miR-628-3p(-1.87) 
>NOVA1 -2.38 hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-33b(2.23),hsa-miR-590-
3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-155(2.7),hsa-miR-1303(2.66),hsa-
miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-146a(2.36),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32),hsa-miR-369-
3p(2.31),hsa-miR-1308(2.03) 
>TMEM47 -2.38 hsa-miR-206(12.8),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-944(2.85),hsa-miR-211(2.6),hsa-miR-369-3p(2.31) 
>GSTM3 -2.39 hsa-miR-31(42.93),hsa-miR-431(3.91),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-
211(2.6),hsa-miR-188-5p(2.36),hsa-miR-1276(2.14) 
>EEF2K -2.39 hsa-miR-142-3p(2.52),hsa-miR-590-3p(1.94),hsa-miR-944(2.85),hsa-miR-487a(2.12),hsa-miR-509-5p(1.61) 
>ADH1B -2.39 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-137(-2.37),hsa-miR-1303(2.66),hsa-miR-
548f(2.32),hsa-miR-486-3p(-2.56) 
>PCYT1B -2.39 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-
211(2.6),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32) 
>LAMB4 -2.40 hsa-miR-590-3p(1.94),hsa-miR-628-3p(-1.87) 
>ZNF677 -2.41 hsa-miR-155(2.7),hsa-miR-369-3p(2.31),hsa-miR-628-3p(-1.87) 
>CLDN1 -2.41 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-590-
3p(1.94),hsa-miR-377(1.81),hsa-miR-21(3.95),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-
1308(2.03),hsa-miR-509-5p(1.61),hsa-miR-1179(-2.02),hsa-miR-885-5p(-2.56) 
>MYLK -2.42 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-18a(2.43),hsa-miR-590-
3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>MAML2 -2.42 hsa-miR-211(2.6),hsa-miR-509-5p(1.61) 
>PAPLN -2.42 hsa-miR-31(42.93),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-
376b(1.73),hsa-miR-1268(4.45),hsa-miR-665(2.34),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>PEG3 -2.44 hsa-miR-135b(5.65),hsa-miR-129-5p(-2.62),hsa-miR-940(2.79),hsa-miR-1303(2.66) 
>SYDE2 -2.44 hsa-miR-31(42.93),hsa-miR-496(3.02),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94) 
>PPFIBP1 -2.44 hsa-miR-542-3p(1.31),hsa-miR-10a(-2.31),hsa-miR-129-5p(-2.62),hsa-miR-135b(5.65),hsa-miR-1268(4.45),hsa-
miR-944(2.85),hsa-miR-369-3p(2.31),hsa-miR-1308(2.03) 
>PPARGC1A -2.44 hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-33b(2.23),hsa-miR-187(2.17),hsa-miR-590-3p(1.94),hsa-miR-
377(1.81),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-147b(2.79),hsa-miR-211(2.6),hsa-
miR-369-3p(2.31),hsa-miR-187(2.17),hsa-miR-487a(2.12),hsa-miR-1308(2.03),hsa-miR-1179(-2.02) 
>HOXA10 -2.45 hsa-miR-135b(5.65),hsa-miR-590-3p(1.94),hsa-miR-1303(2.66),hsa-miR-665(2.34),hsa-miR-369-3p(2.31) 
>SGEF -2.46 hsa-miR-10a(-2.31),hsa-miR-1268(4.45),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-
1276(2.14),hsa-miR-10a(-2.31) 
>GLDC -2.46 hsa-miR-377(1.81),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32) 
>KRT15 -2.47 hsa-miR-940(2.79) 
>CGNL1 -2.47 hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-1268(4.45),hsa-miR-378(2.68),hsa-miR-665(2.34),hsa-miR-
369-3p(2.31) 
>PLLP -2.49 hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-18a(2.43),hsa-miR-548f(2.32) 
>LONRF1 -2.49 hsa-miR-135b(5.65),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-1303(2.66),hsa-miR-548f(2.32),hsa-miR-
1276(2.14) 
>RAI2 -2.49 hsa-miR-590-3p(1.94),hsa-miR-487a(2.12),hsa-miR-885-5p(-2.56) 
>GATA3 -2.50 hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-10a(-2.31),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31) 
>PCP4 -2.50 hsa-miR-33b(2.23),hsa-miR-135b(5.65),hsa-miR-1308(2.03),hsa-miR-1179(-2.02) 
>ZNF91 -2.51 hsa-miR-135b(5.65),hsa-miR-155(2.7),hsa-miR-542-3p(1.31),hsa-miR-486-5p(-1.81),hsa-miR-135b(5.65),hsa-miR-
944(2.85),hsa-miR-455-3p(2.46),hsa-miR-548f(2.32),hsa-miR-223(2.13),hsa-miR-487a(2.12) 
>HAO2 -2.53 hsa-miR-31(42.93) 
>COBL -2.53 hsa-miR-1303(2.66),hsa-miR-487a(2.12) 
>AFF3 -2.54 hsa-miR-31(42.93),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-486-5p(-1.81),hsa-miR-
944(2.85),hsa-miR-455-3p(2.46),hsa-miR-188-5p(2.36),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-509-
5p(1.61),hsa-miR-628-3p(-1.87) 
>PTN -2.55 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-155(2.7) 
>MTBP -2.56 hsa-miR-590-3p(1.94),hsa-miR-1276(2.14) 
>PLN -2.56 hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-369-
3p(2.31),hsa-miR-33b(2.23) 
>PPP4R2 -2.56 hsa-miR-548f(2.32),hsa-miR-509-5p(1.61) 
>POSTN -2.60 hsa-miR-135b(5.65),hsa-miR-18a(2.43),hsa-miR-33b(2.23),hsa-miR-592(2.92),hsa-miR-944(2.85) 
 211 
>ENPP5 -2.60 hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-188-5p(2.36),hsa-miR-
1308(2.03) 
>SYNPO2 -2.60 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-142-3p(2.52),hsa-miR-146a(2.36),hsa-miR-
33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-21(3.95),hsa-miR-
592(2.92),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-146a(2.36),hsa-miR-369-3p(2.31),hsa-miR-
1276(2.14),hsa-miR-885-5p(-2.56) 
>CAB39L -2.60 hsa-miR-31(42.93),hsa-miR-21(3.95),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-
21(3.95),hsa-miR-455-3p(2.46),hsa-miR-146a(2.36),hsa-miR-548f(2.32),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>MFAP5 -2.63 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-369-
3p(2.31),hsa-miR-1179(-2.02) 
>SCEL -2.63 hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-548f(2.32) 
>PRSS23 -2.63 hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-665(2.34),hsa-miR-33b(2.23),hsa-miR-1179(-2.02) 
>SLITRK6 -2.63 hsa-miR-135b(5.65),hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-
548f(2.32),hsa-miR-33b(2.23),hsa-miR-1179(-2.02) 
>OGN -2.64 hsa-miR-206(12.8),hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-548f(2.32),hsa-miR-628-3p(-1.87) 
>PDK4 -2.65 hsa-miR-431(3.91),hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-590-
3p(1.94),hsa-miR-377(1.81),hsa-miR-129-5p(-2.62),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-
miR-885-5p(-2.56) 
>ITM2A -2.66 hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-1276(2.14),hsa-miR-1179(-2.02) 
>AGTR1 -2.67 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-455-
3p(2.46) 
>MAMDC2 -2.67 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1276(2.14),hsa-miR-
628-3p(-1.87) 
>SPRR4 -2.68 hsa-miR-455-3p(2.46) 
>ID4 -2.69 hsa-miR-18a(2.43),hsa-miR-486-5p(-1.81),hsa-miR-10a(-2.31),hsa-miR-18a(2.43),hsa-miR-548f(2.32) 
>ELMOD1 -2.69 hsa-miR-31(42.93),hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-590-3p(1.94),hsa-miR-
431(3.91),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-369-3p(2.31),hsa-miR-
487a(2.12),hsa-miR-1308(2.03),hsa-miR-10a(-2.31) 
>CILP -2.69 hsa-miR-21(3.95),hsa-miR-33b(2.23),hsa-miR-542-3p(1.31),hsa-miR-665(2.34) 
>CA6 -2.71 hsa-miR-155(2.7) 
>SORBS2 -2.72 hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-1276(2.14) 
>GPRASP1 -2.75 hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-487a(2.12) 
>UST -2.80 hsa-miR-206(12.8),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-376b(1.73),hsa-miR-129-5p(-2.62),hsa-miR-
21(3.95),hsa-miR-944(2.85),hsa-miR-378(2.68),hsa-miR-211(2.6),hsa-miR-455-3p(2.46),hsa-miR-665(2.34),hsa-
miR-1276(2.14),hsa-miR-486-3p(-2.56) 
>FHL1 -2.80 hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-146a(2.36),hsa-miR-
369-3p(2.31),hsa-miR-1276(2.14),hsa-miR-509-5p(1.61) 
>CRAT -2.81 hsa-miR-211(2.6),hsa-miR-1276(2.14),hsa-miR-487a(2.12),hsa-miR-486-3p(-2.56) 
>PTPN21 -2.85 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-375(-2.41),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-
155(2.7),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-885-5p(-2.56) 
>SNRPN -2.85 hsa-miR-155(2.7) 
>RGMB -2.85 hsa-miR-7(3.05),hsa-miR-146a(2.36),hsa-miR-137(-2.37),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-
548f(2.32),hsa-miR-1276(2.14) 
>SCD5 -2.86 hsa-miR-18a(2.43),hsa-miR-377(1.81),hsa-miR-542-3p(1.31),hsa-miR-10a(-2.31),hsa-miR-940(2.79) 
>NR3C2 -2.88 hsa-miR-31(42.93),hsa-miR-135b(5.65),hsa-miR-431(3.91),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-590-
3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-940(2.79),hsa-miR-211(2.6),hsa-miR-665(2.34),hsa-
miR-548f(2.32),hsa-miR-1276(2.14) 
>OSR2 -2.90 hsa-miR-142-3p(2.52) 
>ZNF273 -2.90 hsa-miR-155(2.7),hsa-miR-590-3p(1.94),hsa-miR-377(1.81),hsa-miR-10a(-2.31),hsa-miR-137(-2.37),hsa-miR-375(-
2.41),hsa-miR-592(2.92),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-377(1.81),hsa-miR-
509-5p(1.61),hsa-miR-628-3p(-1.87) 
>CST6 -2.91 hsa-miR-542-3p(1.31) 
>GREM2 -2.92 hsa-miR-7(3.05),hsa-miR-377(1.81),hsa-miR-137(-2.37),hsa-miR-375(-2.41),hsa-miR-129-5p(-2.62),hsa-miR-
944(2.85),hsa-miR-211(2.6),hsa-miR-369-3p(2.31),hsa-miR-377(1.81),hsa-miR-509-5p(1.61),hsa-miR-885-5p(-2.56) 
>FAM70A -2.92 hsa-miR-431(3.91),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-590-
3p(1.94),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-223(2.13),hsa-miR-1308(2.03) 
>SOAT1 -2.94 hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-487a(2.12),hsa-miR-
885-5p(-2.56) 
>SP8 -2.95 hsa-miR-496(3.02),hsa-miR-155(2.7),hsa-miR-142-3p(2.52),hsa-miR-146a(2.36),hsa-miR-377(1.81),hsa-miR-542-
3p(1.31),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1308(2.03),hsa-miR-885-5p(-2.56),hsa-miR-486-3p(-
2.56) 
>CYP39A1 -2.98 hsa-miR-18a(2.43),hsa-miR-590-3p(1.94),hsa-miR-129-5p(-2.62),hsa-miR-944(2.85),hsa-miR-1179(-2.02) 
>IGFL2 -3.00 hsa-miR-135b(5.65) 
>FADS2 -3.01 hsa-miR-212(2.08),hsa-miR-486-3p(-2.56) 
>FA2H -3.05 hsa-miR-31(42.93),hsa-miR-940(2.79),hsa-miR-486-3p(-2.56) 
>C1QTNF7 -3.05 hsa-miR-211(2.6),hsa-miR-18a(2.43),hsa-miR-33b(2.23),hsa-miR-223(2.13),hsa-miR-590-3p(1.94),hsa-miR-486-
5p(-1.81),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62),hsa-miR-211(2.6) 
>LRRC17 -3.18 hsa-miR-10a(-2.31),hsa-miR-369-3p(2.31),hsa-miR-1179(-2.02) 
>GREM1 -3.23 hsa-miR-206(12.8),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-33b(2.23),hsa-miR-137(-
2.37),hsa-miR-940(2.79),hsa-miR-155(2.7),hsa-miR-211(2.6),hsa-miR-188-5p(2.36),hsa-miR-369-3p(2.31),hsa-miR-
33b(2.23) 
>CLDN23 -3.27 hsa-miR-590-3p(1.94),hsa-miR-944(2.85) 
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>AQP9 -3.27 hsa-miR-18a(2.43),hsa-miR-146a(2.36),hsa-miR-590-3p(1.94),hsa-miR-1303(2.66),hsa-miR-146a(2.36),hsa-miR-
885-5p(-2.56) 
>FADS1 -3.44 hsa-miR-431(3.91),hsa-miR-496(3.02),hsa-miR-590-3p(1.94),hsa-miR-211(2.6),hsa-miR-1276(2.14) 
>ST7L -3.45 hsa-miR-135b(5.65),hsa-miR-7(3.05),hsa-miR-496(3.02),hsa-miR-211(2.6),hsa-miR-146a(2.36),hsa-miR-10a(-
2.31),hsa-miR-1303(2.66),hsa-miR-211(2.6),hsa-miR-548f(2.32),hsa-miR-369-3p(2.31),hsa-miR-223(2.13) 
>CLDN8 -3.51 hsa-miR-135b(5.65),hsa-miR-21(3.95),hsa-miR-155(2.7),hsa-miR-223(2.13),hsa-miR-940(2.79),hsa-miR-
155(2.7),hsa-miR-548f(2.32) 
>F3 -3.53 hsa-miR-155(2.7),hsa-miR-18a(2.43),hsa-miR-223(2.13),hsa-miR-129-5p(-2.62),hsa-miR-155(2.7),hsa-miR-
548f(2.32),hsa-miR-369-3p(2.31) 
>COCH -3.60 hsa-miR-137(-2.37),hsa-miR-1303(2.66),hsa-miR-1276(2.14) 
>ZDHHC11 -3.71 hsa-miR-142-3p(2.52),hsa-miR-940(2.79),hsa-miR-548f(2.32),hsa-miR-1308(2.03) 
>MUC7 -3.74 hsa-miR-431(3.91),hsa-miR-7(3.05),hsa-miR-590-3p(1.94),hsa-miR-542-3p(1.31),hsa-miR-944(2.85) 
>EMX2 -3.76 hsa-miR-206(12.8),hsa-miR-944(2.85),hsa-miR-211(2.6) 
>TSPAN8 -3.84 hsa-miR-211(2.6),hsa-miR-188-5p(2.36) 
>STXBP6 -3.88 hsa-miR-590-3p(1.94),hsa-miR-548f(2.32),hsa-miR-1179(-2.02) 
>TMEM56 -3.93 hsa-miR-590-3p(1.94) 
>TPPP -3.95 hsa-miR-211(2.6),hsa-miR-377(1.81),hsa-miR-188-5p(2.36) 
>HSD3B1 -4.04 hsa-miR-7(3.05) 
>WDR72 -4.23 hsa-miR-206(12.8),hsa-miR-21(3.95),hsa-miR-7(3.05),hsa-miR-155(2.7),hsa-miR-33b(2.23),hsa-miR-590-
3p(1.94),hsa-miR-21(3.95),hsa-miR-592(2.92),hsa-miR-944(2.85),hsa-miR-1303(2.66),hsa-miR-369-3p(2.31),hsa-
miR-487a(2.12),hsa-miR-509-5p(1.61) 
>HS3ST6 -4.25 hsa-miR-18a(2.43) 
>IL1F7 -4.64 hsa-miR-486-3p(-2.56) 
>HSD11B1 -4.95 hsa-miR-590-3p(1.94),hsa-miR-376b(1.73),hsa-miR-944(2.85) 
>ACSBG1 -5.74 hsa-miR-223(2.13),hsa-miR-548f(2.32),hsa-miR-509-5p(1.61) 
>FABP7 -5.98 hsa-miR-548f(2.32) 
>GAL -6.38 hsa-miR-665(2.34),hsa-miR-378(2.68),hsa-miR-212(2.08),hsa-miR-665(2.34) 
>CCL27 -7.72 hsa-miR-944(2.85) 
>THRSP -9.40 hsa-miR-369-3p(2.31) 
>BTC -13.90 hsa-miR-211(2.6),hsa-miR-129-5p(-2.62),hsa-miR-369-3p(2.31),hsa-miR-628-3p(-1.87) 
>WIF1 -14.03 hsa-miR-33b(2.23),hsa-miR-590-3p(1.94),hsa-miR-137(-2.37),hsa-miR-129-5p(-2.62) 
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Table A-2. TargetScan Custom predicted targets for Top 10 up- 
and downregulated miRNAs 
Identifier PP/NNa 
miR31* 34.51 
CD47 2.91 
FOS -2.17 
KLF9 -2.21 
PRDM1 2.38 
RAI14 -2.37 
STAT3 2.13 
miR-21* 8.80 
ALCAM -2.04 
CREB5 -2.02 
CTPS 2.08 
DCAMKL1 -2.25 
HLF -2.30 
NFIB -2.17 
RNF128 -2.03 
ST7L -3.45 
TAP1 2.02 
UST -2.80 
miR-135b* 8.00 
DMN -2.17 
GSPT1 2.27 
TOP1 2.26 
miR-33b* 5.70 
C19orf2 -2.05 
DCUN1D3 2.26 
GAN -2.04 
LRP8 2.27 
NR3C2 -2.88 
miR-222* 5.59 
BCAR3 -2.03 
DIO2 2.02 
EREG 2.57 
MYO5A 2.62 
NEGR1 -2.09 
NOVA1 -2.38 
NR3C1 -2.04 
PIK3R1 -2.05 
PON2 2.08 
PTPN21 -2.85 
RNF128 -2.03 
SLC7A1 2.18 
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ZIC1 3.42 
Novel #107 -8.07 
DIXDC1 -2.00 
EMX2 -3.76 
FAM13A1 -2.05 
NOVA1 -2.38 
NRBF2 2.05 
PIK3R1 -2.05 
miR-124 -5.87 
ALCAM -2.04 
ARG2 2.55 
C20orf133 -3.66 
CARHSP1 4.05 
CCL2 2.39 
CDON -2.06 
COTL1 2.07 
CRAT -2.81 
DMD -2.22 
EFNB2 -2.16 
ELL2 2.17 
EZH2 2.12 
FA2H -3.05 
FAM117A -2.01 
FLJ20152 -2.21 
GATA6 -2.34 
GPT2 2.57 
HLF -2.30 
IRF1 2.02 
LOC153222 -2.05 
LONRF1 -2.49 
MAP1B -2.15 
MGC13057 -2.03 
MPZL1 2.10 
MYO5A 2.62 
NAP1L3 -2.28 
NEGR1 -2.09 
NFIB -2.17 
NOPE -2.33 
NR3C1 -2.04 
NR3C2 -2.88 
P4HA2 -2.05 
PDZD2 -2.05 
PEG3 -2.44 
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PLEKHH1 -2.27 
PPIF 3.38 
RAB10 2.15 
RAB27A 3.95 
RAB38 2.19 
RAI14 -2.37 
RNF128 -2.03 
SFT2D2 2.64 
SH3PXD2A 4.26 
SLC16A1 2.35 
SLC29A1 -2.07 
SLC2A13 -2.08 
SLC7A1 2.18 
SLITRK6 -2.63 
SMOX 2.32 
SMPD3 2.27 
SORCS2 -2.24 
SPRY2 -2.08 
SPTLC2 4.34 
STAT3 2.13 
TACC2 -2.01 
THAP2 2.05 
TMEM49 2.41 
TUBB6 2.05 
VSNL1 3.18 
YOD1 2.05 
miR-675* -4.44 
AFF3 -2.54 
RABIF 2.04 
Novel #360 -4.16 
AMPD3 2.23 
BHLHB3 -2.62 
C14orf28 -2.04 
C19orf2 -2.05 
CCNE2 2.40 
CORO2B -2.35 
CREB5 -2.02 
DBN1 -2.03 
DMD -2.22 
ENPP5 -2.60 
F3 -3.53 
FAM70A -2.92 
HLF -2.30 
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HN1 2.28 
LPHN3 -2.31 
MCL1 2.12 
RAB10 2.15 
RNF128 -2.03 
TIMP3 -2.11 
ZIC1 3.42 
Novel #200 -3.79 
LPL -2.09 
VAPA -2.05 
miR-483-3p -2.93 
DIXDC1 -2.00 
FHL1 -2.80 
FOSL2 2.10 
GAN -2.04 
HOMER1 2.01 
ITPR2 -2.08 
MFN1 2.00 
aNormal skin, NN; Involved psoriatic skin, PP. 
 
 
